ZA200606720B - Treatment of interstitial cystitis with vitamin D compounds - Google Patents
Treatment of interstitial cystitis with vitamin D compounds Download PDFInfo
- Publication number
- ZA200606720B ZA200606720B ZA200606720A ZA200606720A ZA200606720B ZA 200606720 B ZA200606720 B ZA 200606720B ZA 200606720 A ZA200606720 A ZA 200606720A ZA 200606720 A ZA200606720 A ZA 200606720A ZA 200606720 B ZA200606720 B ZA 200606720B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- methyl
- mmol
- hexane
- cholecalciferol
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 91
- 208000005615 Interstitial Cystitis Diseases 0.000 title claims description 42
- -1 vitamin D compounds Chemical class 0.000 title description 142
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title description 135
- 229930003316 Vitamin D Natural products 0.000 title description 94
- 235000019166 vitamin D Nutrition 0.000 title description 94
- 239000011710 vitamin D Substances 0.000 title description 94
- 229940046008 vitamin d Drugs 0.000 title description 94
- 150000001875 compounds Chemical class 0.000 claims description 291
- 239000011647 vitamin D3 Substances 0.000 claims description 156
- 229940021056 vitamin d3 Drugs 0.000 claims description 156
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 31
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000001188 haloalkyl group Chemical group 0.000 claims description 25
- 229940126062 Compound A Drugs 0.000 claims description 24
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 22
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 206010063057 Cystitis noninfective Diseases 0.000 claims description 5
- LRLWXBHFPGSUOX-GJQYOBCGSA-N (1r,3z,5s)-3-[(2e)-2-[(3as,7as)-1-[(e,2s)-6-ethyl-6-hydroxyoct-4-en-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-ylidene]ethylidene]-5-fluoro-4-methylidenecyclohexan-1-ol Chemical compound C1(/[C@@H]2CC=C([C@]2(CCC1)C)[C@@H](C)C/C=C/C(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](F)C1=C LRLWXBHFPGSUOX-GJQYOBCGSA-N 0.000 claims description 4
- 206010069632 Bladder dysfunction Diseases 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 241000237519 Bivalvia Species 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 235000020639 clam Nutrition 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 344
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 314
- 239000000243 solution Substances 0.000 description 158
- 239000000203 mixture Substances 0.000 description 155
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 138
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 119
- 239000012267 brine Substances 0.000 description 81
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 69
- 210000003932 urinary bladder Anatomy 0.000 description 69
- 230000015572 biosynthetic process Effects 0.000 description 65
- 238000003786 synthesis reaction Methods 0.000 description 63
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 59
- 238000005481 NMR spectroscopy Methods 0.000 description 58
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 50
- 239000003981 vehicle Substances 0.000 description 50
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 48
- 239000011734 sodium Substances 0.000 description 45
- 241001465754 Metazoa Species 0.000 description 43
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 43
- 235000005282 vitamin D3 Nutrition 0.000 description 42
- 238000000034 method Methods 0.000 description 39
- 239000000741 silica gel Substances 0.000 description 39
- 229910002027 silica gel Inorganic materials 0.000 description 39
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 37
- 238000001704 evaporation Methods 0.000 description 35
- 230000008020 evaporation Effects 0.000 description 35
- 210000002966 serum Anatomy 0.000 description 34
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 29
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 239000011575 calcium Substances 0.000 description 26
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000006188 syrup Substances 0.000 description 24
- 235000020357 syrup Nutrition 0.000 description 24
- 239000000463 material Substances 0.000 description 23
- 239000000725 suspension Substances 0.000 description 23
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 229910052791 calcium Inorganic materials 0.000 description 22
- 239000010410 layer Substances 0.000 description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 19
- 230000002757 inflammatory effect Effects 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 239000000284 extract Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 229910052938 sodium sulfate Inorganic materials 0.000 description 17
- 235000011152 sodium sulphate Nutrition 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 229960004397 cyclophosphamide Drugs 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 229940088594 vitamin Drugs 0.000 description 15
- 229930003231 vitamin Natural products 0.000 description 15
- 235000013343 vitamin Nutrition 0.000 description 15
- 239000011782 vitamin Substances 0.000 description 15
- 150000003710 vitamin D derivatives Chemical class 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 108010058846 Ovalbumin Proteins 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 239000012230 colorless oil Substances 0.000 description 14
- 210000003630 histaminocyte Anatomy 0.000 description 14
- 229940092253 ovalbumin Drugs 0.000 description 14
- 150000003722 vitamin derivatives Chemical class 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 12
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 12
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 12
- 230000008602 contraction Effects 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000007903 gelatin capsule Substances 0.000 description 12
- 150000002576 ketones Chemical class 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- MWPUQLIGJYKZIN-BBMMYNIISA-N (2r)-2-[(1r,3ar,4s,7ar)-4-[tert-butyl(dimethyl)silyl]oxy-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-1-yl]-6-methylheptane-1,6-diol Chemical compound CC(C)(C)[Si](C)(C)O[C@H]1CCC[C@]2(C)[C@@H]([C@H](CO)CCCC(C)(O)C)CC[C@H]21 MWPUQLIGJYKZIN-BBMMYNIISA-N 0.000 description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 10
- 230000008595 infiltration Effects 0.000 description 10
- 238000001764 infiltration Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 230000027939 micturition Effects 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- VWBYXJRDIQCSLW-UHFFFAOYSA-N O=[P](c1ccccc1)c1ccccc1 Chemical group O=[P](c1ccccc1)c1ccccc1 VWBYXJRDIQCSLW-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000009310 vitamin D receptors Human genes 0.000 description 9
- 108050000156 vitamin D receptors Proteins 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 150000002009 diols Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 125000003709 fluoroalkyl group Chemical group 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 7
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 208000000450 Pelvic Pain Diseases 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000035563 calcemia Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 108010080042 mast cell protease 4 Proteins 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 150000003338 secosteroids Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000036724 intravesical pressure Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 206010027566 Micturition urgency Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010036018 Pollakiuria Diseases 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010936 aqueous wash Methods 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 3
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 3
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 229960005084 calcitriol Drugs 0.000 description 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 125000004986 diarylamino group Chemical group 0.000 description 3
- 125000005594 diketone group Chemical group 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000000750 endocrine system Anatomy 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000008570 general process Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000011981 lindlar catalyst Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- 208000022934 urinary frequency Diseases 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- WXOZDSHUAIDCND-KBXCAEBGSA-N (3ar,7ar)-1-[1-(4-hydroxy-4-methylpent-1-enyl)cyclopropyl]-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-one Chemical compound C=1([C@@]2(CCCC(=O)[C@@H]2CC=1)C)C1(C=CCC(C)(O)C)CC1 WXOZDSHUAIDCND-KBXCAEBGSA-N 0.000 description 2
- DGQLEXMRZUHONZ-BBMMYNIISA-N (6r)-6-[(1r,3ar,4s,7ar)-4-[tert-butyl(dimethyl)silyl]oxy-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-1-yl]-7-iodo-2-methylheptan-2-ol Chemical compound CC(C)(C)[Si](C)(C)O[C@H]1CCC[C@]2(C)[C@@H]([C@H](CI)CCCC(C)(O)C)CC[C@H]21 DGQLEXMRZUHONZ-BBMMYNIISA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NNHYAHOTXLASEA-UHFFFAOYSA-N 1-(dimethoxymethyl)-4-methoxybenzene Chemical compound COC(OC)C1=CC=C(OC)C=C1 NNHYAHOTXLASEA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VXUOFDJKYGDUJI-OAQYLSRUSA-N 1-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VXUOFDJKYGDUJI-OAQYLSRUSA-N 0.000 description 2
- ZPDIRKNRUWXYLJ-UHFFFAOYSA-N 2,2-dimethyloxolane Chemical compound CC1(C)CCCO1 ZPDIRKNRUWXYLJ-UHFFFAOYSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical class C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 206010056874 Chemical cystitis Diseases 0.000 description 2
- 108090000227 Chymases Proteins 0.000 description 2
- 102000003858 Chymases Human genes 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010034984 D3 compound Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000005698 Diels-Alder reaction Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 description 2
- 101150018591 Mcpt2 gene Proteins 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 235000020964 calcitriol Nutrition 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000050 smooth muscle relaxant Substances 0.000 description 2
- 229910001023 sodium amalgam Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- CHLCPTJLUJHDBO-UHFFFAOYSA-M sodium;benzenesulfinate Chemical compound [Na+].[O-]S(=O)C1=CC=CC=C1 CHLCPTJLUJHDBO-UHFFFAOYSA-M 0.000 description 2
- XZPVPNZTYPUODG-UHFFFAOYSA-M sodium;chloride;dihydrate Chemical compound O.O.[Na+].[Cl-] XZPVPNZTYPUODG-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- ATMUYWZMPLKPEJ-XLMAVXFVSA-N (1r,3ar,7ar)-7a-methyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-one Chemical class O=C1CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]21 ATMUYWZMPLKPEJ-XLMAVXFVSA-N 0.000 description 1
- KLZOTDOJMRMLDX-YBBVPDDNSA-N (1r,3s,5z)-5-[(2e)-2-[(1s,3as,7as)-1-[(1r)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C)OCCCC(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C KLZOTDOJMRMLDX-YBBVPDDNSA-N 0.000 description 1
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- QCCNOVZKDOUJMX-RLFYNMQTSA-N (3ar,4s,7ar)-1-[1-(4-hydroxy-4-methylpent-2-ynyl)cyclopropyl]-7a-methyl-3,3a,4,5,6,7-hexahydroinden-4-ol Chemical compound C=1([C@@]2(CCC[C@H](O)[C@@H]2CC=1)C)C1(CC#CC(C)(O)C)CC1 QCCNOVZKDOUJMX-RLFYNMQTSA-N 0.000 description 1
- SGBKJXIYZGIQQQ-AGRCKSKDSA-N (3ar,4s,7ar)-1-[1-[(z)-4-hydroxy-4-methylpent-2-enyl]cyclopropyl]-7a-methyl-3,3a,4,5,6,7-hexahydroinden-4-ol Chemical compound C=1([C@@]2(CCC[C@H](O)[C@@H]2CC=1)C)C1(C\C=C/C(C)(O)C)CC1 SGBKJXIYZGIQQQ-AGRCKSKDSA-N 0.000 description 1
- IITMJSMJZMPPNP-LAUBAEHRSA-N (3ar,7ar)-7a-methyl-1-[1-(4-methyl-4-trimethylsilyloxypent-2-ynyl)cyclopropyl]-3a,5,6,7-tetrahydro-3h-inden-4-one Chemical compound C=1([C@@]2(CCCC(=O)[C@@H]2CC=1)C)C1(CC#CC(C)(O[Si](C)(C)C)C)CC1 IITMJSMJZMPPNP-LAUBAEHRSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- WWGMPELGMOAGBV-WICQSXRISA-N (6r)-6-[(1r,3ar,4s,7ar)-4-[tert-butyl(dimethyl)silyl]oxy-7a-methyl-1,2,3,3a,4,5,6,7-octahydroinden-1-yl]-7-(benzenesulfonyl)-2-methylheptan-2-ol Chemical compound C([C@H](CCCC(C)(O)C)[C@@H]1[C@]2(CCC[C@@H]([C@@H]2CC1)O[Si](C)(C)C(C)(C)C)C)S(=O)(=O)C1=CC=CC=C1 WWGMPELGMOAGBV-WICQSXRISA-N 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- FKHQVTZBKCBVOA-UHFFFAOYSA-N 1,2,3,3a,5,6,7,7a-octahydroinden-4-one Chemical compound O=C1CCCC2CCCC12 FKHQVTZBKCBVOA-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- NWWCZFWHHGLRNH-UHFFFAOYSA-N 1-(6-ethyl-6-trimethylsilyloxyoct-4-en-2-yl)-7a-methyl-3a,5,6,7-tetrahydro-3h-inden-4-one Chemical compound O=C1CCCC2(C)C(C(C)CC=CC(CC)(O[Si](C)(C)C)CC)=CCC21 NWWCZFWHHGLRNH-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DCHLRESJSA-N 25-Hydroxyvitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C/C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DCHLRESJSA-N 0.000 description 1
- JWUBBDSIWDLEOM-NQZHSCJISA-N 25-hydroxy-3 epi cholecalciferol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@H](O)CCC1=C JWUBBDSIWDLEOM-NQZHSCJISA-N 0.000 description 1
- 102100036285 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Human genes 0.000 description 1
- 101710107416 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Proteins 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 238000006596 Alder-ene reaction Methods 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- CFIFSLBCJAXYTC-FJLAUVHZSA-N Atocalcitol Chemical compound C([C@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)OCC1=CC=CC(C(C)(C)O)=C1 CFIFSLBCJAXYTC-FJLAUVHZSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005033 Bladder dilatation Diseases 0.000 description 1
- 206010005063 Bladder pain Diseases 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 101100452593 Caenorhabditis elegans ina-1 gene Proteins 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- DXWZPQRKPXFQGC-QCUPEZPBSA-N Ecalcidene Chemical compound C([C@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CC(=O)N1CCCCC1 DXWZPQRKPXFQGC-QCUPEZPBSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010047370 Vesicoureteric reflux Diseases 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005575 aldol reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 229950000271 atocalcitol Drugs 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000000125 calcaemic effect Effects 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 229960004361 calcifediol Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MLMODXBPCNLAGP-UHFFFAOYSA-L calcium;propanedioate Chemical compound [Ca+2].[O-]C(=O)CC([O-])=O MLMODXBPCNLAGP-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- KIGALSBMRYYLFJ-UHFFFAOYSA-N chloro-(2,3-dimethylbutan-2-yl)-dimethylsilane Chemical compound CC(C)C(C)(C)[Si](C)(C)Cl KIGALSBMRYYLFJ-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical compound [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical compound C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960000413 doxercalciferol Drugs 0.000 description 1
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 229950006545 ecalcidene Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- XPYGGHVSFMUHLH-UUSULHAXSA-N falecalcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(O)(C(F)(F)F)C(F)(F)F)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C XPYGGHVSFMUHLH-UUSULHAXSA-N 0.000 description 1
- 229950007545 falecalcitriol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229950006761 lexacalcitol Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- ARNWQMJQALNBBV-UHFFFAOYSA-N lithium carbide Chemical compound [Li+].[Li+].[C-]#[C-] ARNWQMJQALNBBV-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 229950006319 maxacalcitol Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- FEUXCWOYVOYVBT-UHFFFAOYSA-N methyl formate;pentane Chemical compound COC=O.CCCCC FEUXCWOYVOYVBT-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000013080 microcrystalline material Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- PWBJWDKDPAPGED-UHFFFAOYSA-N n'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- FNQQBQSISCLVNQ-UHFFFAOYSA-N penta-1,2,4-triene Chemical compound C=CC=C=C FNQQBQSISCLVNQ-UHFFFAOYSA-N 0.000 description 1
- 229940023556 pentosan polysulphate sodium Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000007699 photoisomerization reaction Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- AUMBXYDXKLLKEK-BGMQPCSBSA-N propan-2-yl (e,3r,6r)-6-[(1r,3as,4e,7ar)-4-[(2z)-2-[(3s,5r)-3,5-dihydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-1-yl]-3-hydroxy-2,2-dimethylhept-4-enoate Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@@H](O)C(C)(C)C(=O)OC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C AUMBXYDXKLLKEK-BGMQPCSBSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950004400 secalciferol Drugs 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 229950009921 seocalcitol Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940045872 sodium percarbonate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 229960004907 tacalcitol Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- LOVRVVSIBIVFTN-VSGBNLITSA-N tert-butyl-[(1r,3r)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)cyclohexyl]oxy-dimethylsilane Chemical compound C1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)CC1=CCP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 LOVRVVSIBIVFTN-VSGBNLITSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229950010459 tisocalcitate Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000008618 vesicoureteral reflux Diseases 0.000 description 1
- 208000031355 vesicoureteral reflux 1 Diseases 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 150000003703 vitamin D2 derivatives Chemical class 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
METHODS FOR TREATING INTERSTITIAL CYSTITIS AND RELATED COMPOUNDS
AND COMPOSITIONS
The present invention is concerned with the use of vitamin D compounds for the manufacture of a medicament for the prevention and/or treatment of interstitial cystitis.
It is further concerned with a method for preventing and/or treating interstitial cystitis, by administering a vitamin D compound in an amount effective to prevent and/or to treat such disease alone or in combination with further agents.
Interstitial cystitis, referred to herein as “IC”, is a chronic inflammatory bladder disease, also known as chronic pelvic pain syndrome (CPPS) or painful bladder syndrome (PBS), characterized by pelvic pain, urinary urgency and frequency. This disease affects maintly females, although males are also diagnosed with IC. Unlike other bladder dysfunction conditions, IC is characterized by chronic inflammation of the bladder wall which is responsible for the symptomatology; in other words, the cause of the abnormal bladder contractility and chronic pelvic pain is the chronic inflammation and as a consequence the treatment should target this etiological component. In fact, the traditional treatment of bladder dysfunctions, like overactive bladder, with smooth muscle relaxant agents, is not effective in patients with IC.
Presently a large number of therapies are used for this disease, which reflects that this is a condition without a truly effective treatment. For example, intravesical dimethyl sulphoxide (DMSO) has been the subject of extensive clinical investigation.
However, the mechanism of action is still unknown. The clinical results are not completely satisfactory and the route of administration (intravesical) is not ideal for the prolonged treatment often required in IC.
Some existing therapies are based on the concept of mucosal barrier protection, for example, use of the heparin analog pentosan polysulphate sodium (PPS). Again, the results are disappointing and on a long term basis, less than 20 % of patients show a beneficial effect from the administration of oral PPS.
Other approaches include the use of antihistamines, flavonoids and other agents that may decrease the action of proinflammatory agents mediated by mast cells. Such approaches have shown inconsistent and marginal effectiveness in several studies. A further approach, the use of intravesical BCG (Bacille Calmette Guerin) also failed to show symptom improvement in a controlled cross-over trial versus DMSO.
As a consequence, there is a clear need to identify novel pharmacological approaches targeting all the different immunological factors involved in the etiology of the disease.
As described herein, it has now surprisingly been found that vitamin D analogues can treat and prevent interstitial cystitis.
The importance of vitamin D (cholecalciferol) in the biological systems of higher animals has been recognized since its discovery by Mellanby in 1920 (Mellanby, E. (1921) Spec. Rep. Ser. Med. Res. Council (GB) SRS 61:4). It was in the interval of 1920-1930 that vitamin D officially became classified as a "vitamin" that was essential for the normal development of the skeleton and maintenance of calcium and phosphorous homeostasis.
Studies involving the metabolism of vitamin D3 were initiated with the discovery and chemical characterization of the plasma metabolite, 25-hydroxyvitamin D3 [25(OH)
Ds] (Blunt, JW. et al. (1968) Biochemistry 6:3317-3322) and the hormonally active form, 1-alpha,25(0OH).D; (Myrtle, J.F. et al. (1970) J. Biol. Chem. 245:1190-1196; Norman,
AW. etal. (1971) Science 173:51-54; Lawson, D.E.M. et al. (1971) Nature 230:228- 230; Holick, M.F. (1971) Proc. Natl. Acad. Sci. USA 68:803-804). The formulation of the concept of a vitamin D endocrine system was dependent both upon appreciation of the key role of the kidney in producing 1-alpha,25(0OH).Dj3 in a carefully regulated fashion (Fraser, D.R. and Kodicek, E (1970) Nature 288:764-766; Wong, R.G. et al. (1972) J.
Clin. Invest. 51:1287-1291), and the discovery of a nuclear receptor for 1- alpha, 25(0OH).D; (VD3R) in the intestine (Haussler, M.R. et al. (1969) Exp. Cell Res. 58:234-242; Tsai, H.C. and Norman, A.W. (1972) J. Biol. Chem. 248:5967-5975).
The operation of the vitamin D endocrine system depends on the following: first, on the presence of cytochrome P450 enzymes in the liver (Bergman, T. and Postlind, H. (1991) Biochem. J. 276:427-432; Ohyama, Y and Okuda, K. (1991) J. Biol. Chem.
266:8690-8695) and kidney (Henry, H.L. and Norman, A.W. (1974) J. Biol. Chem. 249:7529-7535; Gray, RW. and Ghazarian, J.G. (1989) Biochem. J. 259:561-568), and in a variety of other tissues to effect the conversion of vitamin D3 into biologically active metabolites such as 1-alpha,25(0H).Ds and 24R,25(0H).D3; second, on the existence of the plasma vitamin D binding protein (DBP) to effect the selective transport and delivery of these hydrophobic molecules to the various tissue components of the vitamin
D endocrine system (Van Baelen, H. etal. (1988) Ann NY Acad. Sci. 538:60-68;
Cooke, N.E. and Haddad, J.G. (1989) Endocr. Rev. 10:294-307; Bikle, D.D. et al. (1986) J. Clin. Endocrinol. Metab. 63:954-959); and third, upon the existence of stereoselective receptors in a wide variety of target tissues that interact with the agonist 1-alpha,25(0OH).D; to generate the requisite specific biological responses for this secosteroid hormone (Pike, J.W. (1991) Annu. Rev. Nutr. 11:188-216). To date, there is evidence that nuclear receptors for 1-alpha,25(OH),D3 (VD3R) exist in more than 30 tissues and cancer cell lines (Reichel, H. and Norman, A.W. (1989) Annu. Rev. Med. 40:71-78), including the normal biadder.
Vitamin Dj; and its hormonally active forms are well-known regulators of calcium and phosphorus homeostasis. These compounds are known to stimulate, at least one of, intestinal absorption of calcium and phosphate, mobilization of bane mineral, and retention of calcium in the kidneys. Furthermore, the discovery of the presence of specific vitamin D receptors in more than 30 tissues has led to the identification of vitamin D3 as a pluripotent regulator outside its classical role in calcium/bone homeostasis. A paracrine role for 1-alpha,25(OH). D3 has been suggested by the combined presence of enzymes capable of oxidizing vitamin Dj into its active forms, e.g., 25-OHD-1-alpha-hydroxylase, and specific receptors in several tissues such as bone, keratinocytes, placenta, and immune cells. Moreover, vitamin D3 hormone and active metabolites have been found to be capable of regulating cell proliferation and differentiation of both normal and malignant cells (Reichel, H. et al. (1989) Ann. Rev.
Med. 40: 71-78).
Given the activities of vitamin D3 and its metabolites, much attention has focused on the development of synthetic analogues of these compounds. A large number of these analogues involve structural modifications in the A ring, B ring, C/D rings, and, primarily, the side chain (Bouillon, R. et al. (1995) Endocrine Reviews 16(2):201-204).
Although a vast majority of the vitamin D; analogues developed to date involve structural modifications in the side chain, a few studies have reported the biological profile of A-ring diastereomers (Norman, A.W. et al. (1993) J. Biol. Chem. 268 (27). 20022-20030). Furthermore, biological esterification of steroids has been studied (Hochberg, R.B., (1998) Endocr Rev. 19(3): 331-348), and esters of vitamin D3 are known (WO 97/11053).
Moreover, despite much effort in developing synthetic analogues, clinical applications of vitamin D and its structural analogues have been limited by the undesired side effects elicited by these compounds after administration to a subject for known indications/applications of vitamin D compounds.
The activated form of vitamin D, vitamin D3, and some of its analogues have been described as potent regulators of cell growth and differentiation. It has previously been found that vitamin D3 as well as an analogue (analogue V), inhibited BPH cell proliferation and counteracted the mitogenic activity of potent growth factors for BPH cells, such as keratinocyte growth factor (KGF) and insulin-like growth factor (IGF 1).
Moreover, the analogue induced bcl-2 protein expression, intracellular calcium mobilization, and apoptosis in both unstimulated and KGF-stimulated BPH cells.
Thus the invention provides vitamin D compounds, and new methods of treatment using such compounds, for the prevention or treatment of interstitial cystitis.
Before further description of the present invention, and in order that the invention may be more readily understood, certain terms are first defined and collected here for convenience.
By “interstitial cystitis” (IC) it is meant a chronic, inflammatory disorder of the bladder characterized by variable degrees of urinary urgency, frequency and bladder pain. As described herein, the Inventor has shown that vitamin D3 analogues have applications in the treatment of both the inflammatory component of IC and the consequent bladder overactivity characterizing IC, which contribute to the symptoms of pain, urgency and frequency seen in IC patients. Some IC patients may experience pain as their main symptom with minimal frequency and urgency, whilst other patients may present with only frequency and urgency symptoms. IC patients may or may not experience the additional symptom of nocturia. Whilst pain is currently considered to be the most important characteristic symptom of IC, nocturia is not considered essential for the diagnosis of IC. lt is also believed that patients with normal frequency but with pain and urgency can also have IC. This indicates that IC patients can present with a wide range of symptomatic combinations. IC should be suspected in all patients who present with urinary discomfort, suprapubic pressure or heaviness or burning micturition with or without pain, in the absence of bacterial infection. IC is currently diagnosed on the basis of clinical features. The recommended tests include urinalysis, urine culture, cytology, urodynamics and cystoscopy under anesthesia with bladder distension.
The term "administration" or “administering” includes routes of introducing the vitamin D compound(s) to a subject to perform their intended function. Examples of routes of administration which can be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally, oral, inhalation, rectal, transdermal or via bladder instillation. The pharmaceutical preparations are, of course, given by forms suitable for each administration route. For example, these preparations are administered in tablets or capsule form, by injection, infusion, inhalation, lotion, ointment, suppository, etc. Oral administration is preferred. The injection can be bolus or can be continuous infusion. Depending on the route of administration, the vitamin D compound can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally effect its ability to perform its intended function. The vitamin D compound can be administered alone, or in conjunction with either another agent as described above, for example with a smooth muscle relaxant (such as alpha blockers or anti-muscarinic drugs) or with a pharmaceutically-acceptable carder, or both. The vitamin D compound can be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent. Furthermore, the vitamin D compound can also be administered in a pro-form which is converted into its active metabolite, or more active metabolite in vivo.
The term “effective amount” includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, i.e. sufficient to treat interstitial cystitis. An effective amount of vitamin D compound may vary according to factors such as the disease state, age and weight of the subject, and the ability of the vitamin D compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the vitamin D compound are outweighed by the therapeutically beneficial effects.
A therapeutically effective amount of vitamin D compound (i.e., an effective dosage) may range from about 0.001 to 30 ug/kg body weight, preferably about 0.01 to ug/kg body weight, more preferably about 0.1 to 20 ug/kg body weight, and even more preferably about 1 to 10 ug/kg, 2 to 9 ug/kg, 3 to 8 ug/kg, 4 to 7 ug/kg, or 510 6 ug/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. In addition, the dose administered will also depend on the particular Vitamin D compound used, the effective amount of each compounds can be determined by titration methods known in the art. Moreover, treatment of a subject with a therapeutically effective amount of a vitamin D compound can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with a vitamin D compound in the range of between about 0.1 to 20 ug/kg body weight, one time per day for a duration of six months or longer, for example for life depending on management of the symptoms and the evolution of the condition. Also, as with other chronic treatments an “on-off” or intermittent treatment regime can be considered. It will also be appreciated that the effective dosage of a vitamin D compound used for treatment may increase or decrease over the course of a particular treatment.
The term "alkyl" refers to the radical of saturated aliphatic groups, including straight-chain alky! groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen, sulfur or phosphorous atoms. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C4-
C3 for straight chain, C3-C3q for branched chain), preferably 26 or fewer, and more preferably 20 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, 6 or 7 carbons in the ring structure.
Moreover, the term alkyl as used throughout the specification and claims is intended to include both "unsubstituted alkyls” and "substituted alkyls," the iatter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkyithiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamide, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "alkylaryl" moiety is an alkyl substituted with an aryl (e.g., phenyimethy! (benzyl)). The term “alkyl” also includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six, and most preferably from one to four carbon atoms in its backbone structure, which may be straight or branched-chain. Examples of lower alkyl groups include methyl, ethyl, n-propyl, i-propyl, tert-butyl, hexyl, heptyl, octyl and so forth. Other examples of lower alkyl include sec-butyl, n-butyl and pentyl. In preferred - embodiment, the term "lower alkyl" includes a straight chain alky! having 4 or fewer carbon atoms in its backbone, e.g., C1-C4 alkyl.
Thus specific examples of alkyl include C1-6 alkyl or C1-4alkyl (such as methyl or ethyl). Specific examples of hydroxyalky! include C1-6hydroxyalkyl or C1-4hydroalky! (such as hydroxymethyl).
The terms "alkoxyalkyl," "polyaminoalkyl!” and "thioalkoxyalkyl" refer to alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
The term "aryl" as used herein, refers to the radical of aryl groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused aromatic groups such as naphthyl, quinolyl, indolyl, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles,” "heteroaryls" or "heteroaromatics.” The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl!, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, aryithio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).
The terms "alkenyl" and “alkynyl!” refer to unsaturated aliphatic groups analogueous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively. For example, the invention contemplates cyano and propargyl groups.
The term "chiral" refers to molecules which have the property of non- superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image pariner.
The term "diastereomers" refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.
The term “enantiomers” refers to two stereoisomers of a compound which are non-superimposable mirror images of one another. An equimolar mixture of two enantiomers is called a "racemic mixture" or a "racemate.”
As used herein, the term "halogen" designates -F, -Cl, -Br or -I; the term “sulfhydryl” or “thiol” means -SH; the term "hydroxyl" means -OH.
The term “haloalkyl” is intended to include alkyl groups as defined above that are mono-, di- or polysubstituted by halogen, e.g., C1-6haloalkyl or C1-4haloalkyl such as fluoromethyl and trifluoromethyl. CL
The term heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus. .
The terms "polycyclyl® or "polycyclic radical” refer to the radical of two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyis, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings.
Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyi, alkoxycarbonyl, aminocarbonyl, alkyithiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including atkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates,
sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, aikyl, alkylaryl, or an aromatic or heteroaromatic moiety.
The term "isomers" or "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.
The terms "isolated" or "substantially purified" are used interchangeably herein and refer to vitamin D3; compounds in a non-naturally occurring state. The compounds can be substantially free of cellular material or culture medium when naturally produced, or chemical precursors or other chemicals when chemically synthesized. In certain preferred embodiments, the terms "isolated" or "substantially purified” also refer to preparations of a chiral compound which substantially lack one of the enantiomers; i.e., enantiomerically enriched or non-racemic preparations of a molecule. Similarly, the terms "isolated epimers” or "isolated diastereomers” refer to preparations of chiral compounds which are substantially free of other stereochemical forms. For instance, isolated or substantially purified vitamin D3 compounds include synthetic or natural preparations of a vitamin D; enriched for the stereoisomers having a substituent attached to the chiral carbon at position 3 of the A-ring in an alpha-configuration, and thus substantially lacking other isomers having a beta-configuration. Unless otherwise specified, such terms refer to vitamin D3 compositions in which the ratio of alpha to beta forms is greater than 1:1 by weight. For instance, an isolated preparation of an a epimer means a preparation having greater than 50% by weight of the alpha-epimer relative to the beta sterecisomer, more preferably at least 75% by weight, and even more preferably at least 85% by weight. Of course the enrichment can be much greater than 85%, providing "substantially epimer-enriched" preparations, i.e., preparations of a compound which have greater than 90% of the alpha-epimer relative to the beta sterecisomer, and even more preferably greater than 95%. The term "substantially free of the beta stereoisomer” will be understood to have similar purity ranges.
As used herein, the term “vitamin D compound” includes any compound being an analogue of vitamin D that is capable of treating or preventing interstitial cystitis.
Generally, compounds which are ligands for the Vitamin D receptor (VDR ligands) and which are capable of treating or preventing interstitial cystitis are considered to be within the scope of the invention. Vitamin D compounds are preferably agonists of the vitamin
D receptor. Thus, vitamin D compounds are intended to include secosteroids.
Examples of specific vitamin D compounds suitable for use in the methods of the present invention are further described herein. A vitamin D compound includes vitamin
D2 compounds, vitamin D3 compounds, isomers thereof, or derivatives/analogues thereof. Preferred vitamin D compounds are vitamin D3 compounds which are ligands of (more preferably are agonists of) the vitamin D receptor. Preferably the vitamin D compound (e.g., the vitamin D3 compound) is a more potent agonist of the vitamin D receptor than the native ligand (i.e. the vitamin D, e.g., vitamin D3). Vitamin D1 compounds, vitamin D2 compounds and vitamin D3 compounds include, respectively, vitamin D1, D2, D3 and analogues thereof. In certain embodiments, the vitamin D compound may be a steroid, such as a secosteroid, e.g., calciol, calcidiol or calcitriol. ~ Non-limiting examples of vitamin D compounds in accordance with the invention include those described in U.S. Patent Nos. 6,017,908, 6,100,294, 6,030,962, 5,428028 and 6,121,312, published international applications WO 98/51633, WO 01/40177A3.
The term "secosteroid" is art-recognized and includes compounds in which one of the cyclopentanoperhydro- phenanthrene rings of the steroid ring structure is broken.
For example, 1-alpha,25(0OH).Ds and analogues thereof are hormonally active secosteroids. In the case of vitamin Ds, the 9-10 carbon-carbon bond of the B-ring is broken, generating a seco-B-steroid. The official IUPAC name for vitamin D3 is 9,10- secocholesta-5,7,10(19)-trien-3B-ol. For convenience, a 6-s-trans conformer of 1alpha,25(0H)2D; is illustrated herein having all carbon atoms numbered using standard steroid notation.
Lon un A “50 > OH @ 17 4
Se a 3 1 15 . 67 3 19 8 y 5 “Nou
In the formulas presented herein, the various substituents on ring A are illustrated as joined to the steroid nucleus by one of these notations: a dotted line (-—) indicating a substituent which is in the beta-orientation (i.e. , above the plane of the ring), a wedged solid line («) indicating a substituent which is in the alpha-orientation (i.e. , below the plane of the molecule), or a wavy line (~~ ) indicating that a substituent may be either above or below the plane of the ring. In regard toring A, it should be understood that the stereochemical convention in the vitamin D field is opposite from the general chemical field, wherein a dotted line indicates a substituent on Ring A which is in an alpha-orientation (i.e. , below the plane of the molecule), and a wedged solid line indicates a substituent on ring A which is in the beta-orientation (i.e. , above the plane of the ring).
Furthermore the indication of stereochemistry across a carbon-carbon double bond is also opposite from the general chemical field in that “Z” refers to what is often referred fo as a “cis” (same side) conformation whereas “E” refers to what is often referred to as a “trans” (opposite side) conformation. Regardless, both configurations, cis/trans and/or Z/E are contemplated for the compounds for use in the present invention.
As shown, the A ring of the hormone 1-alpha,25(0H).D3 contains two asymmetric centers at carbons 1 and 3, each one containing a hydroxyl group in well- characterized configurations, namely the 1-alpha- and 3-beta- hydroxy! groups. in other words, carbons 1 and 3 of the A ring are said to be "chiral carbons” or "carbon centers.”
With respect to the nomenclature of a chiral center, terms "d" and "I" configuration are as defined by the IUPAC Recommendations. As to the use of the terms, diastereomer, racemate, epimer and enantiomer will be used in their normal context to describe the stereochemistry of preparations.
Also, throughout the patent literature, the A ring of a vitamin D compound is often depicted in generic formulae as any one of the following structures:
ve
Ra" Ri (a) wherein X; and X. are defined as H or =CH;; or ue
Ry" Ri @) wherein X; and Xz are defined as Hor CHa.
Although there does not appear to be any set convention, it is clear that one of ordinary skill in the art understands either formula (A) or (B) to represent an A ring in which, for example, Xi is =CHzand X: is defined as H,, as follows:
Ry" 2 (©)
For purposes of the instant invention, formula (B) will be used in all generic structures.
Thus, in one aspect, the invention provides the use of a Vitamin D compound in the prevention or treatment of interstitial cystitis. Also provided is a method of treating a patient with interstitial cystitis by administering an effective amount of a Vitamin D compound. Further provided is the use of a Vitamin D compound in the manufacture of a medicament for the prevention or treatment of interstitial cystitis. Further provided is a vitamin D compound for use in the prevention and/or treatment of interstitial cystitis.
Also provided is a kit containing a vitamin D compound together with instructions directing administration of said compound to a patient in need of treatment and/or prevention of interstitial cystitis thereby to treat and/or prevent interstitial cystitis in said patient. Interstitial cystitis may, for example, be characterized by the presence of symptoms of bladder dysfunction and bladder inflammation.
The methods and uses of the invention may, in one embodiment of the invention, be methods and uses in treating females. In another embodiment they are methods and uses in treating males.
In one embodiment of the invention, the vitamin D compound is a compound of formula (1): wherein:
X is hydroxy! or fluoro;
Y is H, or CH;
Z1 and Z, are H or a substituent represented by formula (ll), provided Z; and Z; are different (preferably Zs and Z do not both represent formula (il)) :
R>
Ry, I... = an) wherein:
Z3 represents the above-described formula (1);
A is a single bond or a double bond;
R1, Ro, and Z4, are each, independently, hydrogen, alkyl, or a saturated or unsaturated carbon chain represented by formula (lll), provided that at least one of Ry, Ry, and Z, is the saturated or unsaturated carbon chain represented by formula (lil) and provided that all of R4, R2, and Z, are not saturated or unsaturated carbon chain represented by formula (Ill):
Rs
ALE
Zs
OH
Rs (1) wherein:
Zs represents the above-described formula (il);
A; is a single bond, a double bond, or a triple bond; and
A; is a single bond or a double bond; and
Rs, and Ry, are each, independently, hydrogen, alkyl, haloalkyl, hydroxyalkyl; and
Rs is Ha or oxygen. Rs may also represent hydrogen or may be absent.
Thus, in the above structure of formula (1lI) (and in corresponding structures below), when A, represents a triple bond Rs is absent. When A; represents a double bond Rs represents hydrogen. When A; represents a single bond Rs represents a carbonyl group or two hydrogen atoms.
In another embodiment of the invention, the vitamin D compound is a compound of formula (IV):
Ro IN
Ru, 0) Re
OH
Rs
Xa LX
HOY OH (Iv) wherein:
Xi and X; are Hz or CH», wherein X41 and X, are not CH, at the same time;
Ais a single or double bond;
A: is a single, double or triple bond;
As is a single or double bond;
R; and R; are hydrogen, C+-Cs alkyl or 4-hydroxy-4-methylpentyl, wherein R; and
R2 are not both hydrogen;
Rs is Hz or oxygen, Rs may also represent hydrogen or may be absent;
R; is C1-C4 alkyl, hydroxyalkyl or haloalkyl, eg., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; and
R, is C4-C, alkyl, hydroxyalkyl or haloalkyl, eg., fluoroalkyi, e.g., flucromethyl and trifluoromethyl. in yet another embodiment of the invention, the vitamin D compound is a compound of formula (V): . Re .
R, s
Ri, 2 Ra
OH
Rs
Xa X4
HOW OH v) wherein:
X4 and X; are Hz or CHa, wherein X4 and X; are not CH. at the same time; ‘ A is a single or double bond;
A; is a single, double or triple bond;
A; is a single or double bond;
R: and R; are hydrogen, Cs-C4 alkyl, wherein Rs and R; are not both hydrogen;
Rs is Hp or oxygen, Rs may also represent hydrogen or may be absent;
Ra is C4-C4 alkyl, hydroxyalkyl or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; and
R4 is C4-C4 alkyl, hydroxyalkyl! haloalkyl, e.g., or fluoroalkyl, e.g., fluoromethyl and trifluoromethyl.
An example of the above structure of formula (V) is 1,25-dihydroxy-16-ene-23-yne cholecalciferol.
In yet another embodiment, the vitamin D compound is a “geminal” compound of formula (Vi): 0 2 Ra
HO --H OH
Ra
Lx,
HOW OH (v1) wherein:
X4 is Hs or CHg;
Az is a single, a double or a triple bond;
Rj is C4-C, alkyl, hydroxyalkyl, or haloalkyl, e.g., fluoroalkyl, e.g., flucromethyl’ “ and trifluoromethyl;
R, is C1-Cs alkyl, hydroxyalkyl or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; and the configuration at Cy is Ror S.
Compounds of this type may be referred to as “geminal” or “gemini” vitamin D3 compounds due to the presence of two alkyl chains at C20.
An example geminal compound of formula (V1) is 1,25-dihydroxy-21-(3-hydroxy- 3-methylbutyl)-19-nor-cholecalciferol hereinafter referred to as “Compound I”:
HG, OH
CH,
H,C OH
CH,
CH,
I A
HO" OH “Compound I”
The synthesis of Compound | is described in W098/49138 and US6,030,962 which are herein incorporated in itheir entirety by reference.
In another embodiment, the vitamin D compound is a compound of formula (VII):
R2
Rs,
Rs
Rs OH
HOY X (vin) ‘wherein: -
A is a single or double bond;
R1 and R; are each, independently, hydrogen, alkyl (for example methyl);
Rs, and Ry, are each, independently, alkyl, and
X is hydroxyl or fluoro. in a further embodiment, the vitamin D compound is a compound having formula (VIII):
R2
Ri) 2
Ra : Rs OH
Ho X vin) wherein:
Rs and Ry, are each, independently, hydrogen, or alkyl, e.g., methyl;
R; is alkyl, e.g., methyl,
R, is alkyl, e.g., methyl; and
X is hydroxyl or fluoro. :
In specific embodiments of the invention, the vitamin D compound is selected from the group consisting of: ,, “,, FZ in, FZ CFa
OH OH CROH
HOW oH HON oH ET oH ’ on, n,, tn, CFa
OH OH CROH
Ho oH no OH , Ho OH ’ . CF3
OH OH ROH l
HOW oH °° no OH Ho OH on, HF CF3 n,, AF OH oH CFa
CF3
OH . OH . , HOV ‘OH FC | CF
Ho OH Fay OF ’ ’ : ,,, Po n,, =
Ho OH ,and HOW OH )
in other specific embodiments of the invention, the vitamin D compound is selected from the group consisting of: o o 0 1,, Ye,
OH -H OH OH not OH ’ Ho OH J Ho OH
[0] [o} (o] 1, mn, -H OH -H OH OH
HOW OH , Ho OH ,and HON F *
In further specific embodiments of the invention, the vitamin D compound is selected from the group of geminal compounds consisting of:
HO -H OH HO -H H
HOY OH , HOY OH ,
H CF;
HO -H OH HO “H £OH :
I y CF3 z CF3 l
HOV OH ’ Ho OH 3 and i CFs
HO OH
H cr
HOV ‘OH *
In still further specific embodiments of the invention, the vitamin D compound is a geminal compound of formula (IX):
Z
Ry A ~~
HO
--H OH
Ry Ry x4
HOW OH (1X) wherein:
Xi is Ha or CHa; .
A, is a single, a double or a triple bond;
Rs, Ro, Rs and Ry are each independently C+-C4 alkyl, hydroxyalkyl, or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl;
Z is -OH, Z may also be =0, -NH; or -SH; and the configuration at Cy is Ror §, and pharmaceutically acceptable esters, salts, and prodrugs thereof.
In a further embodiment, X; is CH,. In another embodiment, A; is a single bond. in another, Rs, Rz, Rs, and R4 are each independently methyl or ethyl. In a further embodiment, Z is OH. In another, X; is CHy; Az is a single bond; R,, Rz, Rj, and Rs are each independently methyl or ethyl; and Z is —OH. In an even further embodiment,
Ri, R2, R3, and Ry4 are each methyl. in a further embodiment of the invention, the vitamin D compound is a geminal compound of the formula:
Ho SH Ho oH $ H : ,
RlH OH S{oH OH
J H | w
HOY OH HO™ OH or . 33 50
The chemical names of compounds 2 and 3 mentioned above are 1,25-dihydroxy-21- (2R,3-dihydroxy-3-methyl-butyl)}-20R-cholecalciferol and 1,25-dihydroxy-21-(2R, 3- dihydroxy-3-methyl-butyl)-20S-cholecalciferol respectively.
Additional embodiments of geminal compounds include the following vitamin D compounds for use in accordance with the invention: oH
HO, H . [ eri \
RO' (+ (1,25-Dihydroxy-21-(2R,3-dihydroxy-3-methyl-butyl)-20S-1 9-nor-cholecalciferol),
HO, 7 ® no oH (1,25-Dihydroxy-20S-21-(3-hydroxy-3-methyl-butyf)-24-keto-1 9-nor-cholecaiciferol), 1)
Fi
HO ‘OH
(1 25-Dihydroxy-20S-21-(3-hydroxy-3-methyl-butyl)-24-keto-cholecalciferol),
FC. =
HO
FC oH CDs
L DC OH
IIH
HO" OH (1,25-Dihydroxy-21 (3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyi)-26,27-hexadeutero- 19-nor-20S-cholecalciferol) and
F3C — H —
HO
FC UH CD;
L DsC OH
I H
HO" OH (1,25-Dihydroxy-21 (3-hydroxy-3-trifluoromethyi-4-triflucro-butynyl)-26,27-hexadeutero- 20S-cholecalciferol).
In further embodiments of the invention, the vitamin D compound is a compound of formula (X):
R
Ra + Rs
OH
Rg
Xo X4 "TR 00 wherein:
X4 and X, are each independently H or =CHa, provided X4 and X4 are not both =CHo;
R; and Raare each independently, hydroxyl, OC(0)C+-C4 alkyl,
OC(O)hydroxyalkyl, OC(O)fluroralkyl;
R; and R, are each independently hydrogen, C4-C4 alkyl hydroxyalkyl or haloalkyl, or Rs and Rs taken together with Cz form C1-Cs cylcoalkyl; and
Rs and Rg are each independently C1-C4 alkyl and pharmaceutically acceptable esters, salts, and prodrugs thereof.
Suitably Rs and R4 are each independently hydrogen, C4-C. alkyl, or Rs and Rs taken together with Coo form C3-Cs cylcoalkyl.
In one example set of compounds Rs and Rg are each independently C1-C4 alkyl.
In another example set of compounds Rs and Rg are each independently haloalkyl e.g., C1-C4 fluoroatkyl.
When Rs and R; are taken together with C20 to form C3-Ce cycloalkyl, an example is cyclopropyl. in one embodiment, X; and X4 are each H,. In another embodiment, Rj is hydrogen and Ry is C4-C, alkyl. In a preferred embodiment Ry is methyl. ) In another embodiment, Rsand Rg are each independently methyl, ethyl fluoromethyl or trifluoromethyl. In a preferred embodiment, Rs and Rg are each methyl.
In yet another embodiment, R, and R, are each independently hydroxyl or
OC(0)C1-C4 alkyl. Ina preferred embodiment, Ry and Ry are each OC(O)C+-C4 alkyl. In another preferred embodiment, R; and Ry are each acetyloxy.
An example of such a compound is 1,3-O-diacetyl-1 ,25-dihydroxy-16-ene-24- keto-19-nor-cholecalciferol, having the following structure:
OQ .
OH
0
A. AN
In another embodiment of the invention the vitamin D compound for use in accordance with the invention is 2-methylene-19-nor-20(S)-1-alpha,25-hydroxyvitamin
D3:
HC OH
~ cH,
H,C
CH, a
HO" OH
CH,
The synthesis of this and related compounds is described in WO02/05823 and
US5,536,713 which are herein incorporated in their entirety by reference. in another embodiment of the invention, the vitamin D compound is a compound of the formula (XI):
R
R, S
Rs | >~_Fe
ORg 1 Ry
Xa X4
Re ~ Ry oil)
wherein:
A is single or double bond;
A; is a single, double or triple bond;
X4 and X2 are each independently H or =CHj, provided X4 and X; are not both =CHo;
R4 and R; are each independently OC(O)C4-C4 alky! (for example OAc),
OC(O)hydroxyalkyl, OROC(O)haloalkyl;
Rs, Rq and Rs are each independently hydrogen, C+-C4 alkyl, hydroxyalkyl, or haloalkyl, or R; and R4 taken together with Cao form Ca-Cs cycloalkyl; and
Rs and Ry are each independently Ci4alkyl or haloalkyl; and
Rs is H, -COC;-Caalkyl (e.g. Ac), -COhydroxyalkyl or -COhaloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.
When R; and Ry are taken together with C»o to form C3-Ce cycloalkyl an example is cyclopropyl.
Suitably Rs and Ry are each independently haloalkyl. Rg may suitably represent
H or Ac.
In one embodiment, A, is a single bond and A; is a single bond, E or Z double bond, or a triple bond. In another embodiment, A; is a double bond and A: is a single bond, E or Z double bond, or a triple bond. One of ordinary skill in the art will readily appreciate that when A; is a triple bond, Rs is absent
In one embodiment, X; and X; are each H. In another embodiment, X; is CH: and X; is H,. In another embodiment, R; is hydrogen and Ry is C1-C4 alkyl. In a preferred embodiment R, is methyi.
In another example set of compounds Rs and R; both represent OAc.
In one set of example compounds Rs and Rz are each independently Ci4alkyl.
In another set of example compounds Re and Ry are each independently haloalkyl. In another embodiment, Rs and Ry are each independently methyl, ethyl or fluoroalkyl. In a preferred embodiment, Rg and Rgare each trifluoroalkyl, e.g., trifluoromethyl.
Suitably Rs represents hydrogen.
Thus, in certain embodiments, vitamin D compounds for use in accordance with the invention are represented by formula (xm):
Rs
Ra
R e) Rg
ORs 1 R7
Xo X4
R Ry ) (XI) wherein:
A, is single or double bond;
A; is a single, double or triple bond,
X4 and X, are each independently H or =CHo,, provided Xs and X are not both =CHpy;
R, and R; are each independently OC(0)C4-Cs alkyl, OC(O)hydroxyalkyl, or
OC(O)haloalkyl;
Rs, Rs and Rs are each independently hydrogen, C1-C alkyl, hydroxyalkyl, or haloalkyl, or Rs and R; taken together with Cap form C3-Ce cycloalkyl;
Rs and Ry are each independently haloalkyl; and
Rs is H, C(O)C1-Ca alkyl, C(O)hydroxyalkyl, or C(O)haloalkyi; and pharmaceutically acceptable esters, salts, and prodrugs thereof.
An example compound of the above-described formula (XII) which is particularly preferred in the context of the present invention is 1,3-di-O-acetyl-1,25- dihydroxy-1 6,232-diene-26,27-hexafluoro-1 g-nor-cholecalciferol (“Compound A”):
OH
] F3C CF4 18
AcO™ OAC “Compound A” in another preferred embodiment the compound is one of formula (X11), wherein
Ry and Rp are each OA; A, is a double bond; A is a triple bond; and Rg is either H or
Ac: h — ~—\CF3
FC” Rg 1
OAc” OAc (xm
In certain embodiments of the above-represented formula (Xil), vitamin D compounds for use in accordance with the invention are represented by the formula (XIV): 2\ Re 1 <
Ry 8
H
ACO” .
OAc a)
Other example compounds of the above-described formula (XIV) include:
1,3-di-O-acetyl-1 ,25-dihydroxy-23-yne-cholecalciferol; 1,3-di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-cholecalciferol; 1,3-di-O-acetyl-1,25-dihydroxy-16,23E-diene-cholecalciferol; 1,3-di-O-acetyl-1,25-dihydroxy-16-ene-cholecalciferol; 1,3,25-Tri-O-acetyl-1,25-dihydroxy-1 6-ene-23-yne-26,27-hexafluoro-cholecalciferol: 1,3-di-O-acetyl-1,25-dihydroxy-1 6-ene-23-yne-26,27-hexafluoro-cholecalciferol; 1,3-Di-O-acetyl-1,25-dihydroxy-1 6,23E-diene-25R-26-trifluoro-cholecalciferol; 1,3-Di-O-acetyl-1,25-Dihydroxy-1 6-ene-23-yne-26,27-hexafiuoro-1 9-nor-cholecalciferol; 1,3,25-Tri-O-acetyl-1,25-Dihydroxy-1 6-ene-23-yne-26,27-hexafluoro-19-nor- cholecalciferol, 1,3-di-O-acetyl-1,25-dihydroxy-16-ene-19-nor-cholecalciferol (“Compound C”); 1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-1 9-nor-cholecaiciferol; 1,3-Di-O-acetyl-1,25-dihydroxy-16-ene-23-yne-26,27-bishomo-1 9-nor-cholecalciferol;
In certain other embodiments of the above-represented formula (XII), the vitamin D compounds for use in accordance with the invention are represented by the formula (XV): 1 ’ Som, a Ry
F
X2 | X4
AO” OAc 3 (XV)
Other example compounds of the above-described formula (XV) include: 1,3-Di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23-yne-19-nor-cholecalciferol: 1,3,25-tri-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23-yne-26,27-hexafluoro-19-nor- cholecalciferol; 1,3-di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23-yne-26,27-hexafluoro-19-nor- cholecalciferol; 1,3-di~-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23-yne-cholecalciferol;
1,3-di-O-acetyl-1,25-dihydroxy-20-cyclopropyl-23Z-ene-26,27-hexafl uoro-19-nor- cholecalciferol; 1,3-di-O-acety!-1 ,25-dihydroxy-20-cyclopropyi-cholecalciferol (“Compound F); 1,3-di-O-acetyl-1,25-dihydroxy-16-ene-20-cyciopropyl-1 g-nor-cholecalciferol; and 1,3-Di-O-acetyl-1,25-dinydroxy-1 6-ene-20-cyclopropyl-cholecalciferol.
A preferred compound of formula XV is 1,3-di-O-acetyl-1 ,25-dihydroxy-20-cyclopropyl- 23E-ene-26,27-hexafluoro-19-nor-cholecalciferol (“Compound E"): = \CF oH OH’
FiC
I +
AcO™ OAc
Compound E ] in a further embodiment, vitamin D compounds for use in the invention are compounds of the formula (XVI):
R2
Rs Rg i
Ry
IH x
HO Ry (XVI) wherein:
X is Hz or CHz
R; is hydrogen, hydroxy or fluorine
R; is hydrogen or methyl
R; is hydrogen or methyl. When R; or Rs is methyl, Rs or R2 must be hydrogen.
R. is methyl, ethyl or trifluoromethyl
Rs is methyl, ethyl or trifluoromethyl
Ais a single or double bond
B is a single, E-double, Z-double or triple bond.
In preferred compounds, each of Rs and Rsis methyl or ethyl, for example 1- aloha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholacalciferol (referred to as "Compound B” in examples, having the formula:
Z{~oH
I
F
HO" F “Compound B"
Such compounds are described in US 5,939,408 and EP808833, the contents of which are herein incorporated by reference in their entirety. The invention also embraces use of esters and salts of Compound B. Esters include pharmaceutically acceptable labile esters that may be hydrolysed in the body to release Compound B. Salts of Compound
B include adducts and complexes that may be formed with alkali and alkaline earth metal ions and metal ion salts such as sodium, potassium and calcium ions and salts thereof such as calcium chloride, calcium malonate and the like. However, although
Compound B may be administered as a pharmaceutically acceptable salt or ester thereof, preferably Compound B is employed as is i.e., it is not employed as an ester or a salt thereof.
Other preferred vitamin D compounds for use in accordance with the invention included those having formula (XVII):
Rs
OH
R4
X X4
HOY OH (XVI) wherein:
B is single, double, or triple bond;
X1 and Xo are each independently Hz or CHa, provided Xi and X; are not both
CHa; and
R, and Rs are each independently alkyl or haloalkyl.
Compounds of formula (XVii) including the following: 1,25-Dihydroxy-16-ene-23-yne-20-cyclopyl-cholecalciferoi:
SH
H OH
Hw aN
HO" OH 1,25-Dihydroxy-16-ene-23-yne-20-cyclopropyl-1 9-nor-cholecalciferol:
SH
H OH
H
Ho™ OH
1,25-Dihydroxy-1 6-ene-20-cyclopropyl-23-yne-26,27-hexafiuoro-1 9-nor-cholecalciferol:
N\
CF; i rH
Ho" OH 1,25-Dihydroxy-16-ene-20-cyclopropyl-23-yne-26,27-hexafl uoro-cholecalciferol:
BAN
CF;
IK: FH
Ho" OH 1,25-Dihydroxy-16,23E-diene-20-cyclopropyl-26,27-hexafluoro-19-nor-cholecalciferol:
CF; x FC OH #
Ho OH 1,25-Dihydroxy-16,23E-~diene-20-cyclopropyl-26,27-hexafiuoro-cholecalciferol:
Nem 3 FG OH «
Ho" oH 1,25-Dihydroxy-1 6,232-diene-20-cyclopropyl-26,27-hexafiuoro-1 9-nor-cholecalciferol:
FC, OH
CF3
I’ wo” H 1,25-Dihydroxy-1 6,232-diene-20-cyclopropyl-26,27-hexafluoro-cholecalciferol:
Fl OH : CF3 :
Ho" OH 1,25-Dihydroxy-1 6-ene-20-cyclopropyl-1 g-nor-cholecalciferol:
2 H
I
Ho OH 1,25-Dihydroxy-1 6-ene-20-cyclopropyl-cholecalciferol (“Compound H): 2 OH i
Ho 'OH
Another vitamin D compound of the invention is 1,25-dihydroxy-21(3-hydroxy-3- trifluoromethyl-4-trifluoro-butynyl)-26,27-hexadeutero-19-nor-20S-cholecalciferol.
The use of compounds having the structures given above is extended to pharmaceutically acceptable esters, salts, and prodrugs thereof.
A vitamin D compound of particular interest is calcitriol.
Other example compounds of use in the invention which are vitamin D receptor agonists include paricalcitol (ZEMPLAR™) (see US Patent 5,587 ,497), tacalcitol (BONALFA™) (see US Patent 4,022,891), doxercalciferol (HECTOROL™) (see Lam et al. (1974) Science 186, 1038), maxacalcitol (OXAROL™) (see US Patent 4,891,364), calcipotriol (DAIVONEX™) (see US Patent 4,866,048), and falecalcitriol (FULSTAN™).
Other compounds include ecalcidene, calcithiazol and tisocalcitate.
Other compounds include atocalcitol, lexacalcitol and seocalcitol.
Another compound of possible interest is secalciferol (“OSTEO D").
Other non-limiting examples of vitamin D compounds that may be of use in accordance with the invention include those described in published international applications: WO 01/40177, WO0010548, WO0061776, WO0084869, WO0064870,
WO0066548, WO0104089, WO0116099, WO0130751, WO00140177, WO0151464, :
WO0156982, WO0162723, WO0174765, WO0174766, WO01 79166, WO0190061,
WO0192224, WO0196293, WO020686424, W0O0212182, WO021 4268, WO03004036,
WO003027065, WO03055854, WO03088977, WO04037781, wWO004067504,
WOB000339, WO8500819, WO8505622, WOB602078, W0O8604333, WO08700834,
WO08910351, WO9009991, WO9009992, WO9010620, WO9100271, wW09100855,
WO09109841, WO9112239, WO9112240, W09115475, W0O92034 14, WQ093090093,
WO9319044, WO9401398, WO9407851, WO9407852, WO9408958, WO09410139,
WO09414766, W09502577, WO9503273, WO8512575, W09527697, WO961 6035,
WO9616036, WO9622973, WO9711053, WO9720811, WO9737972, WO9746522,
WO9818759, WO9824762, WO9828266, WO9841500, WO9841501, WO98491 38,
WO09851663, WO9851664, WO9851678, WO9903829, W09912894, WOS91 5499,
W09918070, WO9943645, W09952863, those described in U.S. Patent Nos.:
US3856780, US3994878, US4021423, US4026882, US4028349, US4225525,
US4613594, US4804502, US4898855, US5039671, US5087618, US5145848,
US5247123, US5342833, US5428029, US5451574, US5612328, US5747479,
US5804574, US5811414, US5856317, US5872113, US5888994, US5939408,
US5962707, US5981780, US6017908, US6030962, US6040461, US6100294,
US6121312 , US6329538, US6331642, US6392071, US6452028, US6479538,
US6492353, US6537981, US6544969, US6559138, US6667298, US6683219,
US6696431, US6774251, and those described in published US Patent Applications:
US2001007907, US2003083319, US2003125309, US2003130241, US2003171605,
US2004167105.
it will be noted that the structures of some of the compounds of the invention include asymmetric carbon atoms. Accordingly, itis to be understood that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included . within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and/or by stereochemically controlled synthesis.
Naturally occurring or synthetic isomers can be separated in several ways known in the art. Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., "Chiral Liquid
Chromatography,” W.J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers . can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers.
For the separation of enantiomers of carboxylic acids, the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts.
The invention also provides a pharmaceutical composition, comprising an effective amount of a vitamin D compound as described herein and a pharmaceutically acceptable carrier. In a further embodiment, the effective amount is effective to treat interstitial cystitis, as described previously.
In an embodiment, the vitamin D compound is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the vitamin D compound to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.
In certain embodiments, these pharmaceutical compositions are suitable for topical or oral administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension, (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound.
The phrase "pharmaceutically acceptable” refers to those vitamin D compounds of the present invention, compositions containing such compounds, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The phrase "pharmaceutically-acceptable carrier" includes pharmaceutically- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oll, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
Compositions containing a vitamin D compound(s) include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
Methods of preparing these compositions include the step of bringing into association a vitamin D compound(s) with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a vitamin D compound with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
Compositions of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a vitamin D compound(s) as an active ingredient. A compound may also be administered as a bolus, electuary or paste.
In solid dosage forms of the invention for oral administration (capsules, tablets, i pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylceliulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be ] employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropyimethyl cellulose), lubricant, inert diluent, preservative,
disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.
The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethy! cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms for oral administration of the vitamin D compound(s) include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3- butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
in addition to inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
Suspensions, in addition to the active vitamin D compound(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
Pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more vitamin D compound(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
Compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
Dosage forms for the topical or transdermal administration of a vitamin D compound(s) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active vitamin D compound(s) may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
The ointments, pastes, creams and gels may contain, in addition to vitamin D compound(s) of the present invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, fragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to a vitamin D compound(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain a4 customary propellants, such as chiorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
The vitamin D compound(s) can be alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A nonaqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are preferred because they minimize exposing the agent to shear, which can result in degradation of the compound.
Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically-acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions.
Transdermal patches have the added advantage of providing controlled delivery of a vitamin D compound(s) to the body. Such dosage forms can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used io increase the flux of the active ingredient across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active ingredient in a polymer matrix or gel.
Pharmaceutical compositions of the invention suitable for parenteral administration comprise one or mare vitamin D compound(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols
(such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chiorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. in some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in tum, may depend upon crystal size and crystalline form.
Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of vitamin
D compound(s) in biodegradable polymers such as polylactide-polyglycolide.
Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
When the vitamin D compound(s) are administered as pharmaceuticals, to humans and animals, they can be given per se oras a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically-acceptable carrier.
Regardless of the route of administration selected, the vitamin D compound(s), which may be used in a suitable hydrated form, andlor the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of the invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. An exemplary dose range is from 0.1 to 300 pg per day
A preferred dose of the vitamin D compound for the present invention is the maximum that a patient can tolerate and not develop hypercalcemia. Preferably, the vitamin D compound of the present invention is administered at a concentration of about 0.001 ug to about 100 ug per kilogram of body weight, about 0.001 — about 10 ug/kg or about 0.001 ug — about 100 ug/kg of body weight. Ranges intermediate to the above- recited values are also intended to be part of the invention.
The vitamin D compound may be administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations with a second medicament for the treatment of interstitial cystitis.
Synthesis of Compounds of the Invention
A number of the compounds of the present invention can be prepared by incubation of vitamin D3 analogues in cells, for example, incubation of vitamin Ds analogues in either UMR 106 cells or Ros 17/2.8 cells results in production of vitamin Dj compounds of the invention. For example, Incubation of 1,25-dihydroxy-16-ene-5,6- trans-calcitriol in UMR 106 cells results in production of the 1,25-dihydroxy-16-ene-24- oxo-5,6-trans-calcitriol.
In addition to the methods described herein, compounds of the present invention : can be prepared using a variety of synthetic methods. For example, one skilled in the art would be able to use methods for synthesizing existing vitamin Ds compounds to prepare compounds of the invention (see e.g., Bouillon, R. et al., (1995) Endocrine
Reviews 16(2):201-204; lkekawa N. (1987) Med. Res. Rev. 7:333-366; DeLuca H.F. and Ostrem V.K. (1988) Prog. Clin. Biol. Res. 259:41-55; lkekawa N. and Ishizuka S. (1992) CRC Press 8:293-316; Calverley M.J. and Jones G. (1992) Academic Press 193-270; Pardo R. and Santelli M. (1985) Bull. Soc. Chim. Fr:98-114; Bythgoe B. (1980)
Chem. Soc. Rev. 449-475; Quinkert G. (1985) Synform 3:41-122; Quinkert G. (1986)
Synform 4:131-256; Quinkert G. (1987) Synform 5:1-85; Mathieu C. et al. (1 994)
Diabetologia 37:552-558; Dai H. and Posner G.H. (1994) Synthesis 1383-1398);
DeLuca et al., WO 97/11053.
Exemplary methods of synthesis include the photochemical ring opening of a 1- hydroxylated side chain-modified derivative of 7-dehydrocholesterol which initially produces a previtamin that is easily thermolyzed to vitamin D3 in a well known fashion (Barton D.H.R. et al. (1973) J. Am. Chem. Soc. 05:2748-2749; Barton D.H.R. (1974)
JCS Chem. Comm. 203-204); phosphine oxide coupling method developed by (Lythgoe et al ( 1978) JCS Perkin Trans. 1:590-595) which comprises coupling a phosphine oxide to a Grundmann's ketone derivative to directly produce a 1-alpha,25(0H).D3 skeleton as described in Baggiolini E.G., et al. (1 986) J. Org. Chem. 51:3098-31 08; DeSchrijver
J. and DeClercq P.J. (1993) Tetrahed Lett 34:4369-4372; Posner G.H and Kinter C.M. (1990) J. Org. Chem. 55:3067-3969; semihydrogenation of dienynes to a previtamin structure that undergoes rearrangement to the corresponding vitamin D3 analogue as described by Harrison R.G. et al. (1974) JCS Perkin Trans. 1:2654-2657; Castedo L. et al. (1988) Tetrahed Lett 29:1203-1206; Mascarenas J.S. (1991) Tetrahedron 47:3485- 3498; Barrack S.A. et al. (1988) J. Org. Chem. 53:1790-1796) and Okamura W.H. et al. (1989) J. Org. Chem. 54:4072-4083; the vinylallene approach involving intermediates that are subsequently arranged using heat or a combination of metal catalyzed isomerization followed by sensitized photoisomerization (Okamura W.H. et al. (1989) J.
Org. Chem. 54:4072-4083; Van Alstyne E.M. et al. (1 994) J. Am. Chem. Soc.116:6207- 6210); the method described by Trost et al. B.M. et al. J. Am. Chem. Soc. 114:9836- 9845; Nagasawa K. et al. (1991) Tetrahed Lett 32:4937-4940 involves an acyclic A-ring precursor which is intramolecular cross-coupled to the bromoenyne leading directly to the formation of 1,25(OH),D3 skeleton; a tosylated derivative which is isomerized to the i-steroid that can be modified at carbon-1 and then subsequently back-isomerized under sovolytic conditions to form 1-alpha,25(0OH).D2 or analogues thereof (Sheves M. and
Mazur Y. (1974) J. Am. Chem. Soc. 07:6249-6250; Paaren H.E. et al. (1 980) J. Org.
Chem. 45:3253-3258; Kabat M. et al. (1991) Tetrahed Lett 32:2343-2346; Wilson S.R. et al. (1991) Tetrahed Lett 32:2339-2342); the direct modification of vitamin D derivatives to 1-oxygenated 5, 6-trans vitamin D as described in (Andrews D.R. et al. (1986) J. Org. Chem. 51:1635-1637); the Diels-Alders cycloadduct method of previtamin
Ds can be used to cyclorevert to 1-alpha,25(0OH)2D. through the intermediary of a previtamin form via thermal isomerization (Vanmaele L. ef al. (1985) Tetrahedron 41:141-144); and, a final method entails the direct modification of 1-alpha,25(0OH)2D; or an analogue through use of suitable protecting groups such as transition metal derivatives or by other chemical transformations (Okarmura W.H. et al. (1 992) J. Cell
Biochem. 49:10-18). Additional methods for synthesizing vitamins D2 compounds are described in, for example, Japanese Patent Disclosures Nos. 62750/73, 26858/76, 26859/76, and 71456/77; U.S. Pat. Nos. 3,639,596; 3,715,374; 3,847,955 and 3,739,001.
Examples of the compounds of this invention having a saturated side chain can be prepared according to the general process illustrated and described in U.S. Patent
No. 4,927,815. Examples of compounds of the invention having an unsaturated side chain can be prepared according to the general process illustrated and described in
U.S. Patent No. 4,847,012. Examples of compounds of the invention wherein R groups together represent a cycloalkyl group can be prepared according to the general process illustrated and described in U.S. Patent No. 4,851,401.
Another synthetic strategy for the preparation of side-chain-modified analogues of 1-alpha,25-dihydroxyergocaliciferol is disclosed in Kutner et al., The Journal of
Organic Chemistry, 1988, 53:3450-3457. In addition, the preparation of 24-homo and 26-homo vitamin D analogues are disclosed in U.S. Patent No. 4,717,721.
The enantioselective synthesis of chiral molecules is now state of the art.
Through combinations of enantioselective synthesis and purification techniques, many chiral molecules can be synthesized as an enantiomerically enriched preparation. For example, methods have been reported for the enantioselective synthesis of A-ring diastereomers of 1-alpha,25(0H).Ds as described in Muralidharan ef al. (1993) J.
Organic Chem. 58(7): 1895-1 899 and Norman et al. (1993) J. Biol. Chem. 268(27). 20022-30. Other methods for the enantiomeric synthesis of various compounds known in the art include, inter alia, epoxides (see, e.g. Johnson, R.A; Sharpless, K.B. In
Catalytic Asymmetric Synthesis, Ojima, I., Ed.: VCH: New York, 1993; Chapter 4.1.
Jacobsen, E.N. Ibid. Chapter 4.2), diols (e.g., by the method of Sharpless, J. Org.
Chem. (1992) 57:2768), and alcohols (e.g., by reduction of ketones, E.J.Corey et al., J.
Am. Chem. Soc. (1987) 109:5551). Other reactions useful for generating optically enriched products include hydrogenation of olefins (e.g., M. Kitamura et al., J. Org.
Chem. (1988) 53:708); Diels-Alder reactions (e.g., K. Narasaka et al., J. Am. Chem.
Soc. (1989) 111:5340); aldol reactions and alkylation of enolates (see, €.g., D.A. Evans et al., J::Am. Chem. Soc. (1981) 103:2127; D.A. Evans et al., J. Am. Chem. Soc. (1982) 104:1737); carbonyl additions (e.g., R. Noyori, Angew. Chem. Int. Ed. Eng. (1991) 30:49); and ring-opening of meso-epoxides (e.g., Martinez, L.E.; Leighton J.L., Carsten,
D.H.; Jacobsen, E.N. J. Am. Chem. Soc. (1995) 117:5897-5898). The use of enzymes to produce optically enriched products is also well known in the art (e.g., M.P. Scheider, ed. "Enzymes as Catalysts in Organic Synthesis”, D. Reidel, Dordrecht (1986).
Chiral synthesis can result in products of high stereoisomer purity. However, in some cases, the stereoisomer purity of the product is not sufficiently high. The skilled artisan will appreciate that the separation methods described herein can be used to further enhance the stereoisomer purity of the vitamin Ds-epimer obtained by chiral synthesis.
Compounds of formula (XVI):
Re 0]
Ral Rg
OH
Rg
Xa X4
Rj Ry (XVII) :
wherein:
X1 and X; are each independently Hz or =CHb,, provided X; and X, are not both =CHoa;
R, and Rp are each independently, hydroxyl, OC(O)C1+-Ca alkyl,
OC(O)hydroxyalkyl, OC(O)fiuroralkyl, provided that R; and Rp are not both hydroxyl;
Rj; and Ry are each independently hydrogen, C-C4 alkyl, or Rs and R, taken together with Cao form C3-Ce cycloalkyl; and
Rs and Rg are each independently C1-Ca alkyl, hydroxyalkyl, or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof, can be synthesized by methods described in this section, and the chemical literature. in particular, compounds of formula (XVII) of the invention are prepared as shown in
Scheme 1 below. Accordingly, compounds of formula (XVII) are prepared by coupling compounds of formula (X1X) with compounds of formula (XX) in tetrahydrofuran with n- butyllithium as a base to give compounds of formula (XXI). Subsequent removal of the protecting silyl groups (R1 = OSi(CH;).t.Bu) affords the 1,3 dihydroxy vitamin D3 compound of formula (XVIif) (Ry = OH, R, = OH). Acylation at the 1 and/or 3 positions is achieved using methods well-known in the art. For example, preparation of the 1,3 diacetoxy compounds of formula IV (R1=R2 = OAc) requires additional acetylation with acetic anhydride and pyridine, as shown in Scheme 2 and described below.
Referring to Scheme 1, compounds of formula (XX) are known compounds, and are prepared starting from the known epoxy-ketone of formula (XXII). The compound of formula (XXII) is converted to the epoxy-olefin of formula (XXII) by a Wittig reaction.
Reduction with LiAlH, to the compound (XXIV) and protection of the hydroxy group resulted in compound (XXV). Then, the ene reaction of forumula (XXV) with the known hydroxy-conjugated ketone (XXVI) (Rs = Re = CH3) in tetrahydrofuran, in the presence of Lewis acid (CHa). Al Cl, provides the compound (XXVI) featuring the C,D-rings and full side chain of the target vitamin D analogs. Finally, removal of the silyl group and oxidation provides the key intermediate, Ketone of formula (XX).
Scheme 1
Ra Fs 0
Rony + PEBr TT
XX | XX
Rags Rin Rs (¢}
Ros, AF + -—
HO
Rg .y MA OH
XXIV
[o] (o]
Ret Re Ret Ry
R, OH oo ’, OH t-Bu(CHy,),SI0 OH xxvii / XXVIII
R,
Ry Ry ° xx
Scheme 2 shows the coupling of compound (XX) with a silylated phosphine oxide under
Witting coupling conditions. Removal of the silyl protecting group provides diols of formula (XVIII), where Rs and R? are both hydroxyl.
Scheme 2
R lo]
PRP =0 R, ) 4 Rg
Re OH x X + +BU(CH,),SIO R, yd 0 yx
XIX
R 0)
Tt Ryn Re
Ry Ry OH
OH Rs
A Ry
SE
“i x, X, . x, X XVI tBu(CH,),Si0 r, XX i M wherein Xi, Xa, Ra, R4, Rs and Rg are as defined above.
Scheme 3 demonstrates the acetylation of the the vitamin Ds derivatives of formula (P) to the acetates of formula (Q).
Scheme 3
Re 0
R4 e Raa, Rs
Ra, Rs OH
OH
6 — 0 0
He oN
OH” OH
A _ g } g 1,3-O-diacetyl-1,25-dihydroxy-16- 1.25 dihydroy » 1G-an 24k eto-19-nor ene-24-keto-19-nor-cholecalcifero! (P) ©
Vitamin D3 compounds of the formula:
Rs a r Rg
ORs 1 R7
Xa | X4 : R2 Ry wherein: ~
A, is single or double bond;
A, is a single, double or triple bond;
X; and Xe are each independently H or =CHj,
R, and R; are each independently OC(0)C1-C4 alkyl, OC(O)hydroxyalkyl, or
OROC(O)haloalkyi;
Rs, Rs and Rs are each independently hydrogen, C1-C4 alkyl, hydroxyalkyl, or haloalkyl, or Rs and Ry taken together with C20 form C3-C6 cycloalkyl;
Rs and R;7 are each independently haloalkyl; and
Rg is H or OC(O)C1-C4 alkyl, OC(O)hydroxyalkyl, or OROC(O)haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. may be prepared analogously to the synthesis of 1,3-Di-O-acetyl-1 ,25-dihydroxy- 16,23Z-diene-26,27-hexafluoro-1 o-nor-cholecalciferol (1) (“Compound A” in the following examples), which is carried out under standard acetylation conditions of the diol to the corresponding diacetate:
OH h oo oF . FiC Pe, ] #
J— [| H ll
HO" OH
AcO” OAC 1 .
The present invention will now be described with reference to the following non- limiting examples, with reference to the figures, in which:
Figure 1 shows a comparison between cystometric parameters recorded in rats treated with a vitamin D3 analogue “Compound A” and control (vehicle treated) rats. ~
Figure 2 shows the effect of a vitamin D3 analogue Compound A (A-E) versus vehicle (miglyol) (F-L) on the histological signs of inflammation in rat bladders. Five different parameters were considered: hemostasis (A,F), edema (B,G), infiltration (C,H), fibrosis (D.1), urothelial damage (E,L). Arrows and bars indicate the signs of inflammation present in the vehicle treated animal versus Compound A treated rats. U= urothelium.
Figure 3 shows a histogram summarizing the histological score of 4 rats per group for each sign of inflammation. Different inflammatory parameters were considered: hemostasis, edema, infiltration of inflammatory cells (mostly lymphocyte and monocyte), epithelial erosion, fibrosis and scored as described in Example 2. The mean of histological scores + standard deviation was plotted.
Figure 4 shows the number of non-voiding bladder contractions experienced by subjects from Example 5. The average number of contractions are shown for each treatment group (vehicle control, 30 ug/kg Compound B and 75 ug/kg Compound B) with error bars indicating the standard deviation.
Figure 5 shows the bladder capacity of subjects from Example 5. The average bladder capacity (ml) is shown for each treatment group (vehicle control, 30 ug/kg Compound B and 75 ug/kg Compound B) with error bars indicating the standard deviation.
Figure 6 shows the serum calcium levels of subjects from Example 5. The calcium levels in serum are shown (mg/dL) for each subject in the treatment groups (vehicle control, 30 ug/kg Compound B and 75 ug/kg Compound B) with the average level in each group indicated by a horizontal line.
Figure 7 illustrates the experimental timeline for Example 6.
Figure 8 shows the total amount of IgE protein detected in serum of subjects from
Example 6. The average total amount of IgE (ug/ml) is shown for each group (pre challenge, vehicle treated control, 75 ug/kg Compound B treated) with error bars indicating the standard deviation.
Figure 9 shows the amount of ovalbumin specific IgE protein detected in serum of subjects from Example 6. The average amount of specific IgE protein in serum (ODA450) is shown for each group (pre challenge, vehicle treated control, 75 ug/kg
Compound B treated) with error bars indicating the standard deviation.
Figure 10 shows the serum MMCP1 protein levels in subjects from Example 6. The average level of serum MMCP1 protein (ug/ml) is shown for each group (pre challenge, vehicle treated control, 75 ug/kg Compound B treated) with error bars indicating the standard deviation. This data is overlaid with the individual values derived from each subject.
Figure 11 shows the serum calcium levels of subjects from Example 6. The calcium levels in serum are shown (mg/dL) for each subject in the treatment groups (vehicle control and 75 ug/kg Compound B) with the average level in each group indicated by a horizontal line. An extended dashed horizontal line indicates the level at which calcium toxicity begins to arise.
Figure 12 shows the variation in body weight of subjects from Example 6. The average body weight is shown (g) at daily timepoints for both treatment groups (vehicle control and 75 ug/kg Compound BY), error bars indicate the standard deviation.
Figure 13 shows the mRNA expression levels of the inflammatory marker genes IL-13,
MCPT2 and FceR1a in subjects from Example 6. Data shows the level of each marker relative to the housekeeping gene for saline challenged (vehicle treated) and ovalbumin challenged (vehicle, 30 ug/kg Compound B and 75 ug/kg Compound B treated).
Figure 14 shows the mRNA expression levels levels of the inflammatory marker genes
IL-13, MMCP4 and FceR1a in subjects from Example 6. The plot shows the level of each marker relative to the housekeeping gene for ovalbumin challenged treatment groups (vehicle or 75 ug/kg Compound B). The individual data points from subjects are plotted, with a horizontal line indicating the average level.
Figure 15 shows the results of histological analysis (Mast cell infiltration, Edema,
Eosinophils and Lymphomono-plasma cells) performed on subjects from Example 6.
The plots show the score allocated to each subject, with the average level for each treatment group (vehicle or 75 ug/kg Compound B) indicated by a horizontal line.
Figure 16 shows representative sections of bladder (x 50 magnification) from vehicle and 75 ug/kg Compound B treated animals. Histological lesions are indicated with arrows.
Figure 17 shows a summary of the experimental results from Example 7.
Figure 18 shows the mRNA expression level of the inflammatory marker gene FceR1a in subjects from Example 7. The plot shows the level of FceR1a relative to the housekeeping gene for saline challenged, untreated and ovalbumin challenged treatment groups (vehicle, Compound C to Compound | treated). The individual data points from subjects are plotted, with a horizontal line indicating the average level.
Figure 19 shows the mRNA expression level of the inflammatory marker gene I1L-13 in subjects from Example 7. The plot shows the level of IL-13 relative to the housekeeping gene for saline challenged, untreated and ovalbumin challenged treatment groups (vehicle, Compound C to Compound | treated). The individual data points from subjects are plotted, with a horizontal line indicating the average level.
Figure 20 shows the mRNA expression level of the inflammatory marker gene MMCP4 in subjects from Example 7. The plot shows the level of MMPCA4 relative to the housekeeping gene for saline challenged, untreated and ovalbumin challenged treatment groups (vehicle, Compound C to Compound 1 treated). The individual data points from subjects are plotted, with a horizontal fine indicating the average level.
Figure 21 shows the serum MMCP1 protein levels in subjects from Example 7. The plot shows the level of MMCP1 protein (ng/mt) in serum for pre-challenge, saline challenged, untreated and ovalbumin challenged treatment groups (vehicle, Compound
C to Compound | treated). The individual data points from subjects are plotted, with a horizontal line indicating the average level
Figure 22 shows the results of histological analysis of mast cell infiltration performed on subjects from Example 7. The plot shows the score allocated to each subject, with the average level for each treatment group (vehicle, Compound C, Compound E,
Compound F, Compound H or Compound |) indicated by a horizontal line.
Figure 23 shows the results of histological analysis of eosinophils performed on subjects from Example 7. The plot shows the score allocated to each subject, with the average level for each treatment group (vehicle, Compound C, Compound E,
Compound F, Compound H or Compound |) indicated by a horizontal line.
Figure 24 shows the results of histological analysis of LMPC performed on subjects from Example 7. The plot shows the score allocated to each subject, with the average level for each treatment group (vehicle, Compound C, Compound E, Compound F,
Compound H or Compound l) indicated by a horizontal line.
Figure 25 shows the results of histological analysis of edema performed on subjects from Example 7. The plot shows the score allocated to each subject, with the average level for each treatment group (vehicle, Compound C, Compound E or Compound F) indicated by a horizontal line.
Figure 26 shows the calcium concentration in serum of subjects from Example 7. The serum calcium concentrations are shown (mg/dL) for each subject in the treatment groups (vehicle control, Compounds C to I) with the average level in each group indicated by a horizontal line.
SYNTHETIC EXAMPLES
All operations involving vitamin D3 analogs were conducted in amber-colored glassware in a nitrogen atmosphere. Tetrahydrofuran was distilled from sodium- benzophenone ketyl just prior to its use and solutions of solutes were dried with sodium sulfate. Melting points were determined on a Thomas-Hoover capillary apparatus and are uncorrected. Optical rotations were measured at 25 °C. 'H NMR spectra were recorded at 400 MHz in CDCl3 unless indicated otherwise. TLC was carried out on silica gel plates (Merck PF-254) with visualization under short-wavelength UV light or by spraying the plates with 10% phosphomolybdic acid in methanol followed by heating.
Flash chromatography was carried out on 40-65 um mesh silica gel. Preparative HPLC was performed on a 5x50 cm column and 15-30 um mesh silica gel at a flow rate of 100 ml/min.
Synthetic Example 1 - Synthesis of 1,3-Di-O-acetyl-1,25-dihydroxy-16,23Z-diene- 26,27-hexafluoro-19-nor-cholecalciferol (1) (Compound A) & — J =
HO OH
ACY OAc 1
The starting material 1,25-dihydroxy-1 6,23Z-diene-26,27-hexafluoro-19-nor- cholecalciferol can be prepared as described in US Patent 5,428,029 to Doran et al.. 3 mg of 1,25-dihydroxy-1 6,23Z~diene-26,27-hexafluoro-1 9-nor-cholecalciferol was dissolved in 0.8 ml of pyridine, cooled to ice-bath temperature and 0.2 ml of acetic anhydride was added and maintained at that temperature for 16 h. Then the reaction mixture was diluted with 1 ml of water, stirred for 10 min in the ice bath and distributed between 5 mi of water and 20 mi of ethyl acetate. The organic layer was washed with 3 x 5 mi of water, once with 5 mi of saturated sodium hydrogen carbonate, once with 3 mi of brine then dried (sodium sulfate) and evaporated. The oily residue was taken up in 1:6 ethyl acetate ~ hexane and fiash-chromatographed using a stepwise gradient of
1:6, 1:4 and 1:2 ethyl acetate - hexane. The column chromatography was monitored by
TLC (1:4 ethyl acetate — hexane, spot visualization with phosphomolybdic acid spray), the appropriate fractions were pooled, evaporated, the residue taken up in methyl formate, filtered, then evaporated again to give 23.8 mg of the title compound (1) as a colorless syrup; 400 MHz 1H NMR 5 0.66 (3H, s), 0.90 (1H, m), 1.06 (3H, d, J=7.2 Hz), 1.51 (1H, m), 1.72-1.82 (3H,m), 1.9-2.1 (3H, m), 1.99 (3H, 5) 2.04 (3H,s), 2.2-2.3 (3m), 2.44-2 64 (6H, m), 2.78 (1H, m), 3.01 (1H, 8), 5.10 (2H, m). 5.38 (1H, m), 5.43 (1H, d,
J=12 Hz), 5.85 (1H, d, J=11.5 Hz), 5.97 (1H, dt, J=12 and 7.3 Hz), 6.25 (1H, d, J= 11.5
Hz).
Synthetic Example 2 - Synthesis of 1,3-Di-O-acetyl-1 ,25-Dihydroxy-16-ene-23-yne- 26,27-hexafluoro-19-nor-cholecalciferol (2) and 1,3,25-Tri-O-acetyl-1,25-
Dihydroxy-1 6-ene-23-yne-26,27-hexafluoro-19-nor-cholecaiciferol (3) : oe oe oe
FaCOH I 5 FCOH 5 FCO [
HOM"YOH AcO™N"Y0Ac AcOM"0Ac 2 3
The starting material 1,25-dihydroxy-16-ene-23-yne-26,27-hexafluoro-1 9-nor- cholecalciferol can be prepared as described in US Patents 5,451,574 and 5,612,328 to
Baggiolini etal.. 314 mg (0.619 mmole) of 1,25-dihydroxy-16-ene-23-yne-26,27- hexafluoro-19-nor-cholecalciferol was dissolved in 1.5 mi of pyridine, cooled to ice-bath temperature, and 0.4 mi of acetic anhydride was added. The reaction mixture was kept at room temperature for 7 hours and then for 23 hours in a refrigerator. It was then diluted with 10 ml water and extracted with 30 ml of ethyl acetate. The organic extract was washed with water and brine, dried over sodium sulfate and evaporated. The residue was FLASH chromatographed on a 10 x 140 mm column with 1:6 and 1:4 ethyl acetate-hexane as the mobile phase to give 126 mg of 1,3-Di-O-acetyl-1,25-Dihydroxy- 16-ene-23-yne-26,27-hexafiuoro-1 g-nor-cholecalciferol (2), and 248 mg of 1,3,25-Tri-O- acetyl-1 ,25-Dihydroxy-16-ene-23-yne-26,27-hexafluoro-1 9-nor-cholecalciferol (3).
Synthetic Example 3 - Synthesis of 1,3-Di-O-acetyl-1 ,25-dihydroxy-16-ene-23-yne- cholecalciferol (4)
y \ | 2 \
IE nn. Ig >
Ho oH aco™ OAC 4
A 10-mL round-bottom flask was charged with 40 mg of 1,25-dihydroxy-16-ene-23-yne- cholecalciferol. This material was dissolved in 1 mL of pyridine. This solution was cooled in an ice bath then 0.3 mL of acetic anhydride was added. The solution was stirred for 30 min, then refrigerated ovemight, diluted with water and transferred to a separatory funnel with the aid of 10 mL of water and 40 mL of ethyl acetate. The organic layer was washed with 4 x 20 mL of water, 10 mL of brine passed through a
Co plug of sodium sulfate and evaporated. The light brown, oily residue was taken up in 1:9 ethyl acetate - hexane then flash chromatographed on a 10x130 mm column using 1:9 ethyl acetate - hexane as mobile phase for fractions 1-5, 1:6 for fractions 6-13 and 1:4 ethyl acetate - hexane for fractions 14-20 (18 mL fractions). Fractions 14-19 contained the main band with Rf0.15 (TLC 1:4). Those fractions were pooled and evaporated to a colorless oil, 0.044 g. The material was taken up in methyl formate, filtered and evaporated to give a colorless, sticky foam, 0.0414 g of the title compound (4).
Synthetic Example 4 - Synthesis of 1,3-Di-O-acetyl-1 ,25-dihydroxy-16,23E-diene- cholecalciferol (5)
H
[ & _— J #
Ho OH Aco OAc 0.0468 g of 1,25-Dihydroxy-16,23E-diene-cholecalciferol was dissolved in 1.5 mL of pyridine. This solution was cooled in an ice bath then refrigerated overnight, diluted with 10 mL of water while still immersed in the ice bath, stirred for 10 min and transferred to a separatory funnel with the aid of 10 mL of water and 40 mL of ethyl acetate. The organic layer was washed with 4x20 mL of water, 10 mL of brine passed through a plug of sodium sulfate and evaporated. The light brown, oily residue was taken up in 1:9 ethyl acetate - hexane then flash chromatographed on a 10x130 mm column using 1:9 ethyl acetate - hexane as mobile phase for fractions 1-3 (20 mL fractions), 1:6 for fractions 6-8 and 1:4 ethyl acetate - hexane for fractions 9-17 (18 mL each). Fractions 11-14 contained the main band with Rf 0.09 (TLC 1:4). Those fractions were pooled and evaporated to a colorless oil, 0.0153 g. This material was taken up in methyl formate, fitered and evaporated, to give 0.014 g of the title compound (5).
Synthetic Example 6 - Synthesis of 1 ,3-Di-O-acetyl-1,25-dihydroxy-16-ene- cholecalciferol (6)
H OH
[
Ho™ ‘OH AO" OAC 6 0.0774 g of 1,25-Dihydroxy-1 6-ene-cholecalciferol was dissolved in 1.5 mL of pyridine.
This solution was cooled in an ice bath then 0.3 mL of acetic anhydride was added. The solution was stirred, refrigerated overnight then diluted with 1 mL of water, stirred for 1 h in the ice bath and diluted with 30 mL of ethyl acetate and 15 mL of water. The organic layer was washed with 4x15 mL of water, once with 5 mL of brine then dried (sodium sulfate) and evaporated. The light brown, oily residue was taken up in 1:9 ethyl acetate - hexane then flash chromatographed on a 10x130 mm column using 1:9 ethyl acetate - hexane as mobile phase for fraction 1 (20 mL fractions), 1:6 for fractions 2-7 and 1:4 ethyl acetate - hexane for fractions 8-13. Fractions 9-11 contained the main band with
Rf 0.09 (TLC 1:4 ethyl acetate - hexane). Those fractions were pooled and evaporated io a colorless oil, 0.0354 g. This material was taken up in methyl formate, filtered and the solution evaporated, 0.027 g colorless film, the title compound (6).
Synthetic Example 7 - Synthesis of 1 ,3,25-Tri-O-acetyl-1 ,25-dihydroxy-16-ene- 23-yne-26,27-hexafluoro-cholecalciferol (7) and 1,3-Di-O-acetyi-1 ,25-dihydroxy- 1 6-ene-23-yne-26,27-hexafluoro-cholecalciferol (8) y, : oy, y, \ N \
CFs Fa CF3 a Fo OH A FAC OAc + 1 4 FC OH
Ho OH Aco™ OAc AcO™ OAc 7 8 0.0291 g of 1,25-dihydroxy-1 6-ene-23-yne-26,27-hexafluoro-cholecalciferol was dissolved in 1.5 mL of pyridine. This solution was cooled in an ice bath then 0.25 mL of acetic anhydride was added. The solution was stirred for 20 min and kept in a freezer ovemight. The cold solution was diluted with 15 mL of water, stirred for 10 min, and diluted with 30 mL of ethyl acetate. The organic layer was washed with 4x15 mL of water, once with 5 mL of brine then dried (sodium sulfate) and evaporated. The light brown, oily residue was taken up in 1:6 ethyl acetate - hexane then flash chromatographed on a 10x110 mm column using 1:6 ethyl acetate - hexane as mobile phase. Fractions 2-3 gave 72.3461 - 72.3285 = 0.0176 g. Evaporation of fractions 6-7 gave 0.0055 g. The residue of fractions 2 - 3 was taken up in methyl formate, filtered and evaporated to give 0.0107 g of the title triacetate (7). The residue of fractions 6-7 was taken up in methyl formate, filtered and evaporated to give 0.0049 g of diacetate (8).
Synthetic Example 8 - Synthesis of 1,3-Di-O-acetyl-1 ,25-dihydroxy-16,23E- diene-25R,26-trifluoro-cholecalciferol (9) = CF; [ = CFs
H OH
Jj H — NE
Ho™ OH Ao OAc
1.5 mL of 1.25-dihydroxy-16,23E-diene-25R, 26-trifiuoro-cholecalciferol was dissolved in 1.5 mL of pyridine, cooled to ice-bath temperature and 0.4 mL. of acetic anhydride was added. The mixture was then refrigerated. After two days the mixture was diluted with 1 mL of water, stirred for 10 min In the ice bath then distributed between 10 mL of water and 30 mL of ethyl acetate. The organic layer was washed with 4x15 mL of water, once with 5 mL of brine then dried (sodium sulfate) and evaporated. The light brown, oily residue was taken up in 1:6 ethyl acetate - hexane then flash chromatographed on a 10x130 mm column using 1:6 ethyl acetate - hexane as mobile phase. Fractions 4-6 (TLC, 1:4) contained the main band (see TLC) These fractions were evaporated and gave 0.0726 g. This residue was taken up in methyl formate, filtered and evaporated, to give 0.0649 g of colorless foam, the title compound (9).
Synthetic Example 8 - Synthesis of 1,3-Di-O-acetyl-1,25-dihydroxy-1 6-ene-19- nor-cholecalciferol (10) (“Compound C”)
OH OH
J — IE
HO™ oH Aco OAc 0.0535 g of 1,25-Dihydroxy-16-ene-1 g-nor-cholecalciferol was dissolved in 1.5 mL of pyridine, cooled to ice-bath temperature and 0.3 mL of acetic anhydride was added and the mixture was refrigerated overnight. The solution was diluted with 1 mL of water, stirred for 10 min in the ice bath then distributed between 10 mL of water and 30 mL of ethyl acetate. The organic layer was washed with 4x15 mL of water, once with 5 mL of brine then dried (sodium sulfate) and evaporated. The nearly colorless, oily residue was taken up in 1:6 ethyl acetate - hexane as mobile phase for fractions 1-6 then 1:4 ethyl acetate - hexane was used. Fractions 9-19 (TLC, 1:4 ethyl acetate - hexane, Rf 0.09, see below) were pooled, evaporated, to give 0.0306 g, which was taken up in methyl formate, filtered, then evaporated. It gave 0.0376 of the title compound (10).
Synthetic Example 9 - Synthesis of 1,3-Di-O-Acetyl-1,25-dihydroxy-1 6-ene-23-yne- 19-nor-cholecalciferol (11)
\ \
I OH iN I oH
Hoo OH AcO™ OAC 1 50 mg of 1,25-dihydroxy-16-ene-23-yne-1 9-nor-cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added.
The mixture was refrigerated for 3 days then diluted with 1 mL of water, stirred for 10 min in the ice bath and distributed between 5 mL of water and 20 mL of ethyl acetate.
The organic layer was washed with 4x5 mL of water, once with 3 mL of brine then dried (sodium sulfate) and evaporated. The nearly colorless, oily residue was taken up in 1:6 ethyl acetate - hexane then flash chromatographed on a 15x120 mm column using 1:6 ethyl acetate - hexane as mobile phase for fractions 1-6, 1:4 for fractions 9-12, 1:3 for fractions 13-15 and 1:2 ethyl acetate - hexane for the remaining fractions. Fractions 11- 16 (TLC, 1:4 ethyl acetate - hexane, Rf 0.09, see below) were pooled, evaporated 76.1487 - 76.1260 = 0.0227 g, taken up in methyl formate, filtered, then evaporated. It gave 0.0186 g of the title compound (11).
Synthetic Example 10 - Synthesis of 1,3-Di-O-acetyi-1,25-dihydroxy-16-ene-23- yne-26,27-bishomo-19-nor-cholecaiciferol (12) \ \
H OH Ti OH
Ho OH Aco™ OAc 12 0.0726 g of 1,25-dihydroxy-16-ene-23-yne-26,27-bishomo-19-nor-cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added. The solution was stirred in the ice-bath then refrigerated ovemight. The solution was then diluted with 1 mL of water, stirred for 10 min in the ice bath and distributed between 10 mL of water and 25 mL of ethyl acetate. The organic layer was washed with 3x10 mL of water, once with 5 mL of saturated sodium hydrogen carbonate, once with 3 mL of brine then dried and evaporated, 33.5512 - 33.4654 = 0.0858 g of a tan oily residue that was flash-chromatographed on a 15x120 mm column using 1:6 as mobile phase. Fractions 7-11 (20 mL each) were pooled (TLC 1:4 ethyl acetate - hexane, Rf 0.14) and evaporated, 67.2834 - 67.2654 = 0.018 g. This residue was taken up in methyl formate, filtered and evaporated. It gave 0.0211 g of the title compound (12).
Synthetic Example 11 - Synthesis of 1,3-Di-O-acetyl-1,25-dihydroxy-20- cyclopropyi-23-yne-1 g-nor-cholecalciferol (13) wH AN eH Nt
J A "
CL
Ho™ OH AcO™ OAc 13 0.282 g of 1,25-Dihydroxy-20-cyclopropyl-23-yne-19-nor-cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added and the mixture was refrigerated ovemight, then diluted with 1 mL of water, stirred for 10 min in the ice bath and distributed between 5 mL of water and 20 mL of ethyl acetate. The organic layer was washed with 3x5 mL of water, once with 5 mL of saturated sodium hydrogen carbonate, once with 3 mL of brine then dried (sodium sulfate) and evaporated. The oily residue was taken up in 1:6 ethyl acetate - hexane then flash chromatographed on a 15x110 mm column using 1:6 ethyl acetate - hexane as mobile phase for fractions 1-4, 1:4 for fractions 5-1 2, 1:3 for fractions 13-15 ethyl acetate - hexane for the remaining fractions. Fractions 7-12 (TLC, 1:4 ethyl acetate - hexane, Rf 0.13) were pooled, evaporated, the residue taken up in methyl formate, filtered, then evaporated to give 0.023 g of the title compound (13).
Synthetic Example 12 - Synthesis of 1,3,25-Tri-O-acetyl-1,25-dihydroxy-20- cyclopropyl-23-yne-26,27-hexafluoro-1 g-nor-cholecalciferol (14) and 1,3-Di-O- acetyl-1 ,25-dihydroxy-20-cyclopropyl-23-yne-26,27-hexafluoro-1 9-nor- cholecalciferol (15)
GAN HN GRAN
CF; CF3 F3
I & FC OH I & FC OH + & Fc OAC
HO OH Aco OAc Ao™ OAC 14 0.1503 g of 1 25-dihydroxy-20-cyclopropyl-23-yne-26,27-hexafiuoro-1 9-nor- cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added. The mixture was refrigerated overnight then diluted with 1 mL of water, stirred for 10 min in the ice bath and distributed between 5 mL of water and 20 mL of ethyl acetate. The organic layer was washed with 3x5 mL of water, once with 5 mL of saturated sodium hydrogen carbonate, once with 3 mL of brine then dried (sodium sulfate) and evaporated. The olly residue was taken up in 1:6 ethyl E acetate - hexane then flash chromatographed on a 15x150 mm column using 1:6 ethy! acetate - hexane as mobile phase for fractions 1-5, 1:4 for the remaining fractions.
Fractions 3-4 and 6-7 were pooled, evaporated, then taken up in methyl formate, filtered, and evaporated to give 0.0476 g of the title triacetate (14) and 0.04670 g of the title diacetate (15).
Synthetic Example 13 - Synthesis of 1,3-Di-O-acetyl-1,25-dihydroxy-20- cyclopropyl-23-yne-cholecalciferol (16)
HN wH Ny gE HoT IE or
Ho OH Aco™ OAc 16 0.0369 g of 1,25-dihydroxy-20-cyclopropyl-23-yne-cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added and the mixture was refrigerated overnight, then diluted with 1 mL of water, stirred for 10 min in the ice bath and distributed between 5 mL of water and 20 mL of ethyl acetate. The organic layer was washed with 3x5 mL of water, once with 5 mL of saturated sodium hydrogen carbonate, once with 3 mL of brine then dried (sodium sulfate) and evaporated. The oily residue was taken up in 1:6 ethyl acetate - hexane then flash-chromatographed on a 143x110 mm column using 1:6 ethy! acetate - hexane as mobile phase for fractions 1-7, 1:4 ethyl acetate - hexane for the remaining fractions.
Fractions 9-11 (TLC, 1:4 ethyl acetate - hexane) were pooled, evaporated, taken up in methyl formate, filtered, then evaporated, to give 0.0099 g of the titte compound (16).
Synthetic Example 14 - Synthesis of 1 ,3-Di-O-acetyl-1 ,25-dihydroxy-20- cyclopropyl-23E-ene-26,27-hexafluoro-1 9-nor-cholecalciferol (17) (Compound E) wH = Fa nH == CF;
FC OH 1 FsC OH
I —_— IE
Fr Ho
Ho OH Aco™ OAc 17 0.0328 g of 1,25~dihydroxy-20-cyclopropyl-23E-ene-26,27-hexafluoro-1 9-nor- cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added. The solution was refrigerated overnight. The solution was then diluted with 1 mL of water, stirmed for 10 min in the ice bath and distributed between 5 mL of water and 20 mL of ethyl acetate. (Extraction of the aqueous layer gave no phosphomolybdic acid-detectable material). The organic layer was washed with 3x5 mL of water, once with 5 mL of saturated sodium hydrogen carbonate, once with 3 mL of brine then dried (sodium sulfate) and evaporated, the residue shows Rf 0.25 as the only spot. The oily residue was taken up in 1:6 ethyl acetate - hexane then flash-chromato-graphed on a 13.5x110 mm column using 1:6 ethyl acetate - hexane as mobile phase for fractions 1-10. Fractions 4-9 were pooled and evaporated, the residue taken up in methyl formate, filtered, then evaporated to give 0.0316 g of the title compound (17).
Synthetic Example 15 - Synthesis of 1,3-Di-O-acetyl-1,25-dihydroxy-20- cyclopropyl-23Z-ene-26,27-hexafluoro-1 9-nor-cholecalciferol (18)
FC. oe Pe FC ers
WH WH ro _— 3
IE I #
HO OH Aco OAc 18 0.0429 g of 1,25-dihydroxy-20-cyclopropyl-23Z-ene-26,27-hexafluoro-1 9-nor- cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added. The solution was refrigerated ovemight. The solution was then diluted with 1 mL of water, stirred for 10 min in the ice bath and distributed between 7 mL of water and 25 mL of ethyl acetate. The organic layer was washed with 3x5 mL of water, once with 5 mL of saturated sodium hydrogen carbonate, once with 3 mL of brine then dried (sodium sulfate, TLC (1:4 ethyl acetate - hexane shows mostly one spot) and evaporated, flash-chromatographed on a 15x120 mm column using 1:6 as mobile phase. Fractions 3-6 (20 mL each) were pooled and evaporated. The residue was taken up in methyl formate, filtered and evaporated, to give 0.0411 g of the title compound (18).
Synthetic Example 16 - Synthesis of 1,3-Di-O-acetyl-1 ,25-dihydroxy-20- cyclopropyl-cholecalciferol (19) (Compound F) wH WH
H OH j © — Jw
HOW oH Aco OAc 19 0.0797 g of 1 .25-dihydroxy-20-cyclopropyl-cholecalciferol was dissolved in 0.8 mL of pyridine, cooled to ice-bath temperature and 0.2 mL of acetic anhydride was added.
The solution was refrigerated overnight. The solution was then diluted with 1 mL of water, stirred for 10 min in the ice bath and distributed between 10 mL of water and 25 mL of ethyl acetate. The organic layer was washed with 3x10 mL of water, once with 5 mL of saturated sodium hydrogen carbonate, once with 3 mL of brine then dried and evaporated, to give 0.1061 g of a tan oily residue that was flash-chromatographed on a 15x120 mm column using 1:6 as mobile phase. Fractions 9-16 (20 mL each) were pooled (TLC 1:4 ethyl acetate - hexane, Rf 0.13) and evaporated. This residue was taken up in methyl formate, filtered and evaporated to give 0.0581 g of the title compound (19).
Synthetic Example 17 - Synthesis of 1,3-DI-O-acetyl-1-alpha,25-dihydroxy-16-ene- 20-cyclopropyl-19-nor-cholecalciferol (20) i Ac,0 a pyridine
HO OH Aco” OAC
To the solution of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl-19-nor-cholecalciferol (94mg, 0.23 mmol) in pyridine (3mL) at 0°C, acetic anhydride (0.5 mL, 5.3 mmol) was added. The mixture was stirred for 1h, refrigerated for 15h. and then was stirred for additional 8h. Water (10 mL) was added and after stirring for 15 min. the reaction mixture was extracted with AcOEt : Hexane 1:1 (25 mL), washed with water (4x 25 mL) and brine (20 mL), dried over Na;SO.. The residue (120 mg) after evaporation of the solvent was purified by FC (15g, 30% AcOEt in hexane) to give the titled compound (20) (91 mg, 0.18 mmol, 80%). [a]*p = +14.4 c 0.34, EtOH; UV Amax (EtOH): 242nm (¢ 34349), 250 nm (¢ 40458), 260 nm (& 27545); 'H NMR (CDCl): 6.25 (1H, d, J=11.1 Hz), 5.83 (1H, d, J=11.3 Hz), 5.35 (1H, m), 5.09 (2H, m), 2.82-1.98 (7H, m), 2.03 (3H, Ss), 1.98 (3H, s), 2.00-1.12 (15H, m), 1.18 (6H, s), 0.77 (3H, s ),0.80-0.36 (4H, m); BC NMR (CDCl): 170.73(0), 170.65(0), 157.27(0), 142.55(0), 130.01(0), 125.06(1), 123.84(1), 115.71(1), 71.32(0), 70.24(1), 69.99(1), 59.68(1), 50.40(0), 44.08(2), 41.40(2), 38.37(2), 35.96(2), 35.80(2), 32.93(2), 29.48(3), 29.31(2), 28.71(2), 23.71(2), 22.50(2), 21.56(3), 21.51(0), 21.44(3), 18.01(3), 12.93(2), 10.53(2); MS HRES Calculated for Ca1HaeOs
M+Na 521.3237, Observed M+Na 521.3233
Synthetic Example 18 - Synthesis of 1,3-Di-O-acetyl-1-alpha,25-hydroxy-16-ene- 20-cyclopropyl-cholecalciferol (21)
OH OH
9) AcO ii “pyridine
HO™ OH AcO™ OAc 21
To the solution of 1-alpha,25-Dihydroxy-16-ene-20-cyclopropyl-cholecalciferol (100 mg, 0.23 mmol) in pyridine (3mL) at 0°C, acetic anhydride (0.5 mL, 5.3 mmol) was added.
The mixture was stirred for 2h and then refrigerated for additional 15h. Water (10 mL) was added and after stirring for 15 min. the reaction mixture was extracted with AcOEt:
Hexane 1:1 (25 mL), washed with water (4x 25 mL), brine (20 mL) and dried over
Na»SO;. The residue (150mg) after evaporation of the solvent was purified by FC (15g, 30% AcOEt in hexane) to give the titled compound (21) (92 mg, 0.18 mmol, 78 %). [a]* = -14.9 ¢ 0.37, EtOH; UV Amax (EtOH): 208 nm (& 15949), 265 nm (¢ 15745); H
NMR (CDCl): 6.34 (1H, d, J=11.3 Hz), 5.99 (1H, d, J=11.3 Hz), , 5.47 (1H, m), 5.33 (1H, m), 5.31 (1H, s), 5.18 (1H, m), 5.04 (1H, s), 2.78 (1H, m), 2.64 (1H, m), 2.40-1.10 (18H, m), 2.05 (3H, s), 2.01 (3H, s), 1.18 (6H, s), 0.76 (3H, s ),0.66-0.24 (4H, m); °C
NMR (CDCla): 170.76(0), 170.22(0), 157.1 8(0), 143.02(0), 142.40(0), 131.94(0), 125.31(1), 125.101), 117.40(1), 115.22(2), 72.97(1), 71.32(0), 69.65(1), 59.71(1), 50.57(0), 44.07(2), 41.73(2), 38.36(2), 37.10(2), 35.80(2), 29.45(3), 29.35(2), 29.25(3), 28.92(2), 23.80(2), 22.48(2), 21.55(3), 21.50(3), 21.35(0), 17.90(3), 12.92(2), 10.54(2);
MS HRES Calculated for C3:HisOs M+Na 533.3237, Observed M+Na 533.3236
Synthetic Example 19 - Synthesis of 1,3-Di-O-acetyl-1,25-dihydroxy-23-yne- cholecalciferol (22)
Ta \ fu N\
OH _ rn OH
HO" OH AcO™ OAc 22 0.2007g of(0.486 mmol) was dissolved in 2 mL of pyridine. This solution was cooled in an ice bath and 0.6 mL of acetic anhydride was added. The solution was kept in an ice bath for 45 h then diluted with 10 mL of water, stirred for 10 min and equilibrated with 10 mL of water and 40 mL of ethyl acetate. The organic layer was washed with 4x20 mL. of water, 10 mL of brine, dried (sodium sulfate) and evaporated. The brown, oily residue was flash chromatographed using 1:19, 1:9, and 1:4 ethyl acetate — hexane as stepwise gradient. The main band with Rf 0.16 (TLC 1:4 acetate —hexane) was evaporated to give 1,3-di-O-acetyl-1 25-dihydroxy-23-yne-cholecalciferol (22) a colorless foam, 0.0939 g.
Synthetic Example 20 - Synthesis of (3aR, 4S,7aR)-7a-Methyl-1-{1 ~(4-hydroxy-4- methyl-pent-2-ynyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol 1.nBulLi
AHS 2.CH3COCH3 HN
A 3.TBAF —te-0 H THF LH OH
To a stirred solution of (3aR, 4S,7aR)-1-{1 -[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- 3a,4,5,6,7,7a-hexahydro-3H-inden-1-yi])-cyclopropyl}-ethynyl (1.09, 2.90 mmol) in tetrahydrofurane (15 mL) at _78°C was added n-BuLi (2.72 mL, 4.35 mmol , 1.6M in hexane). After stirring at —78°C for 1 h., acetone (2.5 mL, 34.6 mmol) was added and the stirring was continued for 2.5h. NH4Clsq was added (15 mL) and the mixture was stirred for 15min at room temperature then extracted with AcOEt (2x 50 mL). The combined extracts were washed with brine (50mL) and dried over Na,SO,. The residue after evaporation of the solvent (2.4 g) was purified by FC (50g, 10% AcOEt in hexane) to give (3aR, 4S,7aR)-5-{1 -[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-3a,4,5,6,7,7a- hexahydro-3H-inden-1 -yi]-cyclopropyl}-2-methyl-pent-3-yn-2-ol (1.05 g, 2.61 mmol)
which was treated with tetrabutylammonium fluoride (6 mL, 6 mmol, 1.0M in THF) and stirred at 65-75°C for 48 h. The mixture was diluted with AcOEt (25 mL) and washed with water (5x 25 mL), brine (25 mL). The combined aqueous washes were extracted with AcOEt (25 mL) and the combined organic extracts were dried over Na,SO4. The residue after evaporation of the solvent (1.1 g) was purified by FC (50g, 20% AcOEt in hexane) to give the titled compound (0.75 g, 2.59 mmol, 90 %). [a]¥o=+2.7 c 0.75,
CHCls. 'H NMR (CDCl): 5.50 (1H, m), 4.18 (1H, m), 2.40 (2H, s), 2.35-1.16 (11H, m), 1.48 (6H, s), 1.20 (3H, s), 0.76-0.50 (4H, m); 13C NMR (CDCly): 156.39, 125.26, 86.39, 80.19, 69.21, 65.16, 55.14, 46.94, 35.79, 33.60, 31.67, 20.91, 27.22, 19.32, 19.19, 17.73, 10.94, 10.37; MS HREI Calculated for C2oH2502 M+ 288.2089, Observed M+ 288.2091.
Synthetic Example 21 - Synthesis of (3aR, 4S,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4- methyl-pent-2Z-enyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol
OH
LH OH TF
The mixture of (3aR, 4S,7aR)-7a-Methyl-1-[1 ~(~4-hydroxy-4-methyl-pent-2-ynyl)- cyclopropyll-3a,4,5,8,7,7a-hexahydro-3H-inden-4-ol (0.72 g, 2.50 mmol), ethyl acetate (10 mL), hexane (24 mL), absolute ethanol (0.9 mL), quinoline (47 L) and Lindlar catalyst (156 mg, 5% Pd on CaCOs ) was hydrogenated at room temperature for 2 h.
The reaction mixture was filtered through a celite pad and the pad was washed with
AcOEt. The filtrates and the washes were combined and washed with 1M HCI, NaHCO3 and brine. After drying over Na;SO, the solvent was evaporated and the residue (0.79 g) was purified by FC (45g, 20% AcOEt in hexane) to give the tiled compound (640 mg, 2.2 mmol, 88 %).
Synthetic Example 22 - Synthesis of (3aR, 4S,7aR)-7a-Methyi-1-[1 ~(4-hydroxy-4- methyl-pentyl)-cyclopropyl}-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol
OH oid Hy, kat. Ap A _— OH : AnH on™
The mixture of (3aR, 4S,7aR)-7a-Methyl-1 -[1-(4-hydroxy-4-methyl-pent-2Z-enyl)- cyclopropyil-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (100 mg, 0.34 mmol), 1,4- bis(diphenyl-phosphino)butane 1,5 cyclooctadiene rhodium tetrafluoroborate (25 mg,0.034 mmol), dichloromethane (56 mL) and one drop of mercury was hydrogenated using Paar apparatus at room temperature and 50 p.s.i. pressure for 3h. The reaction mixture was filtered through Celite pad, which was then washed with ethyl acetate. The combine filtrates and washes were evaporated to dryness (110 mg) and purified by FC (10 g, 20% AcOEt in hexane) to give the titled compound (75 mg, 0.26 mmol, 75 %). '[a]*°%= -8.5 ¢ 0.65, CHCls. H NMR (CDCl3): 5.37 (1H, m,), 4.14 (1H, m), 2.37-1.16 (17H, m), 1.19 (6H, s), 1.18 (3H, 5), 0.66-0.24 (4H, m); MS HREI Calculated for
CioH3202 M+H 292.2402, Observed M+ H 292.2404.
Synthetic Example 23 - Synthesis of (3aR,7aR)-7a-Methyl-1-[1 ~(4-methyl-4- trimethylsilanyloxy-pentyl)-cyclopropyl]-3a.4,5,6,7.7a-hexahydro-3H-inden-4-one
FO 1. PDC/CHoCla Sipe: oH 2.TMS-Im OTMS oH" o"!
To a stirred suspension of (3aR, 4S,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4-methyl- pentenyl)-cyclopropyi}-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (440 mg, 1.50 mmol) and Celite (2.0 g) in dichloromethane (10 mL) at room temperature wad added pyridinium dichromate (1.13 g, 3.0 mmol). The resulting mixture was stirred for5h filtered through silica gel (10 g), and then silica gel pad was washed with 20% AcOEt in hexane. The combined filtrate and washes were evaporated, to give a crude (3aR,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4-methyl-pentenyl)-cyclopropyl}-3a,4,5,6,7,7a- hexahydro-3H-inden-4-one (426 mg, 1.47 mmol, 98 %). To a stirred solution of (3aR,7aR)-7a-Methyl-1-[1 ~(4-hydroxy-4-methyl-pentenyl)-cyclopropyl]-3a,4,5,6,7,7a- hexahydro-3H-inden-4-one (424 mg, 1.47 mmal) in dichloromethane (10 mL) at room temperature was added trimethylsilyl-imidazole (0.44 mL, 3.0 mmol). The resulting mixture was stirred for 1.0 h filtered through silica gel (10 g) and the silica gel pad was washed with 10% AcOEt in hexane. Combined filtered and washes were evaporated to give the titled compound (460 mg, 1.27 mmol, 86 %). [a]%0= -9.9 ¢ 0.55, CHCl. H
NMR (CDCls): 5.33 (1H, dd, J=3.2, 1.5 Hz), 2.81 (1H, dd, J= 10.7, 6.2 Hz), 2.44 (1H, ddd, J=15.6, 10.7, 1.5 Hz), 2.30-1.15 (13H, m) overlapping 2.03 (ddd, J= 15.8, 6.4, 3.2
Hz), 1.18 (6H, s), 0.92 (3H, s), 0.66-0.28 (4H, m), 0.08 (SH, s); *C NMR (CDCl): 211.08 (0), 155.32(0), 124.77(1), 73.98(0), 64.32(1), 53.91(0), 44.70(2), 40.45(2), 38.12(2), 34.70(2), 29.86(3), 29.80(3), 26.80(2), 24.07(2), 22.28(2), 21.24(0), 18.35(3), 12.60(2), 10.64(2), 2.63 (3); MS HRES Calculated for CxoH3s02Si M+ 362.2641.
Observed M+ 362.2648.
Synthetic Example 24 - Synthesis of (3aR,7aR)-7a-Methyl-1-[1 -(4-methyl-4- trimethylsilanyloxy-pent-2-ynyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4- one 1. PDC/CH,Cly ot AN 2.TMS-m oF \
TH OH In OTMS
To a stirred suspension of (3aR, 48,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4-methyl-pent-2- ynyll)}-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (381 mg, 1.32 mmol) and
Celite (2.0 g) in dichloromethane (10 mL) at room temperature wad added pyridinium dichromate (1.0 g, 2.65 mmol). The resulting mixture was stirred for 1.5 h filtered through silica gel (10 g), and then silica gel pad was washed with 20% AcOEt in hexane. The combined filtrate and washes were evaporated, to give a crude (3aR,7aR)-7a-Methyl-1-[1-(4-hyd roxy-4-methyl-pent-2-ynyli)-cyclopropyl]-3a 4,567, 7a hexahydro-3H-inden-4-one (360 mg, 1.26 mmol, 95 %). To a stirred solution of (3aR,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4-methyl-pent-2-ynyll}-cyclopropyl}-3a,4,5,6,7,7a- hexahydro-3H-inden-4-one (360 mg, 1.26 mmol) in dichloromethane (10 mL) at room temperature was added trimethylsilyl-imidazole (0.25 mL, 1.7 mmol). The resulting mixture was stirred for 0.5 h filtered through silica gel (10 g) and the silica gel pad was washed with 5% AcOEt in hexane. Combined filtered and washes were evaporated to give the titled compound (382 mg, 1.07 mmol, 81 %).
Synthetic Example 25 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- 23,24-yne-cholecalciferol (23)
P(O)Ph; ON 1. nBuli $ \ + Te 2. TBAF | H OH
H OSiMes Rad od} ™ .
HO" OH 23
To a stirred solution of a (1S,5R)-1 5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylphosphinoyl)-eth-(Z)-yiidene]-2-methylene-cyclohexane (6513 mg, 0.88 mmol) in tetrahydrofurane (6 mL) at —78°C was added n-BuLi (0.55 mL, 0.88 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methy!-1-[1-(4- methyl-4-trimethylsilanyloxy-pent-2-ynyll}-cyclopropyil-3a.4,5,6,7,7a-hexahydro-3H- inden-4-one (179 mg, 0.50 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at —72°C for 3.5h diluted with hexane (25 mL) washed brine (30 mL) and dried over NazSOa. The residue (716mg) after evaporation of the solvent was purified by FC (15g, 5% AcOEt in hexane) to give 1-alpha,3-beta-Di(tert-Butyl- dimethyl-silanyloxy)-25-trimethylsilanyloxy-16-ene-20-cyclopropyl-23,24-yne- cholecalciferol (324 mg, 045 mmol). To the 1-alpha,3-beta-Di(tert-Butyl-dimethyl- silanyloxy)-25-trimethyisilanyloxy-1 8-ene-20-cyclopropyl-23,24-yne-cholecalciferol (322 mg, 0.45 mmol) tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 18h diluted with AcOEt (256 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,S0,; The residue (280 mg) after evaporation of the solvent was purified by FC (10g, 50% AcOEt in hexane and AcOEt) to give the titled compound (23) (172 mg, 0.41 mmol, 82 %). [a]*'o= +32.4 ¢ 0.50, MeOH. UV Amax (EtOH): 261 nm ( 11930); 'H NMR (CDCl): 6.36 (1H, d, J=11.3 Hz), 6.09 (1H, d, J=11.3 Hz), 5.45(1H, m), 5.33 (1H, m), 5.01 (1H, s), 4.45 (1H, m), 4.22 (1H, m), 2.80 (1H, m), 2.60 (1H, m), 2.50-1.10 (16H, m), 1.45 (6H, s), 0.81 (3H, s),0.72-0.50 (4H, m); MS HRES Calculated for C2sHasO3 M+ 422.2821,
Observed M+ 422.2854. :
Synthetic Example 26 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- 23,24-yne-19-nor-cholecalciferol (24)
P(O)Ph; N\ 1. nBuli C
HN + £ 2. TBAF I H OH
Ia OSiMes Rad 0-8 ™
HO" OH 24
To a stirred solution of a (1 R 3R)-1,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylphosphinoyl)ethylidene]-cyclohexane (674 mg, 1.18 mmol) in tetrahydrofurane (8 mL) at —78°C was added n-BuLi (0.74 mL, 1.18 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1 -(4-methyl-4- tri methylsilanyloxy-pent-2-ynyl)-cyclopropyl}-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one (235 mg, 0.66 mmol, in tetrahydrofurane (3mL) was added dropwise. The reaction mixture was stirred at —72°C for 3.5h diluted with hexane (25 mL) washed brine (30 mL) and dried over Na>SOs. The residue (850mg) after evaporation of the solvent was purified by FC (15g, 5% AcOEt in hexane) to give 1-alpha,3-beta-Di(tert-Butyl-dimethyl- silanyloxy)-25-trimethyisilanyloxy-1 6-ene-20-cyclopropyl-23,24-yne-19-nor- cholecalciferol (330 mg, 0.46 mmol). To the 1-alpha,3-beta-Di(tert-Butyl-dimethyl- silanyloxy)-25-trimethyisilanyloxy-1 8-ene-20-cyclopropyl-23,24-yne-19-nor- cholecalcifero! (328 mg, 0.46 mmol) tetrabutylammonium fluoride (5 mL, 5 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 62h diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,SO,. The residue (410 mg) after evaporation of the solvent was purified by FC (10g, 50% AcOEt in hexane and AcOEt) to give the titled compound (24) (183 mg, 0.45 mmol, 68 %). [[a]*®o= +72.1 ¢ 0.58, MeOH. UV Amax (EtOH): 242nm (¢ 29286),. .. 251 nm (e 34518), 260 nm (c 23875); 'H NMR (CDCl3): 6.30 (1H, d, J=11.3 Hz), 5.94 (1H, d,
J=11.3 Hz), 5.48 (1H, m), 4.14 (1H, m), 4.07 (1H, m), 2.78 (2H, m), 2.52-1.10 (18H, m), 1.49( 6H, s), 0.81 (3H, 5 ),0.72-0.50 (4H,m); MS HRES Calculated for Cy7H3803 M+ 410.2821, Observed M+ 410.2823.
Synthetic Example 27 - Synthesis of (3aR, 4S,7aR)-7a-Methyl-1-[1-(5,5,5-trifluoro- 4-hydroxy-4-rifiuoromethyl-pent-2-ynyl)-cyclopropy]-3a.4,5,6,7,Ta-hexahydro-3H- inden-4-ol 1.nBulLi oi 2.CF3COCF3 os AN
A 3.TBAF so H THF I FaC on 2
To a stirred solution of (3aR, 4S,7aR)-1-{1 -[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- 3a,4,5,6,7,7a-hexahydro-3H-inden-1-yl])-cyclopropyl}-ethynyl (1.95 g, 5.66 mmol) in tetrahydrofurane (35 mL) at _78°C was added n-BuLi (4.3 mL, 6.88 mmol, 1.6Min hexane). After stirring at _78°C for 1 h., hexafluoroacetone (six drops from the cooling finger) was added and the stirring was continued for 1h. NH4Claq was added (10 mL) and the mixture was allowed to warm to room temperature. The reaction mixture was diluted with brine (100 mL) and extracted with hexane (2x 125 mL). The combined extracts were dried over Na;S0,. The residue after evaporation of the solvent (8.2g) was purified by FC (150g, 10% AcOEt in hexane) to give (3aR, 4S,7aR)-5-{1-{4-(tert-
Butyl-dimethyl-sitanyloxy)-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-1-yll- cyclopropyl}1,1 ,1-trifluoro-2-trifluoromethyl-pent-3-yn-2-ol (2.73 g, 5.35 mmol) which was treated with tetrabutylammonium fluoride (20 mL, 20 mmol, 1.0M in THF) and stirred at 65-75°C for 30 h. The mixture was diluted with AcOEt (150 mL) and washed with water (5x 150 mL), brine (150 mL). The combined aqueous washes were extracted with AcOEt (150 mL) and the combined organic extracts were dried over
Na,SO.. The residue after evaporation of the solvent (3.2 g) was purified by FC (150g, 20% AcOEt in hexane) to give the titled compound (2.05 g, 5.17 mmol, 97 %). [a}*®p= +6.0 ¢ 0.47, CHCls. 'H NMR (CDCl3): 5.50 (1H, br. s), 4.16 (1H, br. s), 3.91 (1H, s), 2.48 (1H, part A of the AB quartet, J=17.5 Hz), 2.43 (1H, part B of the AB quartet, J=17.5Hz), 2.27 (1H, m), 2.00-1.40 (9H, m), 1.18 (3H, s), 0.8-0.5 (4H, m); 3C NMR (CDCl3): 155.26(0), 126.68(1), 121.32(0, q, J=284 Hz), 90.24 (0), 71.44(0, sep. J=34Hz), 70.54 (0), 69.57(1), 55.17(1), 47.17(0), 36.05(2), 33.63(2), 30.10(2), 27.94(2), 19.50(3), 19.27(0), 17.90(2), 11.56(2), 11.21(2); MS HREI Calculated for C1gH220:Fg M+ 306.1524, Observed M+ 396.1513.
Synthetic Example 28 - Synthesis of (3aR,7aR)-7a-Methyl-1-{1 -(5,5,5-trifluoro-4- trifluoromethyl-4-hydroxy-pen-2-ynyl)-cyclopropyl]-3a,4,5,6,7.7a-hexahydro-3H- inden-4-one 1. PDCICH,Cl, ye ZI z CF3 z CFs ont F,C OH oH FsC OH
To a stirred suspension of (3aR, 4S,7aR)-7a-Methyl-1-[1-(5,5,5-trifluoro-4-hydroxy-4- trifluoromethyl-pent-2-ynyl)-cyclopropyil-3a,4,5,6,7 7a-hexahydro-3H-indan-4-ol (504 mg, 1.27 mmol) and Celite (1 .5 g) in dichloromethane (12 mL) at room temperature wad added pyridinium dichromate (0.98 g, 2.6 mmol). The resulting mixture was stirred for 2.5 h filtered through silica gel (5 g), and then silica gel pad was washed with 20%
AcOEt in hexane. The combined filtrate and washes were evaporated, to give a titled compound (424 mg, 1.08 mmol, 85 %). [a]%o= +3.1 ¢ 0.55, CHCl3. "H NMR (CDCl): 5.46 (1H, br. s), 3.537 (1H, s), 2.81 (1H, dd, J=10.7, 6.5 Hz), 2.49-1.76 (10H, m), 0.90 (3H, s), 0.77-0.53 (4H, m); MS HREI Calculated for C1gH2002Fs M+H 395.1440,
Observed M+H 395.1443.
Synthetic Example 29 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- 23,24-yne-26,27-hexafluoro-1 9-nor-cholecalciferol (25)
P(O)Phy AN
IN s A
I HFC oSnacs had 0-8 ™
HO" OH
To a stirred solution of a (1R,3R)-1 ,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylphosphinoyl)ethylidene]-cyclohexane (900 mg, 1.58 mmol) in tetrahydrofurane (8 mL) at —78°C was added n-BuLi (1.0 mL, 1.6 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1 -(5,5,5-trifluoro-4- trifluoromethyl-4-hydroxy-pen-2-ynyl)-cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4- one (200 mg, 0.51 mmol, in tetrahydrofurane (3mL) was added dropwise. The reaction mixture was stirred at —72°C for 3.5h diluted with hexane (25 mL) washed brine (30 mL) and dried over Na,SQ,_ The residue (850mg) after evaporation of the solvent was purified by FC (20g, 10% AcOEt in hexane) to give 1-alpha,3-beta-Di(tert-Butyl- dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23 24-yne-26,27-hexafluoro-19- nor-cholecalciferol (327 mg, 0.44 mmol, 86%). To the 1-alpha,3-beta-Di(tert-Butyl- dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyi-23 24-yne-26,27-hexafluoro-19- nor-cholecalciferol (327 mg, 0.44 mmol). Tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 24h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL.) and dried over Na,SO,. The residue (250 mg) after evaporation of the solvent was purified by FC (10g, 50% AcOEt in hexane and AcOEY) to give the titled compound (25) (183 mg, 0.45 mmol, 68 %). [a]¥%= +73.3 ¢ 0.51, EtOH. UV Amax (EtOH): 243 nm (e 29384 251 nm (e 34973), 260 nm (g 23924); 'H NMR (CDCl3): 6.29 (1H, d, J=11.1 Hz), 5.93 (1H, d,
J=11.1 Hz), 5.50 (1H, m), 4.12 (1H, m), 4.05 (1H, m), 2.76 (2H, m), 2.65-1.52 (18H, m), 0.80 (3H, s ),0.80-0.49 (4H, m); "*C NMR (CDCl): 155.24(0), 141.78(0), 131.28(0), 126.23(1), 123.65(1), 121.09(0, q, J=285Hz), 1 15.67(1), 89.63(0), 70.42(0), 67.48(1), 67.29(1), 59.19(1), 49.87(0), 44.49(2), 41 98(2), 37.14(2), 35.76(2), 29.22(2), 28.47(2), 27 57(2), 23.46(2), 19.32(0), 17.97(3), 11.89(2), 10.18(2); MS HRES Calculated for
Co7H320sFs M+H 519.2329. Observed M+H 519.2325.
Synthetic Example 30 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- 23,24-yne-26,27 hexafluoro-cholecalciferol (26)
P(O)Ph; \
TaN i. BE YE eh
Th rc oShies Rad 0-8 ™
HO™ OH 26
To a stirred solution of a (1S,5R)-1 ,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylphosphinoyl)-eth-(Z)-ylidene}-2-methylene-cyclohexane (921 mg, 1.58 mmol) in tetrahydrofurane (8 mL) at —78°C was added n-BuLi (1.0 mL, 1.6 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1-(5,5,5-
trifluoro-4-trifiuoromethyi-4-hydroxy-pen-2-ynyl)-cyclopropyl}-3a,4.5.6.7.7a-hexahydro- 3H-inden-4-one (197 mg, 0.50 mmol, in tetrahydrofurane (2mL.) was added dropwise.
The reaction mixture was stirred at —72°C for 3.5h diluted with hexane (25 mL) washed brine (30 mL) and dried over NazSOa. The residue (876mg) after evaporation of the solvent was purified by FC (20g, 105% AcOEt in hexane) to give 1-alpha,3-beta-Di(tert-
Butyl-dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23,24-yne-26,27- hexafluoro-cholecalciferol (356 mg, 0.47 mmol). To the 1-alpha,3-beta-Di(tert-Butyl- dimethyl-sitanyloxy)-25-hydroxy-16-ene-20-cyclopropyl-23,24-yne-26,27-hexafluoro- cholecalciferol (356 mg, 0.47 mmol) tetrabutylammonium fluoride (5 mL, 5 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 15h. diluted with AcOEt (25 mL) and washed with water (6x20 mL), brine (20 mL) and dried over Na,SOs. The residue (270 mg) after evaporation of the solvent was purified by FC (20g, 50% AcOEt in hexane and AcOEt) to give the titled compound (26) (216 mg, 0.41 mmol, 87 %). [a]*’o= +40.0 ¢ 0.53, EtOH. UV Amax (EtOH): 262 nm (e 12919); H NMR (CDCl3): 6.38 (1H, d, J=11.5 Hz), 6.10 (1H, d, J=11.1 Hz), 5.49 (1H, m), 5.35 (1H, s), 5.02 (1H, s), 4.45 (1H, m), 4.25 (1H, m), 3.57 (1H, s), 2.83-1.45 (18H, m), 0.82 (3H, s ),0.80-0.51 (4H, m); MS HRES Calculated for CogH3203Fs M+H 531.2329. Observed
M+H 531.2337.
Synthetic Example 31 - Synthesis of (3aR, 4S,7aR)-7a-Methyl-1-[1 «(5,5,5-trifluoro- 4-hydroxy-4-trifiuoromethyl-pent-2E-enyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro- 3H-inden-4-ol \| LAH, MeONa "NCF3 x oFs - L F,C OH ont FsC OH OH H
To a lithium aluminum hydride (4.5 mL, 4.5 mmol, 1.0M in THF)at 5°C was added first solid sodium methoxide (245 mg, 4.6 mmol) and then dropwise solution of (3aR, 48,7aR)-7a-Methyl-1-{1 -(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2-ynyl)- cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (360 mg, 0.91 mmol) in tetrahydrofurane (5 mL). After addition was completed the mixture was stirred under reflux for 2.5h. Tehn it was cooled in the ice-bath and quenched with water (2.0 mL) and sodium hydroxide (2.0 mL, 2.0 M water solution); diluted with ether (50 mL) stirred for min, MgSO (5g) was than added and stirring was continued for 30 min. The residue after evaporation of the filtrates ( 0.42 g) was purified by FC (20g, 20% AcOEt in hexane) to give the titled compound (315 mg, 0.79 mmol, 87 %). [a]®o= +2.0 c 0.41,
CHCl; 'H NMR (CDCls): 6.24 (1H, dt, J=15.7, 6.7 Hz), 5.60 (1H, d, J=15.7 Hz), 5.38 (1H, br. s), 4.13 (1H, br. s), 3.27 (1H, s), 2.32-1.34 (12H, m), 1.15 (3H, s), 0.80-0.45 (4H, m); 3C NMR (CDCly): 155.89(0), 138.10(1), 126.21(1), 122.50(0, q, J=287 Hz), 119.15 (1), 76.09(0, sep. J=31Hz), 69.57(1), 55.33(1), 47.30(0), 40.31(2), 36.05(2), 33.71(2), 30.10(2), 20.36(0), 19.46(3), 17.94(2), 11.96(2), 11.46(2); MS REI Calculated for C1gHp4O2Fs M+ 398.1680. Observed M+ 398.1675.
Synthetic Example 32 - Synthesis of (3aR,7aR)-7a-Methyl-1-[1 «(5,5,5-trifluoro-4- trifluoromethyl-4-trimethylsilanyloxy-pen-2E-enyl)-cyclopropyl]-3a4,5,6,7,7a- hexahydro-3H-inden-4-one . ~__CF3 PDC/CH,Cl, A~_CF3 :
Fo¢ OH 2TmS Am F,C OTMS on" of
To a stirred suspension of (3aR, 4S,7aR)-7a-Methyl-1-[1 -(5,5,5-trifluoro-4-hydroxy-4- trifluoromethyl-pent-2E-anyl)-cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (600 mg, 1.51 mmol) and Celite (2.0 g) in dichloromethane (10 mL) at room temperature wad added pyridinium dichromate (1.13 g, 3.0 mmol). The resulting mixture was stirred for 3.5 h filtered through silica gel (10 g), and then silica gel pad was washed with 25%
AcOEt in hexane. The combined filtrate and washes were evaporated, to give a crude (3aR,7aR)-7a-Methyl-1-[1 -(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2E-enyl)- cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one (550 mg, 1.39 mmol, 92 %). To a stirred solution of (3aR,7aR)-7a-Methyl-1-[1-(5,5,5-trifluoro-4-hydroxy-4-trifiuoromethyl- pent-2E-enyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one (550 mg, 1.39 mmol) in dichloromethane (15 mL) at room temperature was added trimethylsilyl- imidazole (1.76 mL, 12.0 mmol). The resulting mixture was stirred for 1.0 h filtered through silica gel (10 g) and the silica gel pad was washed with 10% AcOEt in hexane.
Combined filtered and washes were evaporated to give the titled compound (623 mg, 1.33 mmol, 88 %). [a]®*p=-1.6 ¢ 0.51, CHCl3, TH NMR (CDCl3): 6.14 (1H, dt, J=15.5, 6.7 Hz), 5.55 (1H, d, J=15.5 Hz), 5.35 (1H, m), 2.80 (1H, dd, J= 10.7, 6.4 Hz), 2.47-1.74
(10H, m), 0.90 (3H, s), 0.76-0.40 (4H, m), 0.2 (9H, s); 3c NMR (CDCls): 210.99 (0), 154.28(0), 137.41(1), 126.26(1), 122.59(0, q, J=289 Hz), 120.89 (1), 64.31 (1), 53.96(0), 40.60(2), 40.13(2), 35.00(2), 27.03(2), 24.21(2), 20.57(0), 18.53(3), 12.41(2), 10.79(2), 1.65 (3); MS HRES Calculated for C22H3002F¢Si M+H 469.1992. Observed M+ H 469.1995.
Synthetic Example 33 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- 23,24-E-ene-26,27-hexafluoro-19-nor-cholecalciferol (27)
P(O)Phy ok
Fn or 1. Bul : FaC OH ~ CF + 2. TBAF | H oy dome) (gl mw
NG hood ™
HO" OH 27
To a stirred solution of a (1R,3R)}-1 ,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenyliphosphinoyl)ethylidene]-cyclohexane (514 mg, 0.90 mmol) in tetrahydrofurane (6 mL) at —78°C was added n-BuLi (0.57 mL, 0.91 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-{1 -(5,5,5-trifluoro-4- irifiuoromethyl-4-irimethyisilanyloxy-pent-2E-enyl)-cyclopropyil-3a,4,5,6,7,7a- hexahydro-3H-inden-4-one (200 mg, 0.43 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at —72°C for 3.5h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na-SOys. The residue (750mg) after evaporation of the solvent was purified by FC (15g, 5% AcOEt in hexane) to give a mixture of 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-1 6- ene-20-cyclopropyl-23,24-E-ene-26,27-hexafluoro-19-nor-cholecalciferol and 1- alpha, 3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23,24-
E-ene-26,27-hexafluoro-19-nor-cholecalciferol (250 mg). To the mixture of 1-alpha,3- beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-tri methylsilanyloxy-1 6-ene-20-cyclopropyl- 23,24-E-ene-26,27-hexafluoro-1 9-nor-cholecalciferol and 1-alpha,3-beta-Di(tert-Butyl- dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23,24-E-ene-26,27-hexafl uoro- 19-nor-cholecalciferol (250 mg) tetrabutylammonium fluoride (4 mi, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 24h.
diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,S0s4. The residue (270 mg) after evaporation of the solvent was purified by FC (10g, 50% AcOEt in hexane and AcOEt) to give the titled compound (27) (157 mg, 0.30 mmol, 70%). [a]¥= +63.3 ¢ 0.45, EtOH. UV Amax (EtOH): 243nm (e30821),, .. 251e0m ( 36064), 260 nm (e 24678); H NMR (CDCla): 6.29 (1H, d, J=11.3 Hz), 6.24 (1H, dt,
J=15.9, 6.4Hz), 5.92 (1H, d, J=11.1 Hz), 5.61 (1H, d, J=15.7Hz), 5.38 (1H, m), 4.13 (1H, m), 4.05 (1H, m), 2.88 (1H, s), 2.82-1.34 (19H, m), 0.770 (3H, s ),0.80-0.36 (4H, m); MS HRES Calculated for CoH3403Fs M+H 521.2485. Observed M+H 521.2489.
Synthetic Example 34 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- 23,24-E-ene-26,27-hexafluoro-cholecaliciferol (28) - P(O)Ph, en
FoC OH ir Lt oa 7
I Fi OMS 1 me i —}so oS fe) {
HO® OH 28
To a stirred solution of a (1S,5R)-1 ,5-bis~((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylphosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (525 mg, 0.90 mmol) in tetrahydrofurane (6 mL) at —78°C was added n-BuLi (0.57 mL, 0.91 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1-(5,5,5- trifluoro-4-trifluoromethyl-4-trimethylsilanyloxy-pent-2E-enyl)-cyclopropyil-3a,4,5.6,7,7a- hexahydro-3H-inden-4-one (200 mg, 0.43 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at —72°C for 2.5h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na,S04. The residue (760mg) after evaporation of the solvent was purified by FC (15g, 10% AcOEt in hexane) to give a mixture of 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-1 6- ene-20-cyclopropyl-23,24-E-ene-26,27-hexafluoro-cholecalciferol and 1-alpha,3-beta-
Di (tert-Butyl-dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23,24-E-ene-26,27- hexafiuoro-cholecalciferol (274 mg). To the mixture of 1-alpha,3-beta-Di(tert-Butyl- dimethyl-silanyloxy)-25-trimethylsilanyloxy-16-ene-20-cyclopropyl-23,24-E-ene-26,27- hexafluoro-cholecalciferol and 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-
hydroxy-16-ene-20-cyclopropyl-23,24-E-ene-26,27-hexafluoro-cholecalciferol (274 mg) tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 15h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,SO4. The residue (280 mg) after evaporation of the solvent was purified by FC (15g, 50% AcOEt in hexane and AcOEt) to give the titled compound (28) (167 mg, 0.31 mmol, 73 %). [a]*%= +18.3 c 0.41, EtOH.
UV Amax (EtOH): 207 nm (€ 17778), 264 nm (€ 15767); 'H NMR (CDCla): 6.36 (1H, d,
J=11.1 Hz), 6.24 (1H, dt, J=15.7, 6.7Hz), 6.07 (1H, d, J=11.3 Hz), 5.60 (1H, d, J=15.5
Hz), 5.35 (1H, m), 5.33 (1H, s), 5.00 (1H, s), 4.44 (1H, m), 4.23 (1H, m), 3.14 (1H, s), 2.80 (1H, m), 2.60 (1H, m), 2.40-1.40 (15H, m), 0.77 (3H, s ),0.80-0.36 (4H, m); MS
HRES Calculated for CasHsOsFs M+H 533.2485. Observed M+H 533.2483.
Synthetic Example 35 - Synthesis of (3aR, 4S,7aR)-7a-Methyl-1-[1 (5,5,5-trifluoro- 4-hydroxy-4-trifluoromethyl-pent-2Z-enyl)-cyclopropyi]-3a4,5,6,7,7a-hexahydro- 3H-inden-4-ol
FsC_ OH
SIN Hy/Pd CaCOs A CFs
LH Fac OH ° LH
The mixture of (3aR, 4S,7aR)-7a-Methyl-1-[1 -(5,5,5-rifluoro-4-hydroxy-4- trifluoromethyl-pent-2-ynyl)-cyclopropyil-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (300 mg, 0.76 mmol), ethyl acetate (5 mL), hexane (12 mL), absolute ethanol (0.5 mL) quinoline (30 uL) and Lindlar catalyst (75 mg, 5% Pd on CaCO, ) was hydrogenated at room temperature for 2 h. The reaction mixture was filtered through a celite pad and the pad was washed with AcOEt. The solvent was evaporated to give the titled compound (257 mg, 0.65 mmol, 87%). [a}%5= +1.8 ¢ 0.61, CHCl3, 'H NMR (CDCl): 6.08 (1H, dt, J=12.3, 6.7 Hz), 5.47 (1H, m,), 5.39 (1H, d, J=12.1 Hz), 4.15 (1H, br. 8), 3.28 (1H, s), 2.52-1.34 (12H, m), 1.16 (3H, s), 0.78-0.36 (4H, m); BC NMR (CDCl3): 156.66(0), 141.77(1), 126.51(1), 122.79(0, q, J=285 Hz), 115.77 (1), 69.569(1), 55.41(1), 47.28(0), 36.44(2), 35.90 (2), 33.75(2), 30.22(2), 20.89(0), 19.41(3), 17.94(2), 12.05(2), 11.11(2); MS HRES Calculated for C1oH2402Fs M+H 399.1753. Observed M+ H 399.1757.
Synthetic Example 36 - Synthesis of (3aR,7aR)-7a-Methyl-1-[1 -(5,5,5-trifluoro~4- trifluoromethyl-4-trimethylsitanyloxy-pen-2Z-enyi)-cyclopropyl]-3a4,5,6.7.7a- hexahydro-3H-inden-4-one
FaC. OH F3C_OSiMe3
Silt 1. POCICH; Cl A
OH H (0) H
To a stirred suspension of (3aR, 48,7aR)-7a-Methyi-1-[1 -(5,5,5-trifluoro-4-hydroxy-4- trifluoromethyl-pent-2Z-enyl)cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (617 mg, 1.55 mmol) and Celite (2.0 g) in dichloromethane (10 mL) at room temperature wad added pyridinium dichromate (1.17 g, 3.1 mmol). The resulting mixture was stirred for 2.5 h filtered through silica gel (5 g), and then silica gel pad was washed with 20%
AcOEt in hexane. The combined filtrate and washes were evaporated, to give a crude (3aR,7aR)-7a-Methyl-1-[1 -(5,5,5-trifluoro-4-hydroxy-4-triflucromethyl-pentenyl)- cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one (600 mg, 1.51 mmol, 98 %). To a stirred solution of (3aR,7aR)-7a-Methyi-1-[1 -(5,5,5-trifluoro-4-hydroxy-4-trifiuoromethyl- pent-2Z-enyl)-cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one (600 mg, 1.51 mmol) in dichloromethane (15 mL) at room temperature was added trimethylsilyl- imidazole (1.76 mL, 12.0 mmol). The resulting mixture was stirred for 1.0 h filtered through silica gel (10 g) and the silica gel pad was washed with 10% AcOEt in hexane.
Combined filtered and washes were evaporated to give the titted compound (640 mg, 1.37 mmol, 88 %). [a= -0.2 ¢ 0.55, CHCls. '"H NMR (CDCls): 5.97 (1H, dt, J=12.2, 6.2 Hz), 5.40 (1H, m), 5.38 (1H, d, J=12.2Hz), 2.82 (1H, dd, J= 10.7, 6.6 Hz), 2.60-1.74 (10H, m), 0.89 (3H, s), 0.75-0.36 (4H, m), 0.21 (9H, s); 3C NMR (CDCl3): 210.56 (0), 154.30(0), 139.28(1), 125.81(1), 122.52(0, q, J=289 Hz), 118.17 (1), 64.11(1 ), 53.69(0), 40.43(2), 35.51(2), 34.85(2), 26.94(2), 24.07(2), 20.89(0), 18.39(3), 12.26(2), 10.61 (2), 1.43 (3); MS HRES Calculated for CaoHuO2FeSi M+H 469.1992. Observed M+ H 469.1992.
Synthetic Example 37 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyi- 23,24-Z-ene-26,27-hexafluoro-19-nor-cholecalciferol (29)
FiC OH —/ “CF
F3C. OSiMes ik :
Silt . AL 3 TBAF Ih
Ee
HO™ OH 29
To a stirred solution of a (1R,3R)-1 3-bis-((fert-butyldimethyl)silanyloxy)-5-{2- (diphenylphosphinoyl)ethylidene]-cyclohexane (514 mg, 0.90 mmol) in tetrahydrofurane (6 mL) at —78°C was added n-BuLi (0.567 mL, 0.91 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1 -(5,5,5-trifluoro-4- trifluoromethyl-4-trimethylsilanyloxy-pent-2Z-enyl)-cyclopropyll-3a,4.5,6,7,7a- hexahydro-3H-inden-4-one (194 mg, 0.41 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at —~72°C for 3.0h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na,SOs. The residue (750mg) after evaporation of the solvent was purified by FC (15g, 10% AcOEt in hexane) to give a mixture of 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-16- ene-20-cyclopropyl-23,24-Z-ene-26,27-hexafluoro-1 9-nor-cholecalciferol and 1-alpha,3- beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23,24-Z-ene- 26,27-hexafluoro-19-nor-cholecalciferol (230 mg). To the mixture of 1-alpha,3-beta-
Di(tert-Butyl-dimethyl-silanyloxy)-25-tri methylsilanyloxy-16-ene-20-cyclopropy!-23,24-Z- ene-26,27-hexafluoro-19-nor-cholecalciferol and 1-alpha, 3-beta-Di(tert-Butyl-dimethyl- silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23,24-Z-ene-26,27-hexafl uoro-19-nor- cholecalciferol (230 mg) tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in
THF) was added, at room temperature. The mixture was stirred for 40h. diluted with
AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,SO,,
The residue (260 mg) after evaporation of the solvent was purified by FC (10g, 50%
AcOEt in hexane and AcOEt) fo give the titled compound (29) (1327 mg, 0.25 mmol, 62%). [o]%= +53.6 ¢ 0.33, EtOH. UV Amax (EtOH): 243nm (¢ 26982 .. 251ewm ( 32081), 260 nm (€ 21689); 'H NMR (CDCl3): 6.29 (1H, d, J=10.7 Hz), 6.08 (1H, dt,
J=12.5, 6.7THz), 5.93 (1H, d, J=11.1 Hz), 5.46 (1H, m,), 5.40 (1H, d, J=12.7 Hz)), 4.12 (1H, m), 4.05 (1H, m), 3.14 (1H, s), 2.80-1.40 (19H, m), 0.77 (3H, s ),0.80-0.36 (4H, m);
MS HRES Calculated for Co7Ha403sFg M+H 521.2485. ObservedM+H 521.2487.
Synthetic Example 38 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- 23,24-Z-ene-26,27-hexafluoro-cholecaiciferol (30)
FC. OH
P(O)Ph, =/ Fs
F3C_ OSiMes
A= i. EL
Ho" OH
To a stirred solution of a (15,5R)-1 ,5-bis-((tert-butyldimethyl)silanyloxy)-3-{2- (diphenylphosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (525 mg, 0.90 mmol) in tetrahydrofurane (6 mL) at —78°C was added n-BuLi (0.57 mL, 0.91 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1 -(5,5,5- trifluoro-4-trifluoromethyl-d-trimethylsilanyloxy-pent-2Z-enyl)-cyclopropyll-3a,4,5,6,7,7a- hexahydro-3H-inden-4-one (200 mg, 0.43 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at —72°C for 2.5h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na,SOs. The residue (680mg) after evaporation of the solvent was purified by FC (15g, 10% AcOEt in hexane) to give a mixture of 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-16- ene-20-cyclopropyl-23,24-Z-ene-26,27-hexafluoro-cholecalciferol and 1-alpha,3-beta-
Di(tert-Butyl-dimethyl-silanyloxy)-25-hydroxy-1 6-ene-20-cyclopropyl-23,24-Z-ene-26,27- hexafluoro-cholecalciferol (310 mg). To the mixture of 1-alpha,3-beta-Di(tert-Butyl- dimethyl-silanyloxy)-25-trimethylsilanyloxy-1 6-ene-20-cyclopropyl-23,24-Z-ene-26,27- hexafluoro-cholecalciferol and 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25- hydroxy-1 6-ene-20-cyclopropyl-23,24-Z-ene-26,27-hexafluoro-cholecalciferol (310 mg) tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 15h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over NazSOa. The residue (370 mg) after evaporation of the solvent was purified by FC (10g, 50% AcOEt in hexane and AcOEt) to give the titled compound (30) (195 mg, 0.37 mmol, 85 %). [a]*b= +9.4 ¢ 0.49, EtOH.
UV Amax (EtOH): 262 nm (e 11846); 'H NMR (CDCl3): 6.36 (1H, d, J=11.1 Hz), 6.08 (2H, m), 5.44 (1H, m), 5.40 (1H, d, J=12.3Hz), 5.32 (1H, s), 5.00 (1H, s), 4.43 (1H, m), 4.23 (1H, m), 3.08 (1H, s), 2.80 (1H, m), 2.60 (1H, m), 2.55-1.40 (15H, m), 0.77 (3H,
s),0.80-0.34 (4H, m); MS HRES Calculated for C2sH3403Fe M+H 533.2485. Observed
M+H 533.2602.
Synthetic Example 39 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ane-20-cyclopropyl- 19-nor-cholecalciferol (31) rom Tn
Saat: 2 DL
OTM™MS — i? aad 0-3 THF fo) | [ .
HO" OH 31
To a stirred solution of a (1R,3R)-1 3-bis~((fert-butyldimethyl)silanyloxy)-5-[2- (diphenylphosphinoyl)ethylidene]-cyclohexane (697 mg, 1.22 mmol) in tetrahydrofurane (9 mL) at —78°C was added n-BuLi (0.77 mL, 1.23 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1 -(4-methyl-4- trimethylsilanyloxy-pentyl)-cyclopropyil-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one (220 mg, 0.61 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at —72°C for 3.5h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na,SO.. The residue (900mg) after evaporation of the solvent was purified by
FC (15g, 10% AcOEt in hexane) to give 1-alpha,3-beta-Di(tert-Butyl-dimethyl- silanyloxy)-25-trimethylsilanyloxy-16-ene-20-cyclopropyl-1 9-nor-cholecalcifero! (421 mg, 0.59 mmol). To the 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyloxy)-25- trimethylsilanyloxy-1 6-ene-20-cyclopropyl-26,27-hexadeutero-1 9-nor-cholecalciferol (421 mg, 0.59 mmol) tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 40h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,SO4. The residue (450 mg) after evaporation of the solvent was purified by FC (15g, 50% AcOEt in hexane and AcOE) to give the titted compound (31) (225 mg, 0.54 mmol, 89 %). [a]%0= +69.5 ¢ 0.37, EtOH. UV Amax (EtOH): 243nm (¢ 27945. .. 251083039), 261 nm (ge 22701); H NMR (CDCly): 6.30 (1H, d, J=11.3 Hz), 6.93 (1H, d, J=1 1.3 Hz), , 5.36 (1H, m), 4.12 (1H, m), 4.04 (1H, m), 2.75 (2H, m), 2.52-1.04 (22H, m), 1.18 (6H, s), 0.79 (3H, s ),0.65-0.26 (4H, m); 3C NMR (CDCl3): 157.16(0), 142.33(0), 131.25(0), 124.73(1), 123.76(1), 1156.50(1), 71.10(0), 67.39(1), 67.19(1), 59.47(1), 50.12(0),
44.60(2), 43.84(2), 42.15(2), 38.12(2), 37.18(2), 35.57(2), 29.26(3), 29.11(2), 29.08(3), 28.48(2), 23.46(2), 22.26(2), 21 27(0), 17.94(3), 12.70(2), 10.27(2); MS HRES
Calculated for C27H4203 M+H 415.3207. Observed M+H 415.3207.
Synthetic Example 40 - Synthesis of 1-alpha,25-Dihydroxy-1 6-ene-20-cyclopropyl- cholecalciferol (32)
P(O)Phy Tv
Ax : ie DL . oS | THE if Foo : HO" OH 32
To a stirred solution of a (1S,5R)-1 5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylphosphinoyl)-eth-(2)-ylidene]-2-methylene-cyclohexane (675 mg, 1.16 mmol) in tetrahydrofurane (8 mL) at —78°C was added n-BuLi (0.73 mL, 1.17 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1-( 4- methyl-4-trimethylsilanyloxy-pentyl)-cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4- one (210 mg, 0.58 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at —72°C for 3.5h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na.SO. The residue (850mg) after evaporation of the solvent was purified by FC (15g, 10% AcOEt in hexane) to give 1-alpha,3-beta-Di(tert-Butyl- dimethyl-silanyloxy)-25-timethylsilanyloxy-16-ene-20-cyclopropyi-cholecalciferol (382 mg, 0.53 mmol). To the 1-alpha,3-beta-Di(tert-Butyl-dimethyl-silanyioxy)-25- trimethylsilanyloxy-16-ene-20-cyclopropyl-cholecalcifero! (382 mg, 0.53 mmol) tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 15h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,SO4. The residue (380 mg) after evaporation of the solvent was purified by FC (15g, 50% AcOEt in hexane and AcOEt) to give the titled compound (32) (204 mg, 0.48 mmol, 83 %). [a]*p= +16.1 ¢ 0.36, EtOH.
UV Amax (EtOH): 208 nm (e 17024), 264 nm (e 16028); 'H NMR (CDCls): 6.37 (1H, d,
J=11.3 Hz), 6.09 (1H, d, J=11.1 Hz), 5.33 (2H, m), 5.01 (1H, s), 4.44 (1H, m), 4.23 (1H, m), 2.80 (1H, m), 2.60 (1H, m), 2.38-1.08 (20H, m), 1.19 (6H, s), 0.79 (3H, s ),0.66-
0.24 (4H, m); *C NMR (CDCls): 157.07(0), 147.62(0), 142.49(0), 133.00(0), 124.90(1), 124.73(1), 117.19(1), 111.64(2), 71.1 0(1), 70.70(0), 66.88(1), 59.53(1), 50.28(0), 45.19(2), 43.85(2), 42.86(2), 38.13(2), 35.59(2), 29.27(2), 29.14(3), 28.65(2), 23.57(2), 22.62(2), 21.29(0), 17.84(3), 12.74(2), 10.30(2); MS HRES Calculated for C2sH4203
M+Na 449.3026. Observed M+Na 449.3023.
Synthetic Example 41 - Synthesis of 1,25-Dihydroxy-21 -(2R,3-dihydroxy-3-methyl- butyl)-20R-Cholecalciferol (33).
Ho OM
H
A
OH
J
HO" OH 33 [1R,3aR,4S,7aR]-2(R)-[4-(1,1 -dimethylethyl)dimethyl-silanyloxy)-7a-methyl- octahydro-inden-1 .yi]-6-methyl-heptane-1 ,6-diol (34) and [1R,3aR,4S,7aR]-2(S)-[4- (1,1 -dimethylethyl)dimethyl-silanyloxy)-7a-methyl-octahydro-inden-1 -yl]-6-methyl- heptane-1,6-diol (35)
HO 5 HO H
TBDMSO H TBDMSO H
34 35
A solution of the alkenol in tetrahydrofuran (9 mL) was cooled in an ice bath and a 1 M solution of borane—THF in tetrahydrofuran (17 mL) was added dropwise in an originally effervescent reaction. The solution was stirred overnight at room temperature, re-cooled in an ice bath water (17 mL) was added dropwise followed by sodium percarbonate (7.10g, 68 mmol). The mixture was immersed into a 50 °C bath and stirred for 70 min to generate a solution. The two-phase system was allowed to cool then equilibrated with 1:1 ethyl acetate — hexane (170 mL). The organic layer was washed with water (2x25 mL) then brine (20 mL), dried and evaporated to leave a colorless oil (2.76 g). This material was passed through a short flash column using 1:1 ethyl acetate — hexane and silica gel G. The effluent, obtained after exhaustive elution,
was evaporated, taken up in ethyl acetate, filtered and chromatographed on the 2x1 8 15-20 p silica YMC HPLC column using 2:1 ethyl acetate — hexane as mobile phase and running at 100 mL/min. Isomer 34 emerged at an effluent maximum of 2.9 L, colorless ail, 1.3114 g, [alo + 45.2° (methanol, ¢ 0.58; TH NMR § -0.002 (3H, s), 0.011 (3H, s), 0.89 (9H, s), 0.93 (3H, s), 1.17 (1H, m), 1.22 (6H, s), 1.25-1.6 (16H, m), 1.68 (1H, m), 1.80 (2H, m), 1.89 (1H, m), 3.66 (1H, dd, J =4.8 and 11 Hz), 3.72 (1H, dd, J = 3.3 and 11 Hz), 4.00 (1H, m); LR-ES(-) m/z 412 (M), 411 (M-H); HR-ES(+): calcd for (M+Na) 435.3265, found: 435.3269.
Isomer 35 at was eluted at an effluent maximum of 4.9L, colorless oil, 0.8562 g that crystallized upon prolonged standing: mp 102-3°, [oo + 25.2° (methanol, ¢ 0.49); H
NMR 5 -0.005 (3H, s), 0.009 (3H, s), 0.89 (9 H, s), 0.93 (3H, s), 1.16 (1H, m), 1.22 (6H, s), 1.3-1.5, (14H, m), 1.57 (2H, m), 1.67 (1H, m), 1.80 (2H, m), 1.91 (1H, m), 3.54 (1H, dd, J = 4.8 and 11 Hz), 3.72 (1H, dd, J = 2.9 and 11 Hz), 4.00 (1H, m); ); LR-ES(-) m/z 442 (M), 411 (M-H). Anal. Calcd for C24HssO3Si: C, 69.84, H, 11.72; found: C, 69.91; H, 11.76. [1 R,3aR,4S,7aR]-6(R)-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro- inden-1-yl]-7-iodo-2-methyl-heptan-2-ol (36)
H
TBDOMSO H
36
A stirred mixture of triphenylphosphine (0.333 g, 1.27 mmol) and imidazole (0.255 g, 3 mmol) in dichloromethane (3 mL) was cooled in an ice bath and iodine (0.305 g, 1.20 mmol) was added. This mixture was stirred for 10 min then a solution of 34 (0.4537 g, 1.10 mmol) in dichloromethane (3 mL) was added dropwise over a 10 min period. The mixture was stirred in the ice bath for 30 min then at ambient temperature for 2% h. TLC (1:1 ethyl acetate — hexane) confirmed absence of educt. A solution of sodium thiosulfate (0.1 g) in water (5 mL) was added, the mixture equilibrated and the organic phase washed with 0.1 N sulfuric acid (10 mL) containing a few drops of brine then with 1:1 water — brine (2x10 mL), once with brine (10 mL) then dried and evaporated. The residue was purified by flash chromatography using 1:9 ethyl acetate
— hexane as mobile phase to furnish 36 as a colorless syrup, 0.5637 g, 98%: 'H NMR 3 -0.005 (3H, s), 0.010 (3H, s), 0.89 (9H, s), 0.92 (3H, s), 1.23 (6H, s), 1.1-1.6 (16H, m), 1.68 (1H, m), 1.79 (2H, m), 1.84 (1H, m), 3.37(1H, dd, J = 4 and 10 Hz), 3.47 (1H, dd, J = 3 and 10 Hz), 4.00 (1H, m); LR-EI(+) m/z 522 (M), 465 (M-CsHs), 477 (M-C4Hg-H20);
HR-EI(+): calcd for C24Harl02Si: 522.2390, found: 522.2394. [1 R.3aR.4S,7aR]-6(S)-[4-{tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro- inden-1-yl]-2-methyl-non-8-yn-2-ol (37) oe H
OH
TBDMSO H a7
Lithium acetylide DMA complex (0.110 g, 1.19 mmol) was added to a solution of 36 (0.2018 g (0.386 mmol) in dimethyl sulfoxide (1.56 mL) and tetrahydrofuran (0.15 mL).
The mixture was stirred overnight. TLC (1:4 ethyl acetate — hexane) showed a mixture of two spots traveling very close together (Rf 0.52 and 0.46). Fractions at the beginning of the eluted band contained pure alkenol, which is the elimination product of 36, and was produced as the major product. Fractions at the end of the elution band, however, were also homogeneous and gave the desired acetylene 37 upon evaporation. The
NMR spectra of 37 and its 6-epimer which served for identification were previously reported. [1 R,3aR,4S,7aR]-7-Benzenesulfonyl-6(S)-{4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden-1 -yi]-2-methyl-heptan-2-ol (38). phos J!
Lrtbms 38
A mixture of 37b (0.94 g, 1.8 mmol), sodium benzenesulfinate (2.18 g, 13 mmol) and N,N-dimethylformamide (31.8 g) was stirred at room temperature for 12 h, then in a 40 °C bath for ¢a.6 h until all educt was converted as shown by TLC (1:4 ethyl acetate — hexane). The solution was equilibrated with 1:1 ethyl acetate — hexane (120 mL) and 1:1 brine — water (45 mL). The organic layer was washed with water (4x25 mL) brine
(10 mL), then dried and evaporated to leave a colorless oil, 1.0317 g. This material was flash-chromatographed using a stepwise gradient (1:9, 1:6, 1:3 ethyl acetate — hexane) to give a colorless oil, 0.930 g, 96%: 300 MHz 1H NMR & -0.02 (3H, s), 0.00 (3H, s), 0.87 (9H, s), 0.88 (3H, s), 1.12 (1 H, m), 1.20 (6H, s), 1.2-1.8 (18H, m), 1.81 (1H, m), 3.09 (2H, m), 3.97 (1H, brs), 7.59 (3H, m), 7.91 2H, m). [1R,3aR,4S,7aR]-11 (S)-Benzenesulfonyimethyl-5-methyl-5-trimethylsilanyloxy- hexyl)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-indene (39).
PhO.S H
CH rom ¥ dbus 39 1-(Trimethylsilyl)imidazole (1 mL) was added to a solution of 38 (0.8 g) in cyclohexane (10 mL) and stirred overnight then flash-chromatographed using a stepwise gradient of hexane, 1:39 and 1:19 ethyl acetate — hexane. The elution was monitored by TLC (1:4 ethyl acetate — hexane) leading to 39 as a colorless syrup, 0.7915 g: 300 MHz 1H NMR § 0.00 (3H, s), 0.02 (3H, s), 0.12 (9H, s), 0.90 (12H, s, t- butyl+7a-Me), 1.16 (1H, m), 1.20 (6H, s), 1.2-1.6 (15H, m), 1.66-1 .86 (3H, m), 3.10 (2H, m), 4.00 (1H, brs), 7.56-7.70 (3H, my), 7.93 (2H, m). [1 R,3aR,4S,7aR]-6(R)-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro- inden-1-yl}-2,1 0-dimethyl-undecane-2,3(R),10-triol (40).
Ho OM
H iat
Sebbus 40
A solution of 39 (0.7513 g, 1.23 mmol) and diol (0.508 g, 1.85 mmol) in tetrahydrofuran (28 mL) was cooled to -35 °C then 2.5 M butyllithium in hexane (2.75 mL) was added dropwise. The temperature was allowed to rise to —20 °C and maintained at that temperature for 6 h or until the educt was consumed. Reaction progress was monitored by TLC (1:4 ethyl acetate — hexane) exhibiting the educt (Rf 0.71) and the two epimeric diols (Rf 0.09 and 0.12). Toward the end of the reaction period the temperature was increased briefly to 0 °C, lowered again to —10, then saturated ammonium chloride (25 mL) was added followed by ethyl acetate (50 mL) and enough water to dissolve the precipitated salts. The resulting aqueous phase was extracted with ethyl acetate (15 mL). The combined extracts were washed with brine (15 mL), dried and evaporated. The resulting syrup was flash-chromatographed using a stepwise gradient of 1:9, 1:6, 1:4 and 1:1 ethyl acetate — hexane to give 39aasa colorless syrup, 0.8586 g. This material was dissolved in a mixture of tetrahydrofuran (30 mL) and methanol (18 mL), then 5% sodium amalgam (20 g) was added. The reductive de-sulfonylation was complete after stirring of the mixture for 14 h. Progress of the reaction was monitored by TLC (1:1 ethyl acetate — hexane) which showed the disappearance of the epimeric diols (Rf 0.63 and 0.74) and the generation of 40a (Rf 0.79) and the partially de-silylated analog 40 (Rf 0.16). The mixture was diluted with methanol (20 mL), stirred for 3 min, then ice (20 g) was added, stirred for 2 min and the supernatant decanted into a mixture containing saturated ammonium chloride (50 mL).
The residue was repeatedly washed with small amounts of tetrahydrofuran that was also added to the salt solution, which was then equilibrated with ethyl acetate (80 mL).
The aqueous layer was re-extracted once with ethyl acetate (20 mL), the combined extracts were washed with brine (10 mL) then dried and evaporated. The resulting colorless oil containing both 40a and 40 was dissolved in 10 mL of a 1 N oxalic acid solution in methanol (prepared from the dihydrate) effecting the selective hydrolysis of the trimethylsilyl ether within minutes. Calcium carbonate (1 g) was added and the suspension stirred overnight, then filtered. The solution was evaporated and the resulting residue flash-chromatographed using a stepwise gradient of 1:4, 1:2, 1:1 and 2:1 ethyl acetate — hexane giving a residue of the triol 40 that crystallized in very fine branching needles from acetonitrile, 0.45 g: mp 94-95 °C, [op + 44.1° (methanol, ¢ 0.37); 400 MHz "H NMR & -0.005 (3H, s), 0.007 (3H, s), 0.89 (9H, s), 0.92 (3H, s), 115 (1H, m), 1.16 (3H, s), 1.21 (9H, s), 1.2-1.6 (19H, m), 1.67 (1H, m), 1.79 (2H, m), 1.90 (2H, m), 2.06 (1H, m), 3.31 (1H, brd, J = 10 Hz), 4.00 (1H, brs), LR-ES(-) m/z: 533 (M+ClI), 497 (M-H); HR-ES(+): Calcd for CagHss04Si + Na: 521.3996, found: 521.4003.
Anal Calcd for CagHss04Si: C, 69.82, H, 11.72; found: C, 69.97; H, 11.65. [1 R,3aR,4S,7aR]-6(R)-(4-Hydroxy-7a-methyl-octahydro-inden-1 -yl)-2,10-dimethyl- undecane-2,3(R),10-triol (41).
Ho OM
H
La 41
A stirred solution of the triol 40 (0.4626 g, 0.927 mmol) in acetonitrile (10 mL) and dioxane (0.7 mL) was cooled to 10 °C and a fluorosilicic acid solution (2 mL) was added dropwise. The cooling bath was removed, the 2-phase system further diluted with acetonitrile (2 mL) then stirred at room temperature for 3 % h. The disappearance of educt was monitored by TLC (ethyl acetate). The mixture was equilibrated with water (10 mL) and ethyl acetate (30 mL). The aqueous phase was re-extracted with ethyl acetate (2x20 mL), the combined extracts were washed with water (5 mL) and brine (10 mL), then 1:1 brine — saturated sodium hydrogen carbonate solution and dried. The residue was purified by flash-chromatography using a step-wise gradient from 1:1 to 2:1 ethyl acetate — hexane and neat ethyl acetate to give a residue that was taken up in 1:1 dichloromethane — hexane, filtered and evaporated to furnish amorphous solids, 0.3039 g (85%): [olp + 42.6° (methanol, ¢ 0.48); 'H NMR (DMSO-ds): 3 0.87 (3H, s), 0.97 (3H, s), 1.02 (3H, s), 1.04 (6H, s), 1.1-1.4 (18H, m), 1.5-1.8 (4H, m), 1.84 (1H, m), 2.99 (1H, dd, J = 6 and 10 Hz), 3.87 (1H, brs), 4.02 (1H, s, OH), 4.05 (1H, s, OH), 4.16 (1H, d,
OH, J = 3.6 Hz), 4.20 (1H, d, OH, J = 6.4 Hz); LR-ES(+): m/z 384 (M), 383 (M-H); HR-
ES(+): Calcd for (M+Na) 407.3132, found: 407.3134. [1R,3aR,48,7aR]-1 -{5-Hydroxy-5-methyl-1 (R)-[2+(2,2,5,5-tetramethyl-{1 ,3]dioxolan- 4(R)-y!)-ethyi]-hexyl}-7a-methyl-octahydro-inden-4-ol (42) 2
H
OH
LH
} 42
A solution of the tetraol 40 (0.2966 g, 0.771 mmol) and pyridinium tosylate (100 mg) in acetone (8 mL) and 2,2-dimethoxypropane (8 mL) was kept at room temperature for 12 h. TLC analysis (ethyl acetate) showed the absence of educt (Rf 0.21) and two new spots with Rf 0.82 and 0.71, the former the expected 42 and the latter assumed to be the methylacetal. The reaction mixture was diluted with water (5 mL) and stirred for min. At that time only the spot with higher Rf value was observed. The mixture was neutralized with sodium hydrogen carbonate (0.5 g) then equilibrated with ethyl acetate (50 mL) and brine (5 mL). The organic layer was washed with water (5 mL) and brine (5 mL) then dried and evaporated to leave a sticky residue (0.324 g) that was used directly in the next step: 300 MHz "H NMR: 3 0.94 (3H, s), 1.10 (3H, s), 1.20 (1H, m), 1.22 (6H, s), 1.25 (3H, s), 1.34 (3H, s), 1.41 (3H, s), 1.2-1.65 (20H, m), 1.78-1.86 (3H, m), 1.93 (1H, m), 3.62 (1H, dd, J=4.6 and 8.3 Hz), 4.08 (1H, brs). [1R,3aR,4S,7aR]-Acetic acid 1-{5-hydroxy-5-methyl-1 (R)-2-(2,2,5,5-tetramethyl- [1 3]dioxolan-4(R)-yl)-ethyl]-hexyl)-7a-methyi-octahydro-inden-4-yl ester (43).
Fe
H
OH
AcO H 43
The residue obtained above was dissolved in pyridine (6.9 g) and further diluted with acetic anhydride (3.41 g). The mixture was allowed to stand at room temperature for 24 h, then in a 35 °C bath for ca. 10 h until the educt was no longer detectable (TLC, ethyl acetate). The mixture was diluted with toluene and evaporated. The residue was purified by flash chromatography (1:4 ethyl acetate — hexane) to give 43 as colorless syrup, 0.3452 g, 97%: 1H NMR: § 0.89 (3H, s), 1.10 (3H, s), 1.20 (1H, m), 1.22 (6H, Ss), 1.25 (3H, s), 1.33 (3H, s), 1.41 (3H, s), 1.25-1.6 (19H, m), 1.72 (1H, m), 1.82 (2H, m), 1.95 (1H, m), 2.05 (3H, s), 3.63 (1H, dd, J = 4.4 and 8.4 Hz), 5.15 (1H, brs); LR-FAB(+) m/z 467 (M+H), 465 (M-H), 451 (M-Me). [1R,3aR,4S,7aR]-Acetic acid 1-J4(R),5-dihydroxy-1 (R)-(4-hydroxy-4-methyl-pentyl)- 5-methyl-hexyl]-7a-methyl-octahydro-inden-4-yl ester (44). no, MH
H
OH
Lak
A solution of 43 (0.334 g, 0.716 mmol) in 80 % acetic acid (2 mL) was keptina 68 °C bath. TLC (ethyl acetate, Rf 0.33) monitored the progress of the hydrolysis. The educt was no longer detectable after 2.5 h. The mixture was evaporated then co- evaporated with a small amount of toluene to leave a colorless film (0.303 g) that was used directly in the next step: 300 MHz 1H NMR: 5 0.89 (3H, s), 1.17 (3H, 5), 1.22 (6H, s), 1.56 (3H, s), 1.1-1.6 (21H, m), 1.6-2.0 (5H, m), 2.04 (3H, s), 3.32 (1H, brd, J = 10
Hz), 5.15 (1H, brs). [1R,3aR,4S,7aR]-Acetic acid 1-[4(R)-[dimethyl-(1,1 ,2-trimethyl-propyl)-silanyloxy}- 5-hydroxy-1(R)-{(4-hyd roxy-4-methyl-pentyl)-5-methyl-hexyi]-7a-methyl-octahyd ro- inden-4-yl ester (45)
Ro A
H
Ac H 45
A solution of the triol 44 (0.30 g), imidazole (0.68 g, 10 mmol) and dimethylthexylsilyl chloride (1.34 g, 7.5 mmol) in N,N-dimethyiformamide (6 g) was kept at room temperature. After 48 h 4-(N,N-dimethylamino)pyridine (15 mg) was added and the mixture stirred for an additional 24 h. Reaction progress was monitored by TLC (ethyl acetate; 24, Rf 0.83; 25a, Rf 0.38). The mixture was diluted with water (2 mL), stirred for 10 min then distributed between ethyl acetate (45 mL) and water (20 mL).
The aqueous layer was extracted once with ethyl acetate (10 mL). The combined organic phases were washed with water (4x12 mL) and brine (8 mL.) then dried and evaporated. The residual oil was purified by flash-chromatography using a stepwise gradient of 1:9 and 1:4 ethyl acetate — hexane to give 45 as colorless syrup. A small amount of unreacted educt (80 mg) was eluted with ethyl acetate. The syrupy 45 was used directly in the next step: 400 MHz 'H NMR: 50.13 (3H, s), 0.14 (3H, s), 0.87 (6H, s), 0.91 (9H, m), 1.10 (1H, m), 1.14 (3H, s), 1.15 (3H, s), 1.21 (6H, s), 1.1-1.6 (19H, m), 1.6-1.9 (5H, m), 1.94 (1H, brd, J = 12.8 Hz), 2.05 (3H, s), 3.38 (1H, brs), 5.15 (1 H, brs).
08 [1R,3aR,4S,TaR]-Acetic acid 1-[4(R)-[dimethyl-(1 1,2-trimethyl-propyl)-silanyloxy]- 5-methyl-1 (R)-{d-methyl-4-trimethylsilanyloxy-pentyl)-5-trimethylsilanyloxy-hexyll- 7a-methyl-octahydro-inden-4-yl ester (46). is
TMSO_ =
H
. wt
Fem
Ach H : 46 1-(Trimethylsilyl)imidazole (0.90 mL, 6.1 mmol) was added to a solution of 45 (0.2929 mg) in cyclohexane (6 mL) and stirred for 12 h, then flash-chromatographed (1:79 ethyl acetate — hexane) to yield 46 as colorless syrup (0.3372 g). The elution was monitored by TLC (1:4 ethyl acetate —- hexane) leading to 46 as a colorless syrup, 0.7915 g: "H NMR 3: 0.074 (3H, s), 0.096 (3H, s), 0.103 (9H, s), 0.106 (9H, s), 0.82 (1H, m), 0.83 (6H, s), 0.88 (9H, m), 1.32 (3H, s), 1.20 (9H, s), 1.15-1.6 (17H, m), 1.6-1.9 (5H, m), 1.97 (1H, brd, J = 12.8 Hz), 2.05 (3H, s), 3.27 (1H, m), 5.15 (1H, brs); LR-FAB(+) miz: 712 (M), 711 (M-H), 697 (M-Me), 653 (M-AcO), 627 (M-CgH13). [1R,3aR,48,7aR]-1 -[4(R)-[Dimethyi-(1,1 ,2-trimethyl-propyl)-silanyloxy]-5-methyl- 1(R)«{4-methyl-4-tri methyisilanyloxy-pentyl)-5-trimethylsilanyloxy-hexyl]-7a- methyl-octahydro-inden-4-ol (47) is
TMSO, =
H wH ve
HO H a7
A stirred solution of 46 (0.335 mg, 0.47 mmol) in tetrahydrofuran (15 mL) was cooled in an ice-bath and a 1 M solution of lithium aluminum hydride in tetrahydrofuran (2 mL) was added dropwise. TLC (1:9 ethyl acetate — hexane) showed complete conversion 25b (Rf 0.61) to 26 (Rf 0.29) after 1.5 h. A 2 M sodium hydroxide solution (14 drops) was added, followed by water (0.5 mL) and ethyl acetate (30 mL). A small amount of Celite was added and, after stirring for 15 min, the liquid layer was filtered off.
The solid residue was rinsed repeatedly with ethyl acetate and the combined liquid phases evaporated to leave a colorless syrup, that was taken up in hexane, filtered and evaporated to yield 26 (0.335 g) that was used without further purification: HNMR &: 0.075 (3H, s), 0.10 (21H, brs), 0.82 (1H, m), 0.84 (6H, s), 0.89 (6H,m), 0.93 (3H, s), 1.13 (3H, s), 1.20 (9H, s), 1.2-1.6 (16H, m), 1.6-1.7 (2H, m), 1.82 (3H, m), 1.95 (1H, brd,
J = 12.4 Hz), 3.27 (1H, m), 4.08 (1H, brs); LR-FAB(+) m/z: 585 (M-CeH13), 481 (M-
TMSO); HR-ES(+) m/z: Calcd for CarHzs04Sis + Na: 693.5100 found: 693.5100. [1R,32R,7aR]-1 -[4(R)-[Dimethyl-(1,1 ,2-trimethyl-propyl)-silanyloxy]-5-methy-1 (R)- (4-methyl-4-trimethylsilanyloxy-pentyl)-5-trimethylsilanyloxy-hexyi]-7a-methyl- octahydro-inden-4-one (48)
TMSO FS
H
I H
48
Celite (0.6 g) was added to a stirred solution of 47 (0.310g, 0.462 mmol) in dichloromethane (14 mL) followed by pyridinium dichromate (0.700 g, 1.86 mmol). The conversion of 47 (Rf 0.54) to the ketone 27 (Rf 0.76) was followed by TLC (1:4 ethyl acetate — hexane). The mixture was diluted with cyclohexane after 4.5 h then filtered trough a layer of silica gel. Filtrate and ether washes were combined and evaporated.
The residue was flash-chromatographed (1:39 ethyl acetate — hexane) to give 27 as a colorless syrup, 0.2988 g, 96.6%: H NMR §: 0.078 (3H, s), 0.097 (3H, s), 0.107 (18H, s), 0.64 (3H, s), 0.81 (1H, m), 0.84 (6H, s), 0.89 (6H,m), 1.134 (3H, s), 1.201 (3H, Ss), 1.207 (3H, s), 1.211 (3H, s), 1.3-1.6 (14H, m), 1.6-1 .7 (3H, m), 1.88 (1H, m), 2.04 (2H, m), 2.2-2.32 (2H, m), 2.46 (1H, dd, J=7.5 and 11.5 Hz), 3.28 (1H, m); LR-FAB(+) m/z: 583 (M-CgH13), 479 (M-OTMS); HR-ES(+) m/z: Calcd for Ca7H7604Si3 + Na: 691.4943, found: 691.4949. [1 R,3aR,7aR,AE]-4-{2(2)-[3(S),5(R)-Bis~{tert-butyl-dimethyl-silanyloxy)-2- methylene-cyclohexylidene]-ethylidene}-7a-methyl-1 -[5-methyl-1(R)-(4-methyl-4- trimethylsilanyloxy-pentyl)-4(R)-[dimethyi-(1,1 ,2-trimethyl-propyl)-silanyloxy]-5- trimethylsilanyloxy-hexyl]-octahydro-indene (49)
TS so, © ©
H
Ng [Sotms
J hil
TBDMSO" OTBDMS 49
A solution of 2.5-M butyllithium in hexane (0.17 mL) was added to a solution of 28 in tetrahydrofuran (2 mL) at—70 °C to produce a deep cherry-red color of the ylied.
After 10 min a solution of ketone 27 (0.1415 g, 0.211 mmol) in tetrahydrofuran (2 mL) was added dropwise over a 15 min period. The reaction was quenched after 4 h by the addition of pH 7 phosphate buffer (2 mL). The temperature was allowed to increase to 0 °C then hexane (30 mL) was added. The aqueous layer was re-extracted with hexane (15 mL). The combined extracts were washed with of brine (5 mL), dried and evaporated to give a colorless oil that was purified by flash-chromatography (1:100 ethyl acetate — hexane) to yield 49 as colorless syrup, 0.155 g, 71%: 'H NMR &: 0.068 (15H, m), 0.103 (12H, s), 0.107 (9H, s), 0.53 (3H, 8), 0.82 (1H, m), 0.84 (6H, s), 0.88 (18H,m), 0.89 (6H, m), 1.14 (3H, m), 1.20 (9H, s), 12-1.9 (22H, m), 1.97 (2H, m), 2.22 (1H, dd, J = 7.5 an 13 Hz), 2.45 (1H, brd, J = 13 Hz), 2.83 (1H, brd, J = 13 Hz), 3.28 (1H, m), 4.20 (1H, m), 4.38 (1H, m), 4.87 (1H, d, J=2 Hz), 5.18 (1H, d, J = 2 Hz), 6.02 (1H,d, J = 11.4 Hz, 6.24 (1H, d, J = 11.4 Hz); LR-FAB(+) m/z 1033 (M+H), 1032 (M), 1031 (M-H), 901 (M-TBDMS).
Synthesis of 1,25-Dihydroxy-21 <(2R,3-dihydroxy-3-methyl-butyl)-20R-
Cholecalciferol (33).
Ho OH
H
- OH
Iw
IE
LG
The residue of 49 (0.153 g, 0.148 mmol), as obtained in the previous experiment, was dissolved ina 1 M solution of tetrabutylammonium fluoride (3.5 mL).
TLC (ethyl acetate) monitored reaction progress. Thus, the solution was diluted with brine (5 mL) after 24 h, stirred for 5 min then equilibrated with ethyl acetate (35 mL) and water (15 mL). The aqueous layer was re-extracted once with ethyl acetate (15 mL).
The combined organic layers were washed with water (5x10 mL), once with brine (5 mL) then dried and evaporated. The residue was purified by flash chromatography using a stepwise gradient of ethyl acetate and 1:100 methanol — ethyl acetate furnishing 33 as colorless, microcrystalline material from methyl formate — pentane, 70 mg, 91 %: [ofp + 34.3 ° (methanol, ¢ 0.51); "H NMR (DMSO-dg) 8: 0.051 (3H, s), 0.98 (3H, s), 1.03 (3H, s), 1.05 (6H, s), 1.0-1.6 (17H, m), 1.64 (3H, m), 1.80 (2H, m), 1.90 (1H,d, J = 11.7
Hz), 1.97 (1H, dd, J=J= 9.8 Hz), 2.16 (1H, dd, J = 5.9 and J = 13.7 Hz), 2.36 (1H, brd), 2.79 (1H, brd), 3.00 (1H, dd, J = 5 and 10 Hz), 3.99 (1H, brs), 4.01 (1H, s, OH), 4.04 (1H, s, OH), 4.54 (1H, OH, d, J = 3.9 Hz), 4.76 (1H, brs), 4.87 (1H, OH, d, J = 4.9 Hz), 5.22 ( 1H, brs), 5.99 (1H, d, J = 10.7 Hz), 6.19 (1H, d, J = 10.7 Hz); LR-ES(+) m/z: 519 (M+H), 518 (M), 517 (M-H), 501 (M-OH); HR-ES(+) calcd for CazHs4Os + Na: 541.3863; found 541.3870; UVmax (€): 213 (13554), 241sh (12801), 265 (16029) nm.
Synthetic Example 42 - Synthesis of 1,25-Dihydroxy-21(2R,3-dihydroxy-3-methyl- butyl)-20S-Cholecalciferol (50).
Ho oH
H wH
OH
J hi
HO" OH 50 [1 R,3aR,4S,7aR]-7-Benzenesulfonyl-6(R)-[4-{tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden-1 -yl]-2-methyl-heptan-2-ol (51).
PhO,S J
Libs
A solution of 36 and sodium benzenesulfinate (0.263 9, 1.6 mmol) in N,N- dimethyl formamide (5 mL) was stirred in a 77 °C bath for 3 h. The solution was equilibrated with 1:1 ethyl acetate — hexane (25 mL) and the organic layer washed with water (5x10 mL), dried and evaporated. The residue was fash-chromatographed with a stepwise gradient of 1:9, 1:4, and 1:3 ethyl acetate — hexane to furnish the sulfone as a colorless syrup: '"H NMR 3 -0.02 (3H, s), 0.005 (3H, s), 0.79 (3H, s), 0.87 (9H, s), 1.12 (1H, m), 1.19 (6H, s), 1.12 (1H, m), 1.20 (6H, s), 1.2-1.8 (18H, m), 2.08 (1H, m), 3.09 (1H, dd, J = 9.3 and 14.5 Hz), 3.31 (1H, dd, J = 3 and 14.5 Hz), 3.97 (1H, brs), 7.58 (3H, m), 7.66 (1H, m), 7.91 2H, m}); LR-ES(+) m/z: 600 (M+Na+MeCN), 559 (M+Na),
LR-ES(-) m/z: 536 (M), 535 (M-H); HR-ES(+): Calcd for CaoHs204SSi + Na 559.3248; found 559.3253. [1R,3aR,4S,7aR]-1-1 (R)-Benzenesulfonylmethyl-5-methyl-5-tri methylsilanyloxy- hexyl)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-indene (52).
PhOS J"
CH one ¥ ribs 52 1-(Trimethylsilyl)imidazole (0.146 mL) was added to a solution of 51 (0.145 g, 0.27 mmol) in cyclohexane (2 mL). After 17 h the product was purified by flash chromatography using a stepwise gradient of 1:79 and 1:39 ethyl acetate — hexane to give 52 as colorless residue, 0.157 g 0.258 mmol, TLC (1:9 ethyl acetate — hexane) Rf 0.14. 300 MHz "HNMR: § -0.02 (3H, s), 0.00 (3H, s), 0.87 (12H, s), 1.12 (1H, m), 1.17 (6H, s), 1.2-1.6 (15H, m), 1.6-1.9 (3H, m), 3.08 (2H, m), 3.97 (1H, brs), 7.53-7.70 (3H, m), 7.90 (2H, d, J = THz). [1 R,3aR,AS,TaR]-5(R,S)-Benzenesulfonyl-6(R)-[4-(tert-butyl-dimethyl-silanyloxy)- 7a-methyl-octahydro-inden-1-yi]-2,1 0-dimethyi-10-trimethylsilanyloxy-undecane- 2,3(R)-diol (53)
Ho 9H soph % H ions
TBDMSO H
53
A solution of 152 (0.2588, 0.425 mmol) and diol (0.176 g, 0.638 mmol) in tetrahydrofuran (9 mL) was cooled to _25 °C and 1.6 M butyllithium in hexane (1.4 mL) was added. The temperature was raised to _20 °C and maintained for 3 h then at —10 °C for 2.5 h and 0°C for 10 min. The mixture was cooled again to —10 °C, saturated ammonium chloride solution (5 mL) was added, then equilibrated with ethyl acetate (50 mL) and enough water to dissolve precipitated salts. The aqueous layer was re- extracted with ethyl acetate (15 mL), the combined extracts were dried and evaporated and the residue purified by flash chromatography using a stepwise gradient of 1:6, 1:4, and 1:1 ethyl acetate — hexane to produce 53 as a colorless syrup, 0.212 g, 70 %: 300
MHz 'H NMR: § 0.00 (3H, s), 0.017 (3H, s), 0.12 (SH, s), 0.81 (3H, s), 0.89 (SH, s), 1.16 (1H, m), 1.19 (12H, m), 1.1-1.6 (20H, m), 1.6-1.8 (2H, m), 3.10 (1H, dd, J=8.4 and 14.7
Hz), 3.30 (1H, m), 3.99 (1H, brs), 7.61 (2H, m), 7.67 (1H, m), 7.93 (2H, m). [1R,3aR,4S,7aR]-6( S)-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro- inden-1-y1]-2,10-dimethyl-1 0-trimethylsilanyloxy-undecane-2,3(R)-diol (54).
Ho SH soPh
H .
TBDMSO H
: 54
Compound 53 (0.186 mg, 0.262 mmol) was dissolved in 0.5 M oxalic acid dihydrate in methanol (2.5 mL). The solution was stirred for 15 min then calcium carbonate was added (0.5 g) and the suspension stirred overnight then filtered. The filtrate was evaporated to give 54 as a white foam, 0.188 g, 98 %: TLC (1:1 ethyl acetate — hexane) Rf 0.06. This material was used in the next step without further purification. [1R,3aR,4S,7aR]-6( S)-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahyd ro- inden-1-yl]-2,1 0-dimethyl-undecane-2,3(R),10-triol (triol 55).
Ho oH
H
TBDMSO H
55
Sodium amalgam (6% sodium, 10.8 g) was added to a vigorously stirred solution of 54 (0.426 g, 0.667 mmol) in a mixture of tetrahydrofuran (15 mL) and methanol (9 mL). The suspension was stirred for 24 h and the reaction monitored by TLC (1:1 ethyl acetate — hexane0 to observe the production of 55 (Rf 0.17). The mixture was diluted with methanol (3 mL), stirred for 5 min then further diluted with water (10 mL), stirred for 2 min and decanted into saturated ammonium chloride solution (25 mL). The aqueous layer was extracted with ethyl acetate (2x20 mL). The combined extracts were washed with pH 7 phosphate buffer (5 mL) then brine (10 mL), dried and evaporated. The : residue was purified by flash-chromatography using a stepwise gradient of 1:1 and 2:1 ethyl! acetate — hexane to provide 55 as a colorless syrup, 0.244 g, 73%: TH NMR: § - 0.006 (3H, s), 0.006 (3H, s), 0.86 (SH, s), 0.92 (3H, s), 1.11 (1H, m), 1.15 (3H, s), 1.21 (9H, s), 1.2-1.75 (21H, m), 1.7-1.85 (3H, m), 1.90 (1H, m), 3.29 (1H, brd), 3.99 (1H, brs); LR-ES(+) m/z: 521 (M+Na), 481 (M-OH); LR-ES(-): m/z 544: (M+CH,0,), 543 (M-
H+CH,0,), 533 (M-Cl); HR-ES(+) m/z: Calcd for CaoHss04Si + Na: 521.3996, found 521.3999. [1 R,3aR,48,7aR]-6(S)-(4-Hydroxy-Ta-methyl-octahydro-inden-1 -yl)-2,10-dimethyl- undecane-2,3(R),10-triol (56).
Ho OH
H
LH
56
An aqueous fluorosilicic acid solution (3 mL) was added to a stirred solution of 55 (0.240 g, 0.481 mmol) in acetonitrile (12 mL). TLC (ethyl acetate) monitored the reaction. After 2.5 h compound 56 (Rf 0.37) was the predominating species, produced at the expense of less polar 55. The mixture was equilibrated with ethyl acetate and water (10 mL), the aqueous layer was re-extracted with water (2x10 mL) and the combined extracts were washed with water (6 mL) and brine (2x10 mL) then dried and evaporated. The colorless residue was flash-chromatographed using a stepwise gradient of 1:2, 1:1 and 2:1 ethyl acetate — hexane to elute some unreacted 55, followed by 56, obtained as colorless syrup, 0.147 g, 79 %: 1 NMR: 0.94 (3H, 8), 1.12 (1H, m), 1.15 (3H, s), 1.21 (9H, s), 1.15-1.7 (20H, m), 1.7-1.9 (5H, m), 1.96 (1H, brd), 3.29 (1H, d, J = 9.6 Hz), 4.08 (1H, brs); LR-ES(+): m/z 448: (M+Na+MeCN), 407 (M+Na); LR-ES(- ): miz 419 (M+Cl); HR-ES(+) m/z: Calcd for Cp3HasO4 + Na: 407.3132, found 407.3135. [1R,3aR4S,7aR]-1-(5-Hydroxy-1 (S){2-[2-{4-methoxy-phenyl)-5,5-dimethyl- 1 3]dioxolan-4(R)-yl]-ethyl}-5-methyl-hexyl)-7a-methyi-octahydro-inden-4-ol (57) . o pe
H
57 4-Methoxybenzaldehyde dimethyl acetal (60 uL, 0.35 mmol) was added to a solution of 56 (81.2 mg, 0.211 mmol) in dichloromethane (2 mL), followed by a solution (0.2 mL) containing pyridinium tosylate (200 mg) in dichloromethane (10 mL). Reaction progress was followed by TLC (1:2 ethyl acetate — hexane) which showed 4- methoxybenzaldehyde dimethyl acetal (Rf 0.80), 4-methoxybenzaldehyde (Rf 0.65), educt 56 (Rf 0.42) and product 57 (Rf 0.26). After 5 ¥% h the mixture was stirred for 15 min with saturated sodium hydrogencarbonate solution (5 mL) then equilibrated with ethyl acetate (25 mL). The organic layer was washed with brine (5 mL), dried and evaporated. The residue was fiash-chromatographed using a stepwise gradient of 1:3 and 1:2 ethyl acetate — hexane to yield 57 as colorless syrup, 0.106 mg (100 %): 'H
NMR: 0.94 (3H, s), 1.19, 1.21 (6H, s each, Me.COH), 1.23, 1.35 and 1.24, 1.37 (6H, s each, major and minor 5,5-dimethyloxolane diastereomer), 1.1-1.7 (18H, m), 1.7-1.9 (5H, m), 1.9-2.0 (2H, m), 3.65 (1H, m), 3.81 (3H, s), 4.08 (1H, brs), 5.78 and 5.96 (1H, s each, major and minor acetal diastereomer), 6.89 (2H, m), 7.41 (2H, m).
[1R,3aR,7aR]-1-(5-Hydroxy-1 (S)H{2-[2-(4-methoxy-phenyl)-5,5-dimethy!- [1 3]dioxolan-4(R)-yl]-ethyi}-5-methyl-hexyl)-7a-methyl-octahydro-inden-4-one (58) o” 2
H
H
58
Pyridinium dichromate (230 mg, 0.61 mmol) was added to a stirred mixture containing 57 (0.0838 , 0.167 mmol), Celite (185 mg), and dichloromethane (4 mL). The conversion of 57 (Rf 0.31) to 58 (Rf 0.42) was monitored by TLC (1:25 methanol — chloroform) The mixture was diluted with dichloromethane (10 mL) after 2.5 h, then filtered through a layer of silica gel. Filirate and washings (1:1 dichloromethane — ethyl acetate) were evaporated and the residue chromatographed (1:4 ethyl acetate — hexane) to give ketone 58 , 0.0763 g, 91 %: H NMR: 0.63 (3H, s), 1.19, 1.21 and 1.23 (6H, s each, Me,COH), 1.25, 1.36, 1.38 (6H, m,s,s, 5,5-dimethyloxolane diastereomer), 1.1-1.9 (18H, m), 1.9-2.1 (3H, m), 2.1-2.4 (2H, m), 2.45 (1H, m), 3.66 (1H, m), 3.802 and 3.805 (3H, s each), 5.78 and 5.95 (1H, s each, major and minor acetal diastereomer), 6.89 (2H, m), 7.39 (2H, m). [1R,3aR,7aR]}-1-[4(R),5-Dihydroxy-1 (S)-(4-hyd roxy-4-methyl-pentyl)-5-methyl- hexyl]-7a-methyl-octahydro-inden-4-one (59) ho OH
H
I H
59
The ketone 58 was stirred in a 1 N oxalic acid solution in 90 % methanol. The mixture became homogeneous after a few min. TLC (ethyl acetate) suggested complete reaction after 75 min (Rf 0.24 for 59). Thus, calcium carbonate (0.60 g) was added and the suspension stirred overnight, then filtered. The filtrate was evaporated and flash- chromatographed using a stepwise gradient of 4:1:5 dichloromethane - ethy! acetate —
hexane, 1:1 ethyl acetate — hexane, and neat ethyl acetate produce 59 as a colorless residue, 0.060 mg, 94%: 'H NMR: 0.5 (3H, s), 1.17 (3H, 5), 1.22 (6H, s), 1.23 (3H, 5), 1.2-1.21 (23H, m), 2.15-2.35 (2H, m), 2.45 (1H, dd, J =7 and 11 Hz), 3.30, 1H, brd). [1R,3aR,7aR]-7a-Methyl-1 -[5-methyl-1 (S)<4-methyl-4-triethylsilanyloxy-pentyl)- 4(R),5-bis-triethylsilanyloxy-hexyi]-octahydro-inden-4-one (690)
Co oi
J = H aiansy pe 60 : A mixture of 59 (0.055 g, 0.143 mmol), imidazole, (14.9 mg, 1.69 mmol), N,N- dimethylpyridine (6 mg), triethylchlorosilane (0.168 mL, 1 mmol) and N,N- dimethylformamide (1.5 mL) was stirred for 17 h. The reaction was followed by TLC (1:4 ethyl acetate — hexane) and showed rapid conversion to the disilyl intermediate (Rf 0.47). Further reaction proceeded smoothly overnight to give the fully silylated 60 (Rf 0.90). The solution was equilibrated with water (3 mL), equilibrated with ethyl acetate (20 mL), the ethyl acetate layer was washed with water (3x4 mL), dried and evaporated. The residue was flash-chromatographed using a stepwise gradient of hexane and 1:100 ethyl acetate — hexane to yield 60 as a colorless syrup, 0.0813 g, 78.4%: 'H NMR & 0.55-0.64 (21H, m), 0.92-0.97 (27H, m), 1.12 (3H, s), 1.18 (3H, 8), 1.19 (3H, s), 1.21 (3H, 5), 1.1-1.7 (18H, m), 1.9-2.15 (2H, m), 2.15-2.35 (2H, m), 2.43 (1H, dd, J = 7.7 and 11 Hz), 3.30 (1H, dd, J = 3 and 8.4 Hz). [1 R,3aR,7aR 4E]-4-{2(2)-13(S),5(R)-Bis-(tert-butyl-dimethyl-silanyloxy)-2- methylene-cyclohexylidene]-ethylidene}-7a-methyl-1 -[5-methyl-1(S)-(4-methyl-4- triethylsilanyloxy-pentyl)-4(R),5-bis-triethylsilanyloxy-hexyl]-octahydro-indene
8-0 ny
J a H wH = ilk
Sy (LAK 61
A solution of 1.6 M butyllithium in hexane (0.14 mL) was added to a solution of phosphine (0.1308 g, 0.224 mmol) in tetrahydrofuran (1.5 mL) at-70 °C. After 10 min a solution of ketone 60 (0.0813 g, 0.112 mmol) in tetrahydrofuran (1.5 mL) was added dropwise over a 15 min period. The ylide color had faded after 3 h so that pH 7 : phosphate buffer (2 mL) was added and the temperature allowed to increase 10 0 °C.
The mixture was equilibrated with hexane (30 mL), the organic layer was washed with brine (5 mL), dried and evaporated to give a colorless oil that was purified by flash- chromatography (1:100 ethyl acetate — hexane). Only the band with Rf 0.33 (TLC 1:39 ethyl acetate — hexane) was collected. Evaporation of those fractions gave 61 as colorless syrup, 0.070 g, 57%: 'H NMR § 0.06 (12H, brs), 0.53-0.64 (21H, m), 0.88 (18H, s), 0.92-0.97 (27H, m), 1.11 (3H, 8), 1.177 (3H, s), 1.184 (3H, s), 1.195 (3H, s), 1- 1.9 (22H, m), 1.98 (2H, m), 2.22 (1H, m), 2.45 (1H, m), 2.83 (1H, brd, J = 13 Hz, 3.27 (1H, d, J = 6 Hz), 4.19 (1H, m), 4.38 (1H, m), 4.87 (1H, brs), 5.18 (1H, brs), 6.02 (1H, d,
J = 11 Hz), 6.24 (1H, d, J = 11 Hz).
Synthesis of 1,25-Dihydroxy-21 (2R,3-dihydroxy-3-methyi-butyl)-20S-
Cholecalciferol (50).
Ho, oH
H . wh
OH
Iw hi nov OH
The deprotection reaction of 61 (0.068 g, 0.06238 mmol) in 1M solution of tetrabutylammonium fluoride in tetrahydrofuran, followed by TLC (ethyl acetate), gradually proceeded to give 50 (Rf 0.19). The mixture was diluted with brine (5 mL) after h, stirred for 5 min the equilibrated with ethyl acetate (35 mL) and water (15 mL).
The aqueous layer was re-extracted once with ethyl acetate (35 mL), the combined extracts were washed with water (5x10 mL) and brine (5 mL) then dried and evaporated. The residue was flash-chromatographed using a linear gradient of 1:1 and 2:1 ethyl acetate - hexane, and 2: 98 methanol — ethyl acetate to give a residue that was taken up in methyl formate and evaporated to a white foam, 30 mg, 93 %: [o]o + 29.3 ° (methanol, c 0.34); MHz 1H NMR &: 0.55 (3H, s), 1.16 (3H, s), 1.21 (9H, 5), 1.1- 1.75 (22H, m), 1.80 (2H, m), 1.9-2.1 (5H, m), 2.31 (1H, dd, J = 7 and 13 Hz ), 2.60 (1H, brd), 284 (1H, m), 3.29 (1H, d, J =9.5 Hz ), 4.22 (1H, m), 4.43 (1H, m), 5.00 (1H, s), 5.33 (1H, s), 6.02 (1H, d, J = 11 Hz), 6.02 (1H, d, J = 11Hz); LR-ES(-) m/z: 564 (M+H2C02), 563 M-H+ H2CO2); HR-ES(+) calcd for CsoHssOs + Na: 541.3863; found 541.3854; UVmax (€): 211 (15017), 265 (15850), 204 sh (141 27), 245 sh (13747) nm.
Synthetic Example 43 - Synthesis of 1,25-Dihydroxy-21 -(2R,3-dihydroxy-3-methyl- butyl)-20S-19-nor-cholecalciferol (62)
Ho, oH
H wH
OH
0] hi
HOY OH
62 [1 R,3aR,7aR,AE]-4-{2(2)-]3(S),5(R)-Bis-(tert-butyl-dimethyl-silanyloxy)- cyclohexylidene]-ethylidene}-7a-methyl-1 -[5-methyl-1(S)-(4-methyl-4- triethylsilanyloxy-pentyl)-4(R),5-bis-triethylsilanyloxy-hexyl]-octahydro-indene
8-0 ny
Pe H wH <0 y bike l
Sy [AK 63
A solution of 1.6 M butyllithium in hexane was added to a solution of phosphine in tetrahydrofuran at —70 °C. After 10 min a solution of ketone 60 from Example 2 in tetrahydrofuran was added dropwise over a 15 min period. After the ylide color had faded , pH 7 phosphate buffer was added and the temperature allowed to increase to 0 oC. The mixture was equilibrated with hexane, the organic layer was washed with brine, dried and evaporated to give a colorless oil that was purified by flash-chromatography (1:100 ethyl acetate — hexane) that gave 63. 1,25-Dihydroxy-21 ~(2R,3-dihydroxy-3-methyl-butyl)-20S-1 g-nor-cholecalciferol (62)
Ho, OM
H wH
OH
BG
I
HOY OH
62
The deprotection reaction of 63 was carried out in 1M solution of tetrabutylammonium fluoride in tetrahydrofuran to give 62. The mixture was diluted with brine after 25 h, stirred for 5 min and then equilibrated with ethyl acetate and water.
The aqueous layer was re-exiracted once with ethyl acetate, the combined extracts were washed with water and brine, and then dried and evaporated. The residue was flash-chromatographed to give a residue that was taken up in methyl formate and evaporated to yield 62.
Synthetic Example 44 - Synthesis of 1,25-dihydroxy-20S-21(3-hydroxy-3-methyi- butyl)-24-keto-1 9-nor-cholecalciferol (64) ' 0
HO,
H lal
OH
I %
Ho™" oH 64 (R)-6-[(1 R,3aR,4S,7aR)-4~{tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro- inden-1 ~yl}-2-methyl-7-phenylisulfanyl-heptan-2-ol (65)
OH S
{H GRE oH [H - ool “on procsen Sane
TBSO H TEP T8SO H 88 85
The reaction above was carried out as described in Tet. Left. 1975, 17: 1409-12.
Specifically, a 50 mL round-bottom flask was charged with 1.54 g (3.73 mmol) of (R)- 2-[(1R, 3aR,4S,7aR)-4-(tert-Butyldimethylsilanyloxy)-7a-methyloctahydroinden-1 -yl}-6- methylheptane-1,6-diol (1) (Eur. J. Org. Chem. 2004, 1703-1713) and 2.45 g (11.2 mmol) of diphenylsulfide. The mixture was dissolved in 5 mL of pyridine and 2.27 g (11.2 mmol, 2.80 mL) of tributylphosphine was added. The mixture was stirred overnight and then diluted with 20 mL of toluene and evaporated. The residue was again taken up in toluene and evaporated, the remaining liquid chromatographed on silica gel using stepwise gradients of hexane, 1:39, 1:19 and 1:9 ethyl acetate — hexane to provide the title compound 65 as a syrup, 1.95 g.
(R)-7-Benzenesulfonyl-6-{{1 R,3aR,4S,7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden-1 -yl]-2-methyl-heptan-2-ol (67) and (1R,3aR,4S,7aR)-1- ((R)-1 _Benzenesulfonylmethyl-5-methyl-5-triethylsilanyloxy-hexyl)-4-{tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-indene (68)
Q Ql, Qh
Cp ot 7 ® Eo molar 150.73 Fo wH mol wt 246 [H _ d08%8 [H
TBSO H TB8SO H TBSO H v Ng 65 67 68
A 500-mL round-bottom flask containing 1.95 g (3.9 mmol) of the crude sulfide 65 was admixed with 84 g of dichloromethane (63 mL). The solution was stirred in an ice bath, then 2.77 g (11 mmol) of meta-chloroperbenzoic acid was added in one portion.
The suspension was stirred in the ice bath for 40 min then at room temperature for 2 h.
The reaction was monitored by TLC (1:19 methanol — dichloromethane). At the end of the reaction period, only one spot at Rf 0.45 observed. Then, 1.68 g(20 mmol) of solid sodium hydrogen carbonate was added to the suspension, the suspension was stirred for 10 min, then 30 mL of water was added in portions and vigorous stirring continued for 5 min to dissolve all solids. The mixture was further diluted with 40 mL of hexane, stirred for 30 min, transferred to a separatory funnel with 41.6 g of hexane. The lower layer was discarded and the upper one was washed with 25 mL of saturated sodium hydrogen carbonate solution, dried (sodium sulfate) and evaporated to give 3.48 g of 67. This material was triturated with hexane, filtered, and evaporated, to leave 67 as a cloudy syrup (2.81 g) that was used directly in the next step.
A 100-mL round bottom flask containing 2.81 g of 67 obtained above, was charged with 30 mL of N,N-dimethylformamide 1.43 g of (21 mmol) of imidazole and 1.75 mL of (10 mmol) of triethylsilyl chloride. The mixture was stirred for 17 h then diluted with 50 g of ice-water, stirred for 10 min, further diluted with 5 mL of brine and 60 mL of hexane. The aqueous layer was re-extracted with 20 mL of hexane, both extracts were combined, washed with 2x30 mL of water, dried, evaporated. This material contained a major spot with Rf 0.12 (1:39 ethyl acetate — hexane) and a minor spot with
Rf 0.06. This material was chromatographed on silica gel using hexane, 1:100, 1:79,
1:39 and 1:19 ethyl acetate — hexane as stepwise gradients. The major band was eluted with 1:39 and 1:19 ethyi acetate — hexane to yield 1.83 g of 68. (R)-5-Benzenesulfonyl-6-[(1 R,3aR,4S,7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden-1-yi]-1 0-methyl-2-(R)-methyl-1 0-triethylsilanyloxy- undecane-2,3-diol (69) [o) {8 oH wo. SH SOzPh 3 HO, _= ots
FX FH
OTES OTES
TBSO H TBSO H
68 69
A 100-mL 3-neck round-bottom flask, equipped with magnetic stirrer, thermometer and Claisen adapter with rubber septum and nitrogen sweep, was charged with 1.7636 g of (2.708 mmol) of sulfone 68, 1.1 14 g of (4.062 mmol) tosylate, and 50 mL of tetrahydrofuran freshly distilled from benzophenone ketyl. This solution was cooled to —20 °C and 9.31 mL of a 1.6 M butyllithium solution in hexane was added dropwise at < -20 °C. The temperature range between -10 and -20 °C was maintained for 5 h. The cooling bath was removed and 50 mL. of saturated ammonium chloride solution added followed by 75 mL of ethyl acetate and enough water to dissolve all salts. The organic layer was washed with 15 mLof brine, dried, and evaporated to a colorless oil. This residue was chromatographed on silica gel using hexane, 1:9, 1:6, 1:4 and 1:3 ethyl acetate — hexane as stepwise gradients. The main band was eluted with 1:4 and 1:3 ethyl acetate — hexane to furnish 1.6872 g of compound 69 as colorless syrup. (S)-6-[(1 R,3aR,4S,7aR)-4-{tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro- inden-1-yl]-10-methyl-2-(R)-methyl-1 0-triethylsilanyloxy-undecane-2,3-diol (70)
HO, Jia SO,Ph HO 9° H
H Mg H
H mol wt 24.31 TH
OVES MeOH OTES
TBSO H TBSO H
69 70
A 25-mL 2-neck round-bottom flask, equipped with magnetic stirrer, thermometer and Claisen adapter with rubber septum and nitrogen sweep, was charged with 1.6872 g (2.238 mmol) of sulfone 69 and 40 mL of methanol. Then 1.25 g (51.4 mmol) of magnesium was added to the stirred solution in two equal portions, in a 30 min time interval. The suspension was stirrd for 70 min then another 0.17 g of magnesium and ca. 5 mL of methanol was added and stirring continued 1 h. The mixture was then diluted with 100 mL of hexane and 50 mL of 1 M sulfuric acid was added dropwise to give two liquid phases. The aqueous layer was neutral. The aqueous layer was re- extracted once with 25 mL of 1:1 dichloromethane — hexane. The organic layers were combined then washed once with 15 mL of brine, dried and evaporated. The resulting material was chromatographed on silica gel using hexane, 1:39, 1:19 and 1:9 ethyl acetate — hexane as stepwise gradients. The main band was eluted with 1:9 ethyl acetate — hexane to provide 1.2611 g of 70 as a colorless syrup. : (S)-6-[(1R,3aR,4S,7aR)-4-(fert-Butyl-di methyl-silanyloxy)-7a-methyl-octahydro- inden-1-yl}-2,10-dihydroxy-2,1 0-dimethyl-undecan-3-one (71) ™ [o]
HO H HO H
“H H
OTES OH
OTBS OTBS
0) ”
A 25-mL round-bottom flask, equipped with magnetic stirrer, thermometer, Claisen adapter with nitrogen sweep and rubber septum, was charged with 518 mg (3.88 mmol) of N-chlorosuccinamide and 11 mL of toluene. Stir for 5 min (not all dissolved), then cool to 0 °C and add 2.4 mL (4.8 mmol) of a 2M dimethyl sulfide solution in toluene. The mixture was stirred from 5 min then cooled to -30 °C and a solution of 0.7143 g (1.165 mmol) of the diol 70 in 4x1.5 mL of toluene was added dropwise at -30 °C. Stirring was continued at this temperature for 1 h. The mixture was then allowed to warm to -10 °C during a 2 h time period then cooled to -17 °C and 3.20 mL (6.4 mmol) of 2M triethylamine in toluene added dropwise. The mixture was stirred at -17 to -20 °C for 10 min then allowed to warm to room temperature slowly. The mixture was chromatographed on a silica gel column using hexane, 1:79, 1:39, 1:19, 1: 9, 1: 4, and
1:1 ethyl acetate — hexane as stepwise gradients. The major pand was eluted with 1:1 ethyl acetate — hexane providing 0.3428 g of the compound 71 as solids. (S)-2,10-Dihydroxy-6-((1 R,3aR,4S,7aR)~4-hydroxy-7a-methyl-octahydro-inden-1 - yl)-2,10-dimethyl-undecan-3-one (72) [o] [o]
HO H HO 3 [oH HgSiFg WH
OH OH
H [A oTBS OH ™ n”
A 25-mL round-bottom flask, equipped with magnetic stirrer was charged with 0.3428 g (0.69 mmol) of the diol 71, was dissolved in 5 mL of acetonitrile then 1.25 mL .. of fluorosilicic acid solution. After 3 h, the mixture was distributed between 35 mL of ethyl acetate and 10 mL of water, the aqueous layer was re-extracted with 10 mL of ethyl acetate, the organic layers combined, washed with 2x5 mL. of water, once with 5 mL of 1:1 brine — saturated sodium hydrogen carbonate solution, dried and evaporated.
This material was chromatographed on silica gel using 1:4, 1:3, 1:2, and 1:1 as stepwise gradients furnishing 0.2085g of the title compound 72. (1R,3aR,7aR)-1-[(S)-5-Hydroxy-1 <{4-hydroxy-4-methyl-pentyl)-5-methyl-4-oxo- hexyl]-7a-methyl-octahydro-inden-4-one (73) [o] [o]
HO H HO H
«H WH oH —~ OH
H H
OH
72 3
A 25-mL round bottom flask was charged with 0.2153 g (0.56 mmol) of 72,5 mLof dichloromethane, and 0.20 g of Celite. To this stirred suspension was added, in on portion, 1.00 g (2.66 mmol) of pyridinium dichromate. The reaction stirred for 3 h and the progress was monitored by TLC (1:1 ethyl acetate — hexane). The reaction mixture was diluted with 5 mL of cyclohexane then filtered trough silica gel G. The column was eluted with dichloromethane followed by 1:1 ethyl acetate — hexane until no solute was detectable in the effluent. The effluent was evaporated and the colorless oil. This oil was then chromatographed on a silica gel using 1:4, 1:3, 1:2, 1:1 and 2:1 ethyl acetate — hexane as stepwise gradients to fumish 0.2077 g of the diketone 73. (1R,3aR,7aR)-7a-Methyl-1 -[(S)-5-methyl-1 ~(4-methyl-4-trimethylsilanyloxy-pentyl)- 4A-oxo-5-trimethylsilanyloxy-hexyl]-octahydro-inden-4-one (74)
[0] [o]
HO H TMSO H
WH TMS imidazole +H oH ™ Cass | oTMS oH oH" 73 74
A 25-mL round bottom flask was charged with 0.2077 g (0.545 mmol) of the diketone 73. This material was dissolved in a mixture of 0.5 mL of tetrahydrofuran and 3 mL of cyclohexane. To the resulting mixture was added 0.30 mL (2.0 mmol) Of TMS- imidazole. The reaction mixture was diluted with 3 mL of hexane after 10 h then concentrated and chromatographed on silica gel using hexane, 1:79, 1:39, 1:19 and ethyl acetate — hexane as stepwise gradients to provide 0.2381 g of 74 as a colorless oil. (S)-6-((1 R,3aS,7aR)-4-{2-[(R)-3-((R)-tert-Butyldimethylsilanyloxy)-5-(tert- butyldimethylsilanyloxy)-cyclohexylidene]-ethylidene}-7a-methyloctahydroinden- 1-yl)-2,10-dimethyl-2,1 0-bis-trimethylsilanyloxyundecan-3-one (75) [o}
MSO, H ™so_
H
Ph CH i 0=P-Ph b oTMS oH oTMS of J H
Bull — emer meer temeef 76
T8SO™ 0TBS
TBSO" OTBS
A 15-mL 3-nack pear-shaped flask, equipped with magnetic stirrer, thermometer and a Claisen adapter containing a nitrogen sweep and rubber septum, was charged with 0.2722 g (0.4768 mmol) of [2-[(3R,5R)-3,5-bis(tert-butyldimethylsilanyloxy) cyclohexyl idene]ethylldiphenylphosphine oxide and 2 mL of tetrahydrofuran. The solution was cooled to —70 °C and 0.30 mL of 1.6 M butyllithium in hexane was added.
The deep red solution was stirred at that temperature for 10 min then 0.1261g (0.240 mmol) of the diketone 74, dissolved in2mL of tetrahydrofuran was added, via syringe, dropwise over a 10 min period. After 3 h and 15 min, 5 mL of saturated ammonium chloride solution was added at -65 °C, the mixture allowed to warm to 10 °C then distributed between 35 mL of hexane and 10 mL of water. The aqueous layer was re-extracted once with 10 mL of hexane, the combined layers washed with 5 ml of brine containing 2 mL of pH 7 buffer, then dried and evaporated. This material was chromatographed on a flash column, 15x150 mm using hexane and 1:100 ethyl acetate — hexane as stepwise gradients to yield 0.1572 g of the title compound 75 as a colorless syrup. 1,25-Dihydroxy-20S-21 (3-hydroxy-3-methyl-butyl)-24-keto-1 9-nor-cholecalciferol (64) ™so_ J B Ho, J
H H
Eo) 1 M TBAF H {
BSC" 0TBS HOY OH
Ca ee Oss 63 eae 7a 75 64
A 15-mL 3-neck round-bottom flask, equipped with magnetic stirrer, was charged with 155 mg (0.17 mmol) of tetrasilyl ether 75. This coloriess residue was dissolved is 2 mL of a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran. After 43 han additional 0.5 mL of 1 M solution of tetrabutylammonium fluoride solution was added and stirring continued for 5 h. The light-tan solution was the diluted with 5 mL of brine, stirred for 5 min and transferred to a separatory funnel with 50 mL of ethyl acetate and mL of water then re-extraction with 5 mL of ethyl acetate. The organic layers were combined, washed with 5x10 mL of water, 10 mL of brine, dried and evaporated. The resulting residue was chromatographed on a 15%x123 mm column using 2:3, 1:1, 2:1 ethyl acetate — hexane, and ethyl acetate as stepwise gradients to provide the 64 as a white solid (TLC, ethyl acetate, Rf 0.23) that was taken up in methyl formate, filtered and evaporated furnishing 0.0753 g of the title compound 64 as a solid substance.
Synthetic Example 45 - Synthesis of 1,25-dihydroxy-20S-21 (3-hydroxy-3-methyl- buty!)-24-keto-cholecalciferol (76) [o]
HO, %
Ho*™ 76 (S)-6-{(1 R,3aS,7aR)-4-[2-{(R)-3-(tert-Butyl-dimethyl-silanyloxy)-5-((S)-tert-butyl- dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-eth-(E)-ylidene}-7a-methyl- octahydro-inden-1-yi}-2,10-dimethyi-2,1 0-bis-trimethylsilanyloxy-undecan-3-one (77)
Compound 77 was prepared as described for 75 in Example 4 but by reacting 74 with [(2Z)-2-[(3S,5R)-3,5-bis(fert-butyldimethyisilanyloxy) methylenecyclohexylidene]- ethyildiphenylphosphine oxide. 1,25-Dihydroxy-20S-21 (3-hydroxy-3-methyl-butyl)-24-keto-cholecalciferol (76)
Compound 76 was prepared from 77 by deprotecting 77 as described in Example 44 for 64.
Synthetic Example 46 — Synthesis of_1c,25-Dihydroxy-16-ene-20-cyclopropyl- cholecalciferol (78) (Compound H)
Compound (78) was synthesized according to the following synthetic procedure. \ 1.nBuli 2.CH3COCH3 ! 3.TBAF \
LH THF i —fs-0 onH OH
To a stirred solution of (3aR, 4S,7aR)1-{1 -[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- 3a.4,5,6,7,7a-hexahydro-3H-inden-1 -yl])-cyclopropyl}-ethynyl (1 .0g, 2.90 mmol) in tetrahydrofurane (15 mL) at ~78°C was added n-BuLi (2.72 mL, 4.35 mmol , 1.6M in hexane). After stirring at _78°C for 1 h., acetone (2.5 mL, 34.6 mmol) was added and the stirring was continued for 2.5h. NH4Clgq was added (15 mL) and the mixture was stirred for 15min at room temperature then extracted with AcOEt (2x 50 mL). The combined extracts were washed with brine (50mL) and dried over Na>SO4. The residue after evaporation of the solvent (2.4 g) was purified by FC (50g, 10% AcOEt in hexane) to give (3aR, 4S,7aR)-5{1-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-3a,4,5,6,7,7a- hexahydro-3H-inden-1 ~yl}-cyclopropyl}-2-methyl-pent-3-yn-2-ol (1.05 g, 2.61 mmol) which was treated with tetrabutylammonium fluoride (6 mL, 6 mmol, 1.0M in THF) and stirred at 65-75°C for 48 h. The mixture was diluted with ACOEt (25 mL) and washed with water (5x 25 mL), brine (25 mL). The combined aqueous washes were extracted with AcOEt (25 mL) and the combined organic extracts were dried over Na;SO.. The residue after evaporation of the solvent (1.1 g) was purified by FC (50g, 20% AcOEt in hexane) to give the titled compound (0.75 g, 2.59 mmol, 90 %). [0}*’p=+2.7 0.75,
CHCls, "TH NMR (CDCl): 5.50 (1H, m), 4.18 (1H, m), 2.40 (2H, s), 2.35-1.16 (11H, m), 1.48 (6H, s), 1.20 (3H, s), 0.76-0.50 (4H, m); 3c NMR (CDCl3): 156.39, 125.26, 86.39, 80.19, 69.21, 65.16, 55.14, 46.94, 35.79, 33.60, 31.67, 29.91, 27.22, 19.32, 19.19, 17.73, 10.94, 10.37;
MS HRE! Calculated for CoH2s02 M+ 288.2089 Observed M+ 288.2091.
OH
SH OH I
The mixture of (3aR, 4S,7aR)-7a-Methyl-1-[1-(-4-hydroxy-4-methyl-pent-2-ynyl)- cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (0.72 g, 2.50 mmol), ethyl acetate (10 mL), hexane (24 mL), absolute ethanol (0.9 mL), quinoline (47 pL) and Lindlar catalyst (156 mg, 5% Pd on CaCOj3 ) was hydrogenated at room temperature for 2 h.
The reaction mixture was filtered through a celite pad and the pad was washed with
AcOEL The filtrates and the washes were combined and washed with 1M HC, NaHCO; and brine. After drying over Na,SO, the solvent was evaporated and the residue (0.79 g) was purified by FC (45g, 20% AcOEt in hexane) to give the titled compound (640 mg, 2.2 mmol, 88 %).
OH
A Hy, kat. Ap HO _— OH ouH oH"
The mixture of (3aR, 4S,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4-methyli-pent-2Z-enyl)- cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (100 mg, 0.34 mmol), 1,4- bis(diphenyl-phosphino)butane 1,5 cyclooctadiene rhodium tetrafluoroborate (25 mg,0.034 mmol), dichloromethane (5 mL) and one drop of mercury was hydrogenated using Paar apparatus at room temperature and 50 p.s.i. pressure for 3h. The reaction mixture was filtered through Celite pad, which was then washed with ethyl acetate. The combine filtrates and washes were evaporated to dryness (110 mg) and purified by FC (10 g, 20% AcOEt in hexane) to give the titled compound (75 mg, 0.26 mmol, 75 %).
[0]*°5= -8.5 c 0.65, CHCl3. 'H NMR (CDCls): 5.37 (1H, m,), 4.14 (1H, m), 2.37-1.16 (17H, m), 1.19 (6H, s), 1.18 (3H, s), 0.66-0.24 (4H, m);
MS HREI Calculated for C1gHa20: M+H 292.2402. Observed M+ H 292.2404.
HO 1. PDC/CH,Cla HO
OH 2Tvsm OTMS on! oH
To a stirred suspension of (3aR, 4S,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4-methyl- pentenyl)-cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (440 mg, 1.50 mmol) and Celite (2.0 g) in dichloromethane (10 mL) at room temperature wad added pyridinium dichromate (1.13 g, 3.0 mmol). The resulting mixture was stirred for 5 h filtered through silica gel (10 g), and then silica gel pad was washed with 20% AcOEt in hexane. The combined filtrate and washes were evaporated, to give a crude © (3aR,7aR)-7a-Methyl-1-[1-(4-hyd roxy-4-methyl-pentenyl)-cyclopropyl}-3a,4,5,6,7,7a- hexahydro-3H-inden-4-one (426 mg, 1.47 mmol, 98 %). To a stirred solution of (3aR,7aR)-7a-Methyl-1-[1 -(4-hydroxy-4-methyl-pentenyl)-cyclopropyi}-3a,4,5,6,7,7a- hexahydro-3H-inden-4-one (424 mg, 1.47 mmol) in dichloromethane (10 mL) at room temperature was added trimethylsilyl-imidazole (0.44 mL, 3.0 mmol). The resulting mixture was stirred for 1.0 h filtered through silica gel (10 g) and the silica gel pad was washed with 10% AcOEt in hexane. Combined filtered and washes were evaporated to give the titled compound (460 mg, 1.27 mmol, 86 %). [a]*’p=-9.9 ¢ 0.55, CHCls. K
NMR (CDCl): 5.33 (1H, dd, J=3.2, 1.5 Hz), 2.81 (1H, dd, J= 10.7, 6.2 Hz), 2.44 (1H, ddd, J=15.6, 10.7, 1.5 Hz), 2.30-1.15 (13H, m) overlapping 2.03 (ddd, J= 15.8, 6.4, 3.2
Hz), 1.18 (6H, s), 0.92 (3H, s), 0.66-0.28 (4H, m), 0.08 (9H, s); 3C NMR (CDCl): 211.08 (0), 155.32(0), 124.77(1), 73.98(0), 64.32(1), 53.91(0), 44.70(2), 40.45(2), 38.12(2), 34.70(2), 29.86(3), 29.80(3), 26.80(2), 24.07(2), 22.28(2), 21.24(0), 18.35(3), 12.60(2), 10.64(2), 2.63 (3); MS HRES Calculated for CooM3s02Si M+ 362.2641.
Observed M+ 362.2648.
P(O)Ph, on
SiRer . i. 2 Tear IE os LW } THF
Gi otto
HO" OH 78
To a stirred solution of a (1S,5R)-1 ,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylphosphinoyl)-eth-(Z)-ylidene}-2-methylene-cyclohexane (675 mg, 1.16 mmol) in tetrahydrofurane (8 mL) at —78°C was added n-BuLi (0.73 mL, 1.17 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-1-[1-( 4- methyl-4-trimethylsilanyloxy-pentyl)-cyclopropyll-3a,4,5,6,7,7a-hexahydro-3H-inden-4- one (210 mg, 0.58 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at ~72°C for 3.5h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na,SQs. The residue (850mg) after evaporation of the solvent was purified by FC (15g, 10% AcOEt in hexane) to give 10, 3p-Di(tert-Butyl-dimethyl- silanyloxy)-25-trimethylsilanyloxy-1 6-ene-20-cyclopropyl-cholecalciferol (382 mg, 0.53 mmol). To the 1a,3p-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-1 6-ene-20- cyclopropyl-cholecalciferol (382 mg, 0.53 mmol) tetrabutylammonium fluoride (4 mL, 4 mmol, 1M solution in THF) was added, at room temperature. The mixture was stirred for 15h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,SO4. The residue (380 mg) after evaporation of the solvent was purified by FC (15g, 50% AcOEt in hexane and AcOEt) to give the titled compound (78) (204 mg, 0.48 mmol, 83 %). [0f?’p= +16.1 ¢ 0.36, EtOH. UV Amax (EtOH): 208 nm (¢
17024), 264 nm (¢ 16028); H NMR (CDCl): 6.37 (1H, d, J=11.3 Hz), 6.09 (1H, d,
J=11.1 Hz), 5.33 (2H, m), 5.01 (1H, s), 4.44 (1H, m), 4.23 (1H, m), 2.80 (1H, m), 2.60 (1H, m), 2.38-1.08 (20H, m), 1.19 (6H, 8), 0.79 (3H, s ),0.66-0.24 (4H, m); 3C NMR (CDCla): 157.07(0), 147.62(0), 142.49(0), 133.00(0), 124.90(1), 124.73(1), 117.1901), 111.64(2), 71.10(1), 70.70(0), 66.88(1), 59.53(1), 50.28(0), 45.19(2), 43.85(2), 42.86(2), 38.13(2), 35.59(2), 29.27(2), 29.14(3), 28.65(2), 23.57(2), 22.62(2), 21.29(0), 17.84(3), 12.74(2), 10.30(2); MS HRES Calculated for CasH4203 M+Na 449.3026. Observed
M+Na 449.3023. :
Synthetic Example 47 — Synthesis of_ 1-alpha-fluoro-25-hydroxy-16,23E-diene- 26,27-bishomo-20-epi-cholecalciferol (79) (Compound B)
Compound (79) is synthesized according to the following synthetic procedure. 1. PDC/CH,Ch =
HO 2 TMSm Hm on™ 0 H
To a stirred suspension of 11-(5-Hydroxy-1 ,5-dimethyl-hex-3-enyl)-7a-methyl- 3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol and Celite in dichloromethane (10 mL.) at room temperature is added pyridinium dichromate. The resulting mixture is stirred for 5 h filtered through silica gel, and then silica gel pad is washed with 20% AcOEt in hexane.
The combined filtrate and washes are evaporated, to give a ketone. To a stirred solution of ketone in dichloromethane at room temperature is added trimethylsilyl-imidazole. The resulting mixture is stirred for 1.0 h filtered through silica gel and the silica gel pad is washed with 10% AcOEt in hexane. Combined filtered and washes are evaporated to give the titled compound. : — P(O)Ph2 1. n-BuLi OH
THF
0 TBSO™ F
HO" F i
To a stirred solution of a tert-Butyl-{3-[2-(diphenyl-phosphinoyl)-ethylidene]-5-fluoro-4- methylene-cyclohexyloxy}-dimethyl-silanein tetrahydrofurane at -78°C is added n-BuLi.
The resulting mixture is stirred for 15 min and solution of 1-(5-Ethyl-1-methyl-5- trimethylsilanyloxy-hept-3-enyl)-7a-methyl-3,3a,5,6,7,7a-hexahydro-inden-4-one in tetrahydrofurane is added dropwise. The reaction mixture is stirred at —78°C for 3.5h diluted with hexane washed brine and dried over Na,SO4. The residue after evaporation of the solvent was purified by FC (15g, 10% AcOEt in hexane) to give the silylated compound. To the silylated compound, tetrabutylammonium fluoride is added, at room temperature. The mixture is stirred for 15h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na,SQs4. The residue (380 mg) after evaporation of the solvent is purified by FC (15g, 50% AcOEt in hexane and AcOEt) to give the titled compound (79).
BIOLOGICAL EXAMPLES
Biological Example 1: Evaluation of Vitamin D3 analogues (Compound A) in an in vivo model —cyclophosphamide (CYP) induced chronic IC in rats.
The rat model of chemical cystitis induced by intraperitoneal injection of CYP has been well accepted. CYP is used in clinical practice in the treatment of a number of malignant tumors. One of its metabolites, acrolein, is excreted in urine in large concentrations causing hemorrhagic cystitis associated with symptoms of urinary frequency, urgency and pelvic pain. The inflammatory process is characterized by changes in gross histology of bladder, increase in number and distribution of inflammatory cell infiltrates (mast cells, macrophage, PMNs), cyclo-oxygenase-2 expression and prostaglandin production, growth factor and cytokine production. The rat model of chemical cystitis closely resembles interstitial cystitis, a chronic, painful urinary bladder syndrome and has been used for the testing of therapeutic agents in the past.
This model was used to test the effects of oral administration of 1,25 dihydroxyvitamin D3 analogue in rats with CYP-induced cystitis. The effects of the treatment on the cystometric parameters in a conscious freely moving rat with CYP-
induced cystitis were monitored. The following cystometric parameters were recorded in each animal: * bladder capacity e filling pressure (pressure at the beginning of the bladder filling) e threshold pressure (bladder pressure immediately prior to micturition) eo micturition pressure (the maximal bladder pressure during micturition) presence or absence of non-voidng bladder contractions (increases in bladder pressure of at least 10 cm H.0 without release of urine) « amplitude of non-voididng bladder contraction.
Animals: Wistar female rats, age 8 weeks, weighing 125-175g were used. Two groups of animals had a tube implanted into the urinary bladder for intravesical pressure recording. Following recovery all animals received three intraperitoneal injections of
CYP and subsequently were divided into the treatment and sham control groups.
Treatment group: Rats treated with oral 1,25-dihydroxyvitamin D3 analog (1,3-Di-
O-acetyl-1,25-dihydroxy-16,23Z-d iane-26,27-hexafluoro-19-nor-cholecaiciferol) “Compound A” for 14 days (daily dose of 0.1ug/kg)
Control group: Rats treated with oral vehicle (miglyol) in the dose identical to that delivered in the treatment group
Cystometry was performed 24 hours following the last dose of the drug or vehicle on awake freely moving animals.
Number of animals per group:
Sham control animals 4
Treated animals 3
Methods
Implantation of the polyethylene tubing into the urinary bladder:
A lower midline abdominal incision was performed under general inhalation anesthesia (isoflurine with 02) and polyethylene tubing (PE-50, Clay Adams,
Parsippany, NJ) with the end flared by heat was inserted into the dome of the bladder and secured in place with a 8-0 prolene purse string suture. The distal end of the tubing was heat-sealed, tunneled subcutaneously and externalized at the back of the neck, out of the animal's reach. Abdominal and neck incisions were closed with 4-0 nylon sutures.
Intraperitoneal injection of cyclophosphamide:
Following recovery (5 days) subject animals underwent three intraperitoneal injections of CYP (Sigma Chemical, St. Luis, MO; 75 mg/kg each, intraperitoneal) over the period of nine days. On the tenth day following the first CYP injection the sham control animals received the vehicle only, whereas the experimental group were treated with the 1,25-dihydroxyvitamin D3 analogue 1,3-Di-O-acetyl-1 25-dihydroxy-16,232Z- diene-286,27-hexafluoro-19-nor-cholecalciferol “Compound A" (delivered orally using gavage). Two weeks following the initiation of the treatment animals underwent a conscious cystometrogram to assess the function of the urinary bladder.
Cysfometrogram
An animal was placed unrestrained in a cage and the catheter was connected via a T-tube to a pressure transducer (Grass® Model PT300, West Warwick, RI) and microinjection pump (Harvard Apparatus 22, South Natick, MA). A 0.9% saline solution was infused at room temperature into the bladder at a rate of 10 mi/hour. Intravesical pressure was recorded continuously using a Neurodata Acquisition System (Grass®
Model 15, Astro-Med, Inc, West Warwick, RI). At least three reproducible micturition cycles were recorded after the initial stabilization period of 25 - 30 minutes.
Timeline of an experiment:
Procedure Days
Acclimation period 1-5
Tube implantation + recovery period 6-10
CYP treatment (three doses of 75mg/kg i.p. every three days) 11-17
Treatment (sham or active) 18 — 31
Cystometric evaluation 32
Results
The data analysis is summarized in Tables 1 and 2 and Figure 1 in which:
Bl. Cap = bladder capacity (ml)
FP = filling pressure (cmH:0)
TP = threshold pressure (cmH20)
MP = micturition pressure (cmH20) # of NVBC = number of non-voiding bladder contractions amplitude of NVBC = amplitude of non-voiding bladder contraction
Rat Bl. Cap. FP TP MP #of Amplitude of
NVBC NVBC
RB 8 1,2 15 15 100 22 15 1,2 13 18 100 14 14 1.1 16 15 82 12 11
RB10 0,7 30 40 110 26 25 0,9 32 26 94 32 28 0,6 26 26 108 35 16
RB12 1,7 35 40 115 40 17 1,7 25 30 125 35 14 1,9 30 25 118 22 17
RB14 1,3 16 16 104 10 10 1,2: 17 17 95 4 8 1,1 19 21 92 9 18
Table 1: cystometric parameters for the control group.
#of amplitude of
Rat Bl. Cap. FP TP NP NVBC NVBC
RB7 0,7 13 14 98 0 0 0,7 14 14 97 0 0 0,8 13 14 101 0 0
RB13 1,4 14 15 104 8 11 1,9 15 16 105 4 10 1,3 14 17 97 8 11
RB15 2,5 12 14 90 0 0 1,3 1 12 100 0 0 1,5 10 1 108 0 0
Table 2:cystometric parameters for the treatment group
Changes were noted in a number of cystometric parameters. Dramatic reductions in both the number and amplitude of non-voiding bladder contractions were observed in the drug treated animals. Less pronounced but still statistically significant reductions in the filling and threshold pressures were also recorded. The treatment did "not result in a change of the bladder capacity.
Bladder overactivity associated with chronic cystitis manifests itself in frequent contractions of the bladder wall associated with irritative often painful urinary symptoms.
The fact that non-voiding bladder contractions were reduced both in their frequency and amplitude strongly suggest that if the effects on the bladder function in patients with interstitial cystitis will be similar, oral treatment with vitamin D3 analogues has a potential to relieve these debilitating symptoms. Reduction in filling and threshold pressures is significant from a clinical standpoint because the increased intravesical pressure associated with interstitial cystitis is a condition potentially jeopardizing the upper urinary tract.
Biological Example 2: Histological Analysis of Rat Bladders
Rat bladders from the experiments of Example 1 were fixed in formalin, embedded in paraffin and stained with hematoxylin and eosin by methods known in the art. :
Histopathological examination was performed on at least 10 sections per bladder. Different inflammatory parameters were considered: e hemostasis e oadema « infiltration of inflammatory cells (mostly lymphocytes and monocytes) e opithelial erosion o fibrosis and were scored as follows: 0= normal without any sign of inflammation, 1= mild, 2= moderate, 3= severe, 4= severe signs diffused across all of the section. . Results
Tables 3 and 4 below show the effect of Compound A on histological score.
Table 3 refers to vehicle treated animals and Table 4 to “Compound A” treated animals.
Each inflammatory parameter was scored from 0 to 4, where 0 is normal and 4 the most severe symptom.
EPITHELIAL
RAT # INFILTRATION | HEMOSTASIS | FIBROSIS | EROSION TREATED
ER eml om A a FH] A
Table 3
EPITHELIAL
RAT # INFILTRATION |HEMOSTASIS | FIBROSIS [EROSION |TREATED
ReT | 05] ~~ 05] of Of OjCompoundA
EPITHELIAL
RAT # INFILTRATION |HEMOSTASIS | FIBROSIS EROSION |TREATED we oss os oO] soos] or on] 0 Of
Tablr. A.
Figure 2 shows the effect of Compound A on the histological signs of inflammation in rat bladders, whilst Figure 3 shows a histogram summarizing the histological score for each sign of inflammation.
The data of Examples 1 and 2 clearly demonstrate the utility of vitamin D3 analogues for treating the inflammatory component of interstitial cystitis as well as the consequent bladder overactivity characterizing interstitial cystitis.
Biological Example 3: Evaluation of Vitamin D3 analogues (Compound B) in an in vivo model — cyclophosphamide (CYP) induced chronic IC in rats.
Method
Implantation of the polyethylene tubing into the urinary bladder
Wistar rats (250gr female weighing 125-175 g, age 8 weeks) were used. Under general inhalation anesthesia with 2% isoflurane, polyethylene tubing (PE-50, Clay
Adams, Parsippany, NJ) with the end flared by heat was inserted into the dome of the bladder and secured in place with a 6-0 nylon purse string suture. The distal end of the tubing was sealed, tunnelled subcutaneously and externalized through a small incision at the back of the neck. The tubing was then coiled and buried subcutaneously.
Intraperitoneal injection of cyclophosphamide
Following recovery (5 days) subject animals underwent three intraperitoneal injections of CYP (Sigma Chemical, St. Louis, MO; 75 mg/kg each, intraperitoneal) over the period of nine days. On the tenth day following the first CYP injection the sham control animals received the vehicle only, whereas the experimental group were treated with the 1,25-dihydroxyvitamin D3 analogue 1,3-Di-O-acetyl-1,25-dihydroxy-16,23Z- diene-26,27-hexafluoro-19-nor-cholecalciferol “Compound A” (delivered orally using gavage). Two weeks following the initiation of the treatment animals underwent a conscious cystometrogram to assess the function of the urinary bladder.
Treatment
Treatment Group: 4-6 rats were treated with oral vitamin D3 analogue (1-alpha-fluoro- 25-hydroxy-1 6,23E-diene-26,27-bishomo-20-epi-cholecalciferol) Compound “B” continuously for 14 days (daily dose of either 30 or 75 ug/kg).
Control Group: 4 rats were treated with oral vehicle (miglyol) at a dose identical to that delivered in the treatment group.
An ethanol stock solution of Compound B (1 mg/ml) was dissolved in Miglyol vehicle at the appropriate concentration. Control animals received the vehicle containing the same amount of ethanol. Drug (or vehicle) treatment was carried out by daily gavage after weighing the animal. Drug solution was prepared calculating a final volume of 100 ul/10 grams body weight,.
Cystometrogram
Following two weeks of treatment, animals were placed unrestrained in a cage and the distal end of the catheter was extracted from the subcutaneous pouch and connected via T-tube to a pressure transducer (Grass® Model PT300, West Warwick,
RI) and microinjection pump (Harvard Apparatus 22, South Natick, MA). Saline solution (0.9%, room temperature) was infused into the bladder at a rate of 10 mi/h. Intravesical pressure was recorded continuously using a Neurodata Acquisition System (Grass®,
Astro-Med, West Warwick, RI). At a minimum, three reproducible micturition cycles were recorded. The following cystometric parameters were recorded in each animal: filling pressure (FP: pressure at the beginning of the bladder filling), threshold pressure (TP: bladder pressure immediately prior to micturition), micturition pressure (MP: the maximal bladder pressure during micturition), presence or absence of non-voiding bladder contractions (NVBC: increases in bladder pressure of at least 10 cm HO without release of urine). The post-void residual (PVR) was measured by aspirating the residual urine remaining in the bladder after the last micturition or draining the bladder by gravity. Bladder capacity (BC) was calculated as the sum of voided volume and PVR.
The bladder was harvested and its weight was recorded following euthanasia.
Calcemia assessment
Serum calcemia was evaluated by a commercially available colorimetric assay (Calcium Dry-Fast, Sentinel CH. italy). Briefly, 10 ul serum were added to 100 ul reaction solution prepared according to the manufacturer's procedure in a 96-wells plate. After 5 min incubation at RT samples were read at 570 nm with a spectrophotometer and the calcium levels were calculated in triplicate by using a standard reference as directed.
Results
Group Bl. FP TP MP # of Amplitude of
Cap. (cm (em (cm NVBC NVBC
H.0) H20) H20)
Control 1.2 22.8 24.1 103.6 21.8 (4.0) 16.8 (1.9) (0.1) (8.0) (8.2) (4.1)
Compound 2.0 23.3 29.3 79.3 11.7 16.6 (9.7)
B (0.6) (10.6) (12.6) (26.8) (16.6) (30 ug/kg)
Compound 2.1 26.1 36.3 90.5 8.3 (1.9) 13.6 (1.3)
B (0.1) (9.0) (7.6) (3.1) (75 ug/kg) :
Table 5: cystometric parameters (standard error values are shown in brackets)
Changes were again noted in a number of cystometric parameters as a result of treatment with a vitamin D compound (in this case Compound B).
Non-voiding bladder contractions were significantly reduced in their frequency at both dosage levels (30 uglkg, p<0.01; 75ugfkg, p<0.005), see Figure 4. The treatment with Compound B resulted in an increased bladder capacity at both dosage levels (30 ug/kg, p<0.01; 75ug/kg, p<0.01) as shown in Figure 5.
Marginal increase in the filling and threshold pressures were seen as a result of treatment with Compound B (not statistically significant). The amplitude of non-voiding bladder contractions was reduced by treatment with Compound B at the higher dose level (not statistically significant).
At both dosage levels of Compound B average serum calcium levels were only slightly but not significantly elevated, see Figure 6 (the dotted line indicated the limit of normal range of 10.7 mg/dl in rats).
Biological Example 4: Evaluation of Vitamin D3 analogues (Compound B) in an in vivo model — allergic IC in mice.
Method
General
Mice (BALB/c, females 8 weeks old, weight 18-20 g, Charles River, Calco ITA) were sensitized by injecting 10 ug/mouse of chicken ovalbumin from Sigma (OVA, grade V) in the presence of 4 mg of alum (SERVA, Germany) by intraperitoneal injection , once a week for 4 weeks. This induces a sustained level of IgE detectable in serum.
One or two weeks after the last immunization boost , sensitized mice were anesthetized (1.5% Isoflurane) and then trans-urethrally catheterized (24 gauge, 3/4 in.;
Angiocath, Becton- Dickson). Slight digital pressure was applied the lower abdomen to drain the urine.
The urinary bladders were instilled with either 150 ul of either saline or OVA alone, (1 mg/150 ul) infused at a slow rate to avoid trauma and vesico-ureteral reflux and repeated twice within a 30-min interval with the syringe kept in place on the catheter for at least 30 min. Intravesical challenge was repeated 7-10 days after the first one with the same procedure.
Treatment Group: 10 mice were treated with oral vitamin D3 analogue (1-alpha- fluoro-25-hydroxy-16,23Ediene-26,27-bishomo-20-epi-cholecalciferol) Compound “B” for 14 days (daily dose of either 30 or 75 ug/kg).
Control Group: 10 mice treated with oral vehicle (miglyol) in the dose identical to that delivered in the treatment group.
An ethanol stock solution of Compound B (1 mg/ml) was dissolved in Miglyol vehicle at the appropriate concentration. Control animals received the vehicle containing the same amount of ethanol. Drug (or vehicle) treatment was carried out by daily gavage after weighing the animal. Drug solution was prepared calculating a final volume of 100 ul/10 grams body weight, and treatment was started on the day of the first intravesical ovalbumin challenge, maintained daily, but discontinued over the weekends, for 12 days total treatment. Figure 7 illustrates the timeline of the experiment.
ELISAS
Serum total IgE levels were measured by using a commercially available kit (BD
Opteia, Mouse IgE ELISA Set Cat. No. 555248) and following manufacturer's instructions. Briefly, microwells were coated with 50 uL per well of Capture Antibody diluted in Coating Buffer (0.1 M Sodium Carbonate, pH 9.5 8.40 g NaHCO3, 3.56 g
Na2CO3; q.s. to 1.0 L; pH to 9.5; freshly prepared or used within 7 days of preparation, stored at 2- 8°C). Recommended antibody coating dilution 1:250 as from lot-specific
Instruction/ Analysis Certificate. Plates were sealed and incubated overnight at 4°C.
After washes (6x in PBS/tween 0.1%) plates were blocked with 2 200 pL/well PBS/10%
FBS) and incubated at room temperature (RT) for 1 hour. 100 uL of each standard, sample, and control were pipetted into appropriate wells and plates were incubated for 2 hours at RT. After 6 washes 100 uL of prepared Detection Antibody + Avidin-HRP (1:250) reagent were dispensed to each well and let them stand for 1 hour at RT. After washes as above, 0.1 ml of Substrate Solution were added to the plates and further incubated (without plate sealer) for 30 minutes RT in the dark. After reaction stopping (H2S04 1M, 50 uliwell) absorbance at 450 nm was recorded within 30 minutes.
Ova-specific IgE were measured according to the following procedure. An anti- mouse IgE antibody (1 ug/ml Pharmingen, cat.) was coated in carbonate buffer and plates were incubated ON at 4°C. After blocking (>200 ul PBS/10% FBS, 1 hr 37°C) plates were further incubated with sample sera appropriately diluted ON at 4°C. After extensive washes, PBS/5% FBS containing biotinylated ovalbumin (10 ug/ml final,) was added to each well and plates were incubated 2 hrs at RT. Ova-specific IgE were revealed by adding streptavidin-HRP (1:5000, Pharmingen, 45 min RT) and the specific substrate. Finally, 450nm absorbance was recorded after the reaction was stopped.
Histology and immunohistochemistry
Bladders were explanted from the animals, longitudinally divided in two moieties, one half was either immediately fixed in formalin (10% buffered) for at least 3 hrs or snap frozen in liquid nitrogen upon inclusion in OCT freezing medium (Tissue-Tek
Sakura). For histological analysis, fixed bladders were further processed and finally paraffin embedded. Five um sections were serially cut then stained with GIEMSA (BDH, 20% solution, 3 hrs RT) and then de-stained in 0.1% acetic acid for 10 sec. After a clarification step in Xylene, slides were permanently mounted with Eukitt medium and analyzed by a pathalogist in a blinded fashion in order to evaluate for inflammatory cell infiltrate, mast cell numbers, and the presence of interstitial edema. A semi-quantitative histological score was used, assigning: 1 for mild infiltrate, no edema; 2 for intermediate infiltration, little edema; and 3 for severe infiltration and edema.
In selected bladder tissues, the expression of vitamin D3 receptor (VDR) was checked by performing immunohistochemical staining on frozen sections. Sections were fixed in acetone 10 min at RT. After 5 PBS washes, slides are incubated 30 min RT with methanol containing 0.3% H20,, in order to quench endogenous peroxidase and then pre- incubated 1 hr with 5% normal rabbit serum. Anti VDR antibody (Affinity Bio
Reagents clone 9A7 isotype 1gG2b) was then added to slides (Sug/ml final) and incubation was prolonged ON at 4°C.
After thorough washes, sections were incubated with rabbit anti rat IgG (10 ug/ml) for 1 hr at RT, washed again, and further incubated with streptavidin-HRP (vector
Labs) for 30 min RT. Slides were developed by adding the specific chromogen (Vector labs) until visually good staining was achieved, counterstained with hematoxilin, and finally permanently mounted with Eukitt medium (Bio-optica).
Tag-man analysis
Total RNA was extracted from one half of bladder by using RNeasy Mini kit (Qiagen), treated with DNase 1 (Qiagen) and reverse transcription performed with
Reverse Transcription Reagent (Applied Biosystems) with Random Hexamers (according to the manufacturer's instructions). cDNA was synthesized from 1 ug of
RNA. Real-Time PCR was performed in 96-well optical reaction plates (Applied
Biosystems). For each sample we amplified both the target gene and the housekeeping gene (HPRT) in different wells (singleplex) and in duplicate. The amplification Master
Mix was prepared according to the following protocol (volumes refer to a single well with a final volume of 40 ul/well)): 2X TagMan® Universal PCR Master Mix (Applied
Biosystems, 4304437): 20 ul; 20X Assay target gene: 2 ul; HO: 8 ul; cDNA: 10 ul.
Reaction was run on an SDS 7000 (Applied Biosystems) instruments, with the following amplification program: 2' at 50°C; 10’ at 95°C; 15” at 95°C and 1’ at 60°C for 40 cycles;.
Cycle thereshold (Ct) values were exported into Excel Worksheets for analysis and relative quantitations were performed using the ACt method. All primers used carried the FAM reporter.
Calcemia assessment
Serum calcemia was evaluated by a commercially available colorimetric assay (Calcium Dry-Fast, Sentinel CH. Italy). Briefly, 10 ul serum were added to 100 ul reaction solution prepared according to the manufacturer's procedure in a 96-wells plate. After 5 min incubation at RT samples were read at 570 nm with a spectrophotometer and the calcium levels were calculated in triplicate by using a standard reference as directed.
Results
ELISAS
Figure 8 shows the total amounts of IgE, and Figure 9 shows the amounts of antigen specific IgE. The data represent a single experiment repeated at least three time, with 8-10 subject animals per group (treatment, control and serum levels pre- challenge). Results for only one dose of 75 ug/kg are shown, similar results were obtained with a dose of 30 ug/kg (not shown).
The data indicate that the procedure has been very effective in inducing an immune response, providing a 8-fold increase of antigen specific serum IgE in ovalbumin/alum treated animals compared to pre-challenged sera of the same animals.
However, no significant changes were detected in the levels of either the total amount of
IgE or ovalbumin specific IgE between vehicle and Compound B treated animals. This finding is as would be expected.
Serum levels of mast-cell derived chymase MMCP1 protein are shown in Figure 10. Upon exposure to the antigen, the bladder mucosa reacts by triggering degramulation of resident mast cells and causing the release of a variety of inflammatory mediators. The serum levels of chymase MMCP1 protein are significantly lower (p<0.05) in mice treated with Compound B (75 ug/kg) than those treated with the vehicle, suggesting an inhibitory effect on mast cell induced inflammatory responses.
Calcemia
Treatment with Compound B (75 ug/kg) did not cause calcemic levels to rise above the toxicity threshold, as shown in Figure 11 (the dotted line indicates the toxicity threshold of 10.7 mg/d! in mice). A small, but statistically significant increase in serum calcium level is noted in the Compound B treated group (p<0.05). No significant changes in serum calcium levels was detected in mice treated with a lower dosage (30 mg/kg) of Compound B (not shown)
Body Weight
Figure 12 illustrates the variation in body weight of treated (compound B, 75ug/kg) and control animals. Data are represented as mean values with standard deviation values shown. 8-10 subject animals per group. Data points for the two groups show no significant difference. As body weight is a good indicator of toxicity, this finding is supportive of a lack of adverse effects resulting from treatment with Compound B.
Tag-man analysis
The levels of various inflammatory markers are shown in Figure 13: IL-13,
MCPT2 and FceR1a are presented for saline challenged (vehicle treated) and ovalbumin challenged (vehicle, Compound B 30 ug/kg and Compound B 75 ug/kg treated). Results were obtained by pooling equal amounts of serum recovered from test subjects. Oral treatment with Compound B significantly reduces the expression of ali three inflammatory markers at both dosage levels (in a dose dependent fashion).
Challenge with saline does not show any increase in the Th2/mast-cell specific markers.
Figure 14 illustrates data on the presence of the inflammatory markers. IL-13,
MMCP4 and FceR1a for ovalbumin challenged (vehicle and Compound B treated 75ug/kg) mice. The data is presented showing the individual values from single animals. Up-regulation of the markers is observed to varying degrees within the control group, suggesting that the animals may recover from challenge at different rates.
However, oral treatment with the vitamin D3; analogue down-modulates expression of the inflammatory markers, this finding suggests that the compounds of the invention may modulate Th2 type inflammatory responses in the bladder.
Histology
Data from the blind histological analysis of bladder sections from both vehicle and Compound B treated (75ug/kg) animals are presented in Figure 15. A significant reduction in mast cells (p<0.05), eosinophils (p<0.01) and lymphocytes (p<0.01) is observed, with edema appearing to be completely resolved (p<0.001).
The effects of treatment with Compound B are also apparent in the representative slides shown in Figure 16, where no signs of edema are visible in the
Compound B treated animal (75ug/kg), but a number of lesions indicated by arrows) are visible in the control animal (vehicle treated).
Discussion
The data presented in this Example support a hypothesis that the vitamin Ds analogue Compound B is effective in modulating the Th2-type inflammatory response in the bladder by down-modulating the expression of typical markers such as IL-13 or
FceR1a. Additionally, a diminished inflammatory cell infiltrate is also detectable within the ovalbumin-challenged bladders upon drug treatment, indicating that migration of inflammatory cells might be reduced, possibly because of a reduced cytokine/chemokine environment and an impairment of cell maturation in bone marrow.
Compound B treatment also inhibits the release of MMCP1 protein in the serum, suggesting a direct effect on mast cell activation. However, it is still unclear whether this observed effect is generated by a lower number of mast cell migrating into the bladder mucosa or by a direct effect of vitamin D; analogues on mast cell de-granulation.
It can be concluded that oral treatment with vitamin D3 analogue Compound B exerts anti-inflammatory and effects on the bladder in the allergen induced model of chronic bladder inflammation suggesting that vitamin D compounds represent a new therapeutic option for interstitial cystitis.
Biological Example 5: Evaluation of Vitamin D3 analogues (Compounds C — 1) in an in vivo model — allergic IC in mice
Method
Experiments in Example 7 were performed according to the general procedures described previously in Example 6. Mice were challenged with saline (untreated) or ovalbumin (treatment with vehicle or one of Compounds C-l at a dosage indicated in
Table 6 in ug/kg).
Compound C 1,3-Di-O-acetyl-1,25- dihydroxy-16-ene-19-nor- cholecalciferol
Compound A 1,3-Di-O-acetyl-1,25- : 0.1 dihydroxy-16,23Z-diene- 26,27-hexafluoro-19-nor- cholecalciferol
Compound E 1,3-Di-O-acetyl-1,25- dihydroxy-20-cyclopropyl- 23E-ene-26,27-hexafluoro- 19-nor-cholecalciferol
Compound F 1,3-Di-O-acetyl-1,25- dihydroxy-20-cyclopropyl- =
Compound H 1,25-Dihydroxy-16-ene-20- 1
TT ona
Compound | 1,25-dihydroxy-21-(3- hydroxy-3-methylbutyl)-19- nor-cholecalciferol
Table 6- Chemical names and dosages of Compounds A-l used in Example 7.
Results
Experimental results for Example 7 are summarised in Figure 17. The data is illustrated graphically in Figures 18 to 26.
Expression of the FceR1a inflammatory marker is shown in Figure 18. Treatment with Compound E (p<0.05), Compound H (p<0.05) and in particular Compound F (p<0.001) led to statistically significant reductions in the mRNA expression level of the
FceR1a gene.
ay
Expression of the IL-13 inflammatory marker is shown in Figure 19. Treatment with Compound H (p<0.05) and Compound 1 (p<0.05), and in particular Compound E (p<0.001) and Compound F (p<0.001) led to statistically significant reductions in the mRNA expression level of the IL-13 gene.
Expression of the MMCP4 inflammatory marker is shown in Figure 20.
Treatment with Compound H (p<0.05) and Compound | (p<0.05), and in particular
Compound E (p<0.001) and Compound F (p<0.001) led to statistically significant reductions in the mRNA expression level of MMCP4 gene.
Figure 21 shows serum levels of MMCP1. Treatment with Compound F (p<0.05) and in particular Compound A (p<0.001) and Compound E (p<0.001) led to a statistically significant reduction in the serum level of the MMCP1 protein.
Data from the blind histological analysis is illustrated in Figures 22 to 25. Note that data for treatment with some of the tested compounds is not available at this time.
Treatment with the vitamin D3 analogue Compound C results in significantly reduced numbers of mast cells in the bladder wall (p<0.05) relative to the control (vehicle treated) animals, as shown in Figure 22. Treatment with Compound A results in significantly reduced numbers of eosinophils in the bladder wall (p<0.05), as shown in
Figure 23. Figure 24 shows that treatment with Compound E and Compound | both led to a significant reduction in the number of LMPC in the bladder wall (p<0.05 for both treatments. EDEMA evaluation is illustrated in Figure 25.
Treatment with Compound C, Compound E, Compound F, Compound H and
Compound ! led to slight elevation of serum calcium levels relative to the vehicle treated control group (p<0.001 in all cases), with the degree of serum calcium elevation varing among treatment groups. Treatment with Compound A or Compound G showed no significant increase in serum calcium levels.
Summarizing all the results presented above in Example 7, we can conclude that these compounds can be ranked with respect to their efficacy in reducing several parameters measuring inflammation of the bladder in the allergen-induced chronic bladder inflammation model of interstitial cystitis. Efficacy ranking is as follows:
Compound E>Compound F>Compound B>Compound H>Compound 1>Compound
A>Compound A=Compound G. Taken together, these data confirm that vitamin D compounds represent a new therapeutic option for interstitial cystitis.
FORMULATION EXAMPLES
Formulation Example 1A: Soft Gelatin Capsule Formulation item Ingredients mg/Capsule 1 Compound A 10.001-0.02 2 Butylated Hydroxytoluene (BHT) 0.016 3 Butylated Hydroxyanisole (BHA) 0.016 4 Miglyol 812 gs. 1160.0
Manufacturing Procedure: 1. BHT and BHA is suspended in Miglyol 812 and warmed to about 50 °C with stirring, until dissolved. 2. Compound A is dissolved in the solution from step 1 at 50 °C. 3. The solution from Step 2 is cooled at room temperature. 4. The solution from Step 3 is filled into soft gelatin capsules.
Note: All manufacturing steps are performed under a nitrogen atmosphere and protected from light.
Formulation Example 1B: Soft Gelatin Capsule Formulation 1] ltem Ingredients mg/Capsule 1 Compound A 10.001-0.02 2 di-.alpha.-Tocopherol 0.016 3 Miglyol 812 gs. 160.0
Manufacturing Procedure: 1. Di-alpha-Tocopheral is suspended in Miglyol 812 and warmed to about 50 °C with stirring, until dissolved. 2. Compound Ais dissolved in the solution from step 1 at 50 °C.
3. The solution from Step 2 is cooled at room temperature. 4. The solution from Step 3 Is filled into soft gelatin capsules.
Formulation Example 2A: Oral Dosage Form Soft Gelatin Capsule
A capsule for oral administration is formulated under nitrogen in amber light from 0.01 to 25.0 mg of Compound B in 150 mg of fractionated coconut ail (e.g. Miglyol 812), with 0.015 mg butylated hydroxytoluene (BHT) and 0.015 mg butylated hydroxyanisole (BHA), filled in a soft gelatin capsule.
The capsule is prepared by the following process: 1. BHT and BHA are suspended in fractionated coconut oil (e.g. Miglyol 812) and warmed to around 50 °C with stirring, until dissolved. 2. Compound B is dissolved in the solution from step 1 at 50 °C. 3. The solution from step 2 is cooled to room temperature. 4. The solution from step 3 is filled into soft gelatin capsules.
All manufacturing steps are performed under a nitrogen atmosphere and protected from natural light.
Formulation Example 2B: Oral Dosage Form Soft Gelatin Capsule
A capsule for oral administration is formulated under nitrogen in amber light: 150pg of Compound B in 150 mg of fractionated coconut ail (Migiyol 812), with 0.015 mg butylated hydroxytoluene (BHT) and 0.015 mg butylated hydroxyanisole (BHA), filled in a soft gelatin capsule.
Formulation Example 2C: Oral Dosage.Form Soft Gelatin Capsule
A capsule for oral administration Is formulated under nitrogen in amber light: 75ug of Compound B in 150 mg of fractionated coconut oil (Miglyol 812), with 0.015 mg butylated hydroxytoluene (BHT) and 0.015 mg butylated hydroxyanisole (BHA), filled in a soft gelatin capsule.
Throughout the specification and the claims which follow, unless the context requires otherwise, the word ‘comprise’, and variations such as ‘comprises’ and ‘comprising’, will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps :
Incorporation by Reference
The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended with be encompassed by the following claims.
Claims (1)
- “ BXL-P029ZA - Claims - 11 February 2008 a 144 CLAIMS 1, A compound as defined by the formula (XN): R Ra Rj 3 Rg ORg 1 R7 Xo X, Ra Ry (XII) wherein: At is single or double bond: A: is a single, double or triple bond; Xy and X; are each independently H or =CH,, provided Xs and X; are not both =CHy; Ri and R; are each independently OC(0)C4-C,4 alkyl, OC(0)C,-Cshydroxyalkyl, or OC(0O)Cs-Cahaloalkyl; Rs, Rs and Rs are each independently hydrogen, C;-C,4 alkyl, C4-Cshydroxyalky!, or Cy-Cshaloalkyl, or Rs and Rj taken together with C, form C3-Cg cycloalkyl: Re and Ry are each independently haloalkyl; and Rs is H, C(0)C4-C,4 alkyl, C(O)C-Cshydroxyalkyl, or C(O)Cy-Cashaloalky!; or a compound as defined by the formula (XVI):R2 . LL fon ila HO Ry (XVI) wherein: AMENDED SHEETBXL-P029ZA - Claims - 11 February 2008 N 145 Xis H or =CH, Ri is hydrogen, hydroxy or fluorine; R2 is hydrogen or methyl; Rs is hydrogen or methyl; provided that R, and Rj do not both represent methyl and Rz and R3 do not both represent hydrogen.R4 is methyl, ethyl or trifluoromethyi; Rs is methyl, ethyl or trifluoromethyl; Ais a single or double bond: B is a single, E-double, Z-double or triple bond; or a compound as defined by the formula (XVI): Rs OH Rs X5 | X4 wr HOY OH (XVII) wherein: B is single, double, or triple bond; Xi and X; are each independently H or =CH,, provided X; and X, are not both =CHpy; and R4 and Rs are each independently C,-Calky! or C1-Cahaloalkyl; or a compound as defined by the formula (VI): AMENDED SHEET iBXL-P029ZA - Claims - 11 February 2008 146 R4 HO H OH -— Rj; - wt HOY OH (VI) wherein: Xi isH or =CHy; A: is a single, a double or a triple bond; Rais C4-C,4 alkyl, Ci-Cshydroxyalky!, or C1-Cshaloalkyi; Rais C4-C4 alkyl, C1-C4hydroxyalkyl or Ci-Cshaloalkyl; and the configuration at C, is R or S; or a pharmaceutically acceptable ester or salt of any one thereof: for use in the treatment or prevention of interstitial cystitis. 2 A compound according to claim 1 wherein said compound is a compound of formula (Xl) or a pharmaceutically acceptable ester or salt thereof.3. A compound according to claim 2, wherein said compound is a compound of formula (XIV): AMENDED SHEETBXL-P028ZA - Claims - 11 February 2008 Z, Re ! OR R+ 8 I A X2 | X4 at AcO® OAC (XIV) or a pharmaceutically acceptable ester or salt thereof.4. A compound according to claim 3, wherein said compound is 1,3-di-O-acetyl- 1,25-dihydroxy-16-ene-1 9-nor-cholecalciferol ( “Compound C*).5. A compound according to claim 2, wherein said compound is a compound of formula (XV): Re ! OR R; 8 A Xz | X4 aw AcO® OAc (XV) AMENDED SHEETBXL-P0O29ZA - Claims - 11 February 2008 or a pharmaceutically acceptable ester or salt thereof.6. A compound according to claim 5, wherein said compound is 1,3-di-O-acetyl- 1 25~dihydroxy-20-cyclopropyl-23E-ene-26, 27-hexafluoro-1 9-nor-cholecalciferol (“Compound E”): “CF pee 3 H OH FiC II H AcO™ OAc Compound E7. A compound according to claim 5, wherein said compound is 1,3-di-O-acetyl- 1 ,25-dihydroxy-20-cyclopropyl-cholecalciferol ("Compound F”).8. A compound according to claim 2, wherein said compound is 1,3-di-O-acetyl- 1,25-dihydroxy-1 6,23Z-diene-26,27-hexaflucro-1 9-nor-cholecalciferof (“Compound A”): OH I H Ry AcO OAc “Compound A".9. A compound according to claim 1 wherein said compound is a compound of formula (XVI) or a pharmaceutically acceptable ester or salt thereof. AMENDED SHEETBXL-PO29ZA - Claims - 11 February 200810. A compound or a pharmaceutically acceptable ester or salt thereof according to claim 9, wherein each of R4 and Rsis methyl or ethyl.11. A compound according to claim 10, wherein said compound is 1-alpha-fluoro-25- hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, (*Compound B”); Z OH IA = HO" F Compound B.12. A compound according to claim 1 wherein said compound is a compound of formula (XVI) or a pharmaceutically acceptable ester or salt thereof.13. A compound according to claim 12, wherein said compound is 1,25-Dihydroxy- 16-ene-20-cyclopropyl-cholecalciferol (*Compound H"): H I Ho oH Compound H.14. A compound according to claim 1 wherein said compound is a compound of formula (VI) or a pharmaceutically acceptable salt thereof.16. A compound according to claim 14, wherein said compound is 1,25-dihydroxy- 21-(3-hydroxy-3-methylbutyl)-1 9-nor-cholecalciferol (“Compound 1°): AMENDED SHEET i :BXL-P029ZA - Claims - 11 February 2008 150 H,C OH CH, H,C OH CH, CH, I HO" OH “Compound I”.16. A compound according to any one of claims 1 to 15, wherein said interstitial cystitis is characterized by the presence of symptoms of bladder dysfunction and bladder inflammation.17. A compound according to any one of claims 1 to 16 wherein the compound is administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations with a second medicament for the treatment of interstitial cystitis.18. A pharmaceutical formulation comprising a compound as defined in any one of claims 1to 17 and a pharmaceutically acceptable carrier for use in the prevention and/or treatment of interstitial cystitis.19. A pharmaceutical formulation comprising a compound as defined in any one of clams 1to 17 and a pharmaceutically acceptable carrier packaged with instructions for use in the prevention and/or treatment of interstitial cystitis.20. Akit containing a compound as defined in any one of claims 1 to 17 together with instructions directing administration of said compound to a patient in need of treatment and/or prevention of interstitial cystitis thereby to treat and/or prevent interstitial Cystitis in said patient. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0404571A GB0404571D0 (en) | 2004-03-01 | 2004-03-01 | Methods for treating interstitial cystitis and related compounds and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200606720B true ZA200606720B (en) | 2008-02-27 |
Family
ID=32088494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200606720A ZA200606720B (en) | 2004-03-01 | 2006-08-14 | Treatment of interstitial cystitis with vitamin D compounds |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1953752A (en) |
GB (1) | GB0404571D0 (en) |
ZA (1) | ZA200606720B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104758300A (en) * | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | Antibacterial applications of vitamin D and vitamin D composition |
-
2004
- 2004-03-01 GB GB0404571A patent/GB0404571D0/en not_active Ceased
-
2005
- 2005-03-01 CN CN 200580013744 patent/CN1953752A/en active Pending
-
2006
- 2006-08-14 ZA ZA200606720A patent/ZA200606720B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB0404571D0 (en) | 2004-04-07 |
CN1953752A (en) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2557809A1 (en) | Treatment of interstitial cystitis with vitamin d compounds | |
US20190060456A1 (en) | 1-deoxy analogs of vitamin d-related compounds | |
JP2007506765A (en) | 1,3-diacylated 26,27-alkyl / haloalkylvitamin D3 compounds and methods of use thereof | |
CA2601545A1 (en) | Use of vitamin d compounds to treat endometriosis | |
AU2004275845A1 (en) | Methods for treating bladder dysfunction | |
ZA200606720B (en) | Treatment of interstitial cystitis with vitamin D compounds | |
US20090298799A1 (en) | Methods of Treating Osteoporosis and Secondary Hyperparathyroidism Using 20-Methyl, Gemini Vitamin D3 Compounds | |
AU2005303773A1 (en) | Combined use of vitamin D derivatives and anti-proliferative agents for treating bladder cancer | |
NZ515138A (en) | Vitamin D analogues and their pharmaceutical use | |
ZA200602097B (en) | Methods for treating bladder dysfunction | |
WO2006035075A1 (en) | Use of vitamin d compounds for the prevention or treatment of chronic prostatitis | |
JP2005503434A (en) | 3-Desoxy-vitamin D3 analog | |
WO2007110109A1 (en) | Novel method | |
US20100093675A1 (en) | Novel method |